<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T08:40:22Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:6199786" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:6199786</identifier>
        <datestamp>2018-10-31</datestamp>
        <setSpec>bmccanc</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id>
              <journal-id journal-id-type="iso-abbrev">BMC Cancer</journal-id>
              <journal-title-group>
                <journal-title>BMC Cancer</journal-title>
              </journal-title-group>
              <issn pub-type="epub">1471-2407</issn>
              <publisher>
                <publisher-name>BioMed Central</publisher-name>
                <publisher-loc>London</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC6199786</article-id>
              <article-id pub-id-type="pmcid">PMC6199786</article-id>
              <article-id pub-id-type="pmc-uid">6199786</article-id>
              <article-id pub-id-type="pmid">30352568</article-id>
              <article-id pub-id-type="publisher-id">4937</article-id>
              <article-id pub-id-type="doi">10.1186/s12885-018-4937-x</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Study Protocol</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Protocol for a phase III RCT and economic analysis of two exercise delivery methods in men with PC on ADT</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7815-6046</contrib-id>
                  <name>
                    <surname>Alibhai</surname>
                    <given-names>Shabbir M. H.</given-names>
                  </name>
                  <address>
                    <phone>(416) 340-5125</phone>
                    <email>shabbir.alibhai@uhn.ca</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                  <xref ref-type="aff" rid="Aff6">6</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ritvo</surname>
                    <given-names>Paul</given-names>
                  </name>
                  <address>
                    <email>paul.ritvo@gmail.com</email>
                  </address>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Santa Mina</surname>
                    <given-names>Daniel</given-names>
                  </name>
                  <address>
                    <email>daniel.santamina@uhn.ca</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Sabiston</surname>
                    <given-names>Catherine</given-names>
                  </name>
                  <address>
                    <email>catherine.sabiston@utoronto.ca</email>
                  </address>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Krahn</surname>
                    <given-names>Murray</given-names>
                  </name>
                  <address>
                    <email>murray.krahn@theta.utoronto.ca</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Tomlinson</surname>
                    <given-names>George</given-names>
                  </name>
                  <address>
                    <email>george.tomlinson@utoronto.ca</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Matthew</surname>
                    <given-names>Andrew</given-names>
                  </name>
                  <address>
                    <email>andrew.matthew@uhn.ca</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Lukka</surname>
                    <given-names>Himu</given-names>
                  </name>
                  <address>
                    <email>lukkahim@hhsc.ca</email>
                  </address>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Warde</surname>
                    <given-names>Padraig</given-names>
                  </name>
                  <address>
                    <email>Padraig.Warde@rmp.uhn.on.ca</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Durbano</surname>
                    <given-names>Sara</given-names>
                  </name>
                  <address>
                    <email>sara.durbano@uhnresearch.ca</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>O’Neill</surname>
                    <given-names>Meagan</given-names>
                  </name>
                  <address>
                    <email>meagan.oneill@uhnresearch.ca</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Culos-Reed</surname>
                    <given-names>S. Nicole</given-names>
                  </name>
                  <address>
                    <email>nculosre@ucalgary.ca</email>
                  </address>
                  <xref ref-type="aff" rid="Aff5">5</xref>
                </contrib>
                <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0474 0428</institution-id><institution-id institution-id-type="GRID">grid.231844.8</institution-id><institution>University Health Network, </institution></institution-wrap>Toronto, ON M5G 2C4 Canada </aff>
                <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2157 2938</institution-id><institution-id institution-id-type="GRID">grid.17063.33</institution-id><institution>University of Toronto, </institution></institution-wrap>Toronto, ON M5S 2J7 Canada </aff>
                <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0747 0732</institution-id><institution-id institution-id-type="GRID">grid.419887.b</institution-id><institution>Cancer Care Ontario, </institution></institution-wrap>Toronto, ON M5G 2L3 Canada </aff>
                <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0408 1469</institution-id><institution-id institution-id-type="GRID">grid.477522.1</institution-id><institution>The Juravinski Cancer Centre, </institution></institution-wrap>Hamilton, ON L8V 5C2 Canada </aff>
                <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 7697</institution-id><institution-id institution-id-type="GRID">grid.22072.35</institution-id><institution>University of Calgary, </institution></institution-wrap>Calgary, AB T2N 1N4 Canada </aff>
                <aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0661 1177</institution-id><institution-id institution-id-type="GRID">grid.417184.f</institution-id><institution>Toronto General Hospital, </institution></institution-wrap>200 Elizabeth St Room EN14-214, Toronto, ON M5G 2C4 Canada </aff>
              </contrib-group>
              <pub-date pub-type="epub">
                <day>23</day>
                <month>10</month>
                <year>2018</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>23</day>
                <month>10</month>
                <year>2018</year>
              </pub-date>
              <pub-date pub-type="collection">
                <year>2018</year>
              </pub-date>
              <volume>18</volume>
              <elocation-id>1031</elocation-id>
              <history>
                <date date-type="received">
                  <day>27</day>
                  <month>12</month>
                  <year>2017</year>
                </date>
                <date date-type="accepted">
                  <day>10</day>
                  <month>10</month>
                  <year>2018</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© The Author(s). 2018</copyright-statement>
                <license license-type="OpenAccess">
                  <license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
                </license>
              </permissions>
              <abstract id="Abs1">
                <sec>
                  <title>Background</title>
                  <p id="Par1">Androgen deprivation therapy (ADT) is commonly used to treat prostate cancer. However, side effects of ADT often lead to reduced quality of life and physical function. Existing evidence demonstrates that exercise can ameliorate multiple treatment-related side effects for men on ADT, yet adherence rates are often low. The method of exercise delivery (e.g., supervised group in-centre vs. individual home-based) may be important from clinical and economic perspectives; however, few studies have compared different delivery models. Additionally, long-term exercise adherence and an understanding of predictors of adherence are critical to achieving sustained benefits, but such data are lacking. The primary aim of this multi-centre phase III non-inferiority randomized controlled trial is to determine whether a home-based delivery model is non-inferior to a group-based delivery model in terms of benefits in fatigue and fitness in this population. Two other key aims include examining cost-effectiveness and long-term adherence.</p>
                </sec>
                <sec>
                  <title>Methods</title>
                  <p id="Par2">Men diagnosed with prostate cancer of any stage, starting or continuing on ADT for at least 6 months, fluent in English, and living close to a study centre are eligible. Participants complete five assessments over 12 months (baseline and every 3 months during the 6-month intervention and 6-month follow-up phases), including a fitness assessment and self-report questionnaires. Biological outcomes are collected at baseline, 6, and 12 months. A total of 200 participants will be randomized in a 1:1 fashion to supervised group training or home-based training supported by smartphones, health coaches, and Fitbit technology. Participants are asked to complete 4 to 5 exercise sessions per week, incorporating aerobic, resistance and flexibility training. Outcomes include fatigue, quality of life, fitness measures, body composition, biological outcomes, and program adherence. Cost information will be obtained using patient diary-based self-report and utilities via the EQ-5D.</p>
                </sec>
                <sec>
                  <title>Discussion</title>
                  <p id="Par3">To disseminate publicly funded exercise programs widely, clinical efficacy and cost-effectiveness have to be demonstrated. The goals of this trial are to provide these data along with an increased understanding of adherence to exercise among men with prostate cancer receiving ADT.</p>
                </sec>
                <sec>
                  <title>Trial registration</title>
                  <p id="Par4">The trial has been registered at clinicaltrials.gov (Registration # <ext-link ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov/ct2/show/study/NCT02834416">NCT02834416</ext-link>). Registration date was June 2, 2016.</p>
                </sec>
                <sec>
                  <title>Electronic supplementary material</title>
                  <p>The online version of this article (10.1186/s12885-018-4937-x) contains supplementary material, which is available to authorized users.</p>
                </sec>
              </abstract>
              <kwd-group xml:lang="en">
                <title>Keywords</title>
                <kwd>Prostate cancer</kwd>
                <kwd>Androgen deprivation therapy</kwd>
                <kwd>Exercise</kwd>
                <kwd>Randomized controlled trial</kwd>
                <kwd>Quality of life</kwd>
                <kwd>Fatigue</kwd>
                <kwd>Physical fitness</kwd>
                <kwd>Cost-effectiveness</kwd>
                <kwd>Patient adherence</kwd>
              </kwd-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000024</institution-id>
                      <institution>Canadian Institutes of Health Research</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>MOP130252</award-id>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>issue-copyright-statement</meta-name>
                  <meta-value>© The Author(s) 2018</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec id="Sec1">
              <title>Background</title>
              <p id="Par46">Prostate cancer (PC) is the most common cancer in men [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>], affecting an estimated 21,600 Canadian men in 2016. With increased screening and better treatment of early disease, 10-year disease-specific survival has reached almost 95% [<xref ref-type="bibr" rid="CR2">2</xref>]. This means that more men are living longer with PC, with many progressing to advanced disease over time. Androgen deprivation therapy (ADT), an effective treatment, blocks the production of testosterone, leading to apoptosis and decreased proliferation of PC cells. It has been used in advanced PC for 7 decades [<xref ref-type="bibr" rid="CR3">3</xref>]. At present, almost 50% of men with PC can expect to receive ADT at some point after diagnosis [<xref ref-type="bibr" rid="CR4">4</xref>–<xref ref-type="bibr" rid="CR6">6</xref>]. Although ADT improves disease control and prolongs survival (often by several years) [<xref ref-type="bibr" rid="CR7">7</xref>–<xref ref-type="bibr" rid="CR9">9</xref>], it is associated with numerous adverse effects, predominantly due to depriving organs and tissues of testosterone. These adverse effects include worsening quality of life (QOL) and fatigue [<xref ref-type="bibr" rid="CR10">10</xref>–<xref ref-type="bibr" rid="CR13">13</xref>], significant declines in muscle mass and physical strength, loss of bone mineral density (BMD), and various metabolic side effects (e.g. increased blood glucose and cholesterol).</p>
              <p id="Par47">The effects of ADT on health-related QOL (hereinafter referred to as QOL), are diverse and persistent, including worse global QOL, worse physical function, more fatigue, poorer sexual function, hot flushes, and breast tenderness [<xref ref-type="bibr" rid="CR14">14</xref>–<xref ref-type="bibr" rid="CR24">24</xref>]. Some studies have reported worse social function [<xref ref-type="bibr" rid="CR15">15</xref>] and mental well-being [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. These effects are typically seen within 3 to 12 months of ADT initiation [<xref ref-type="bibr" rid="CR12">12</xref>] and persist or slowly worsen over the next 3 years with ongoing ADT use [<xref ref-type="bibr" rid="CR25">25</xref>]. Such effects are profoundly disruptive to patients, spouses or partners, and families [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR26">26</xref>–<xref ref-type="bibr" rid="CR28">28</xref>].</p>
              <p id="Par48">Multiple studies have reported reductions in overall muscle mass, upper and lower extremity strength, grip strength, and daily functioning in men on ADT [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR29">29</xref>–<xref ref-type="bibr" rid="CR36">36</xref>]. Two studies suggested an increased risk of falls in men on ADT, most of whom are elders [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>]. Numerous studies have also shown reductions in BMD within 6–12 months of ADT initiation, with further declines with ongoing ADT use for at least 10 years [<xref ref-type="bibr" rid="CR39">39</xref>–<xref ref-type="bibr" rid="CR46">46</xref>]. Loss of BMD has been associated with a 40–60% increased risk of fracture [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR47">47</xref>–<xref ref-type="bibr" rid="CR50">50</xref>]. Finally, ADT has also been associated with increased fat mass, insulin resistance, increased blood glucose, and unfavourable alterations in lipids [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR51">51</xref>–<xref ref-type="bibr" rid="CR55">55</xref>]. These metabolic changes are associated with an increased risk of diabetes [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR56">56</xref>–<xref ref-type="bibr" rid="CR58">58</xref>] and cardiovascular outcomes [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR59">59</xref>–<xref ref-type="bibr" rid="CR63">63</xref>], although the latter remains controversial [<xref ref-type="bibr" rid="CR64">64</xref>, <xref ref-type="bibr" rid="CR65">65</xref>].</p>
              <p id="Par49">Exercise-based interventions have been shown in at least 14 clinical trials to ameliorate most of these adverse effects [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR66">66</xref>–<xref ref-type="bibr" rid="CR77">77</xref>]. As summarized in several recent systematic reviews [<xref ref-type="bibr" rid="CR78">78</xref>–<xref ref-type="bibr" rid="CR82">82</xref>], the benefits of exercise have been shown in interventions of 8 to 24 weeks’ duration, including improved general or overall QOL [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR70">70</xref>, <xref ref-type="bibr" rid="CR74">74</xref>], prostate-specific QOL [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR74">74</xref>], and fatigue [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR66">66</xref>, <xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR70">70</xref>, <xref ref-type="bibr" rid="CR73">73</xref>, <xref ref-type="bibr" rid="CR74">74</xref>]. Exercise has also been associated with improved muscular endurance (upper body = 22–115%, lower body = 23–167%), increased maximal strength (upper body = 40%; lower body = 96%), increased quadriceps muscle thickness by 16%, preserved or improved total body lean mass, and prevention of fat gain [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR68">68</xref>, <xref ref-type="bibr" rid="CR70">70</xref>, <xref ref-type="bibr" rid="CR73">73</xref>]. No other intervention has been shown to improve as many side effects of ADT.</p>
              <p id="Par50">Three small studies found preliminary evidence of benefits of exercise in insulin parameters, glucose, lipids, or inflammatory markers, but effects on BMD remain unclear [<xref ref-type="bibr" rid="CR73">73</xref>, <xref ref-type="bibr" rid="CR74">74</xref>, <xref ref-type="bibr" rid="CR83">83</xref>]. These effects need to be confirmed in larger studies, given the potential benefits of preventing diabetes or reducing cardiac risk factors in older men on ADT, the majority of whom will die of heart disease rather than PC [<xref ref-type="bibr" rid="CR84">84</xref>–<xref ref-type="bibr" rid="CR91">91</xref>]. Importantly, there is a robust literature in the general population showing that exercise improves glucose [<xref ref-type="bibr" rid="CR92">92</xref>–<xref ref-type="bibr" rid="CR94">94</xref>], lipids [<xref ref-type="bibr" rid="CR95">95</xref>], and BMD [<xref ref-type="bibr" rid="CR96">96</xref>–<xref ref-type="bibr" rid="CR98">98</xref>]. And regular exercise after a diagnosis of PC may be associated with improved survival [<xref ref-type="bibr" rid="CR99">99</xref>].</p>
              <p id="Par51">Although multiple studies have demonstrated many benefits of exercise for men with PC on ADT, the strongest and most consistent benefits have been shown with 1:1 supervised (i.e. personal training), in-centre interventions [<xref ref-type="bibr" rid="CR100">100</xref>]. As summarized in recent reviews [<xref ref-type="bibr" rid="CR81">81</xref>, <xref ref-type="bibr" rid="CR82">82</xref>, <xref ref-type="bibr" rid="CR101">101</xref>], four trials have featured 1:1 supervised exercise interventions, all of which reported positive effects on QOL or fitness outcomes. Two studies (only one was randomized) were group-supervised interventions, and both showed benefits in QOL and/or fitness outcomes. In contrast, of the four home-based studies (two randomized controlled trials (RCTs)), only two were positive, and the magnitude and breadth of benefits were smaller than with supervised exercise interventions. Of note, these three exercise delivery models have not been directly compared to one another. Prior trials have used different outcome measures, assessment time points, and training routines, making indirect comparisons difficult.</p>
              <p id="Par52">Despite the accumulating evidence of benefits, few men with PC, including those on ADT, exercise regularly [<xref ref-type="bibr" rid="CR99">99</xref>, <xref ref-type="bibr" rid="CR102">102</xref>–<xref ref-type="bibr" rid="CR105">105</xref>]. For exercise interventions to be most useful to men on ADT, long-term exercise adherence and benefits must be achieved. Long-term exercise adherence has been defined as engaging in regular exercise for at least 6 months post-intervention [<xref ref-type="bibr" rid="CR106">106</xref>]. In the general population, about 50% of individuals stop exercising after 6 months. Experience with cancer survivors suggests that they fare no better [<xref ref-type="bibr" rid="CR107">107</xref>]. Cessation of exercise leads to loss of benefits in virtually every setting [<xref ref-type="bibr" rid="CR108">108</xref>]. Unfortunately, most previous research in men on ADT has been limited to reporting exercise benefits and adherence only to the end of the supervised exercise intervention [<xref ref-type="bibr" rid="CR79">79</xref>, <xref ref-type="bibr" rid="CR80">80</xref>]. In two studies examining participants 4–6 months post intervention, weekly exercise was reduced and QOL benefits were diminished over time [<xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR74">74</xref>].</p>
              <p id="Par53">Relatively little is known about what factors are associated with adherence in this population. Only one study has formally examined adherence in an exercise intervention in men on ADT, finding that age, exercise stage of change, and intention were independent predictors of adherence [<xref ref-type="bibr" rid="CR109">109</xref>]. However, only supervised in-centre exercise was examined and adherence was assessed only during the intervention phase. In summary, although adherence to exercise is crucial, little is known about adherence with different exercise delivery models and factors predicting adherence after the formal intervention phase in men on ADT. It is particularly important to identify factors that support long-term adherence, since men on ADT often continue this treatment for at least 2 to 3 years (and often indefinitely, depending on the indication).</p>
              <p id="Par54">Two other important barriers to exercise uptake relate to resources. First, despite its clinical value, no publicly funded exercise program exists in Canada for anyone with a cancer diagnosis, including men on ADT. This is likely due, in part, to the absence of any data on cost-effectiveness of exercise interventions in patients with PC. In contrast, cardiac rehabilitation is widely available and publicly funded because it has been shown to be both efficacious and cost-effective [<xref ref-type="bibr" rid="CR92">92</xref>, <xref ref-type="bibr" rid="CR110">110</xref>]. Given increasing fiscal pressures, all levels of government are carefully evaluating both efficacy and cost-effectiveness of potentially insurable services.</p>
              <p id="Par55">Second, a related resource issue is alternate exercise delivery models. As outlined above, three main exercise delivery models have been studied in men on ADT – supervised 1:1, group-supervised, and home-based programs; however, our group has conducted the only clinical trial directly comparing 2 exercise delivery models (supervised 1:1 and group supervised) in men on ADT [<xref ref-type="bibr" rid="CR77">77</xref>]. This trial was a pilot study that demonstrated the feasibility of enrolling patients into a RCT of different exercise modalities along with high intervention adherence and study retention [<xref ref-type="bibr" rid="CR77">77</xref>]. However, multiple comparative trials have been conducted in other settings [<xref ref-type="bibr" rid="CR111">111</xref>, <xref ref-type="bibr" rid="CR112">112</xref>]. For example, a systematic review of 12 RCTs of almost 2000 patients in cardiac rehabilitation has shown similar benefits of home-based versus in-centre rehabilitation on exercise capacity, cardiac events, modifiable risk factors (lipids, blood pressure, etc.), and mortality [<xref ref-type="bibr" rid="CR112">112</xref>]. Of note, adherence was greater among home-based compared to in-centre participants in those studies. Clearly, both models require significantly fewer resources for population-level delivery than the gold-standard of 1:1 supervised, facility-based training. In addition, these models of exercise delivery may have added benefits such as improved adherence or social interaction, yet these modalities have never been effectively and directly compared for clinical efficacy or cost-effectiveness in men on ADT.</p>
              <p id="Par56">Given the gaps in the published evidence, we recently conducted a phase II trial to assess the feasibility and efficacy of these 3 delivery models in a 6-month intervention [<xref ref-type="bibr" rid="CR113">113</xref>] (manuscript submitted). The preliminary results suggested that group-supervised exercise and home-based exercise were generally non-inferior to 1:1 supervised exercise for both QOL and fitness outcomes. Specifically, group-supervised exercise was shown to have less than a 20% probability of being inferior to 1:1 exercise for 2 of 3 QOL and 3 of 3 fitness outcomes. The home-based arm had less than a 25% probability of being inferior to the 1:1 arm for 1 of 3 QOL and 3 of 3 fitness outcomes. Moreover, the home-based arm was associated with the highest adherence based on accelerometry. Altogether, this provided a foundation to refine our phase II protocol and conduct the present phase III trial, in which we decided to directly compare 2 exercise delivery methods that are least resource intensive. Although efficacious, the 1:1 supervised intervention arm appeared to provide minimal benefit over a group-supervised program and is cost-prohibitive within a publicly funded health care system.</p>
              <p id="Par57">The primary aims of this phase III non-inferiority RCT are:<list list-type="simple"><list-item><label>i.</label><p id="Par58">To determine, in men with PC on ADT, whether a home-based supported exercise program is non-inferior to a group supervised in-centre (facility-based) exercise program on the primary outcomes of fatigue and functional endurance;</p></list-item><list-item><label>ii.</label><p id="Par59">To examine adherence to exercise and predictors of adherence in each exercise group during the 6-month intervention and for 6 months after program completion;</p></list-item><list-item><label>iii.</label><p id="Par60">To conduct an economic analysis comparing both exercise interventions and usual care.</p></list-item></list></p>
            </sec>
            <sec id="Sec2">
              <title>Methods</title>
              <sec id="Sec3">
                <title>Study design</title>
                <p id="Par61">This trial is a multi-centre, 2-arm non-inferiority RCT with blinded, validated, and clinically relevant outcome measures (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). It will take place at two of Canada’s largest, university-affiliated cancer centres with large genitourinary site groups and significant RCT and exercise expertise: the Princess Margaret Cancer Centre (PM) in Toronto and the Tom Baker Cancer Centre in Calgary (TBCC). Participants will also be recruited from 2 community-based hospitals (in the Greater Toronto Area), Southlake Regional Health Centre and Scarborough and Rouge Hospital – Centenary site. Ethics approval has been obtained at all institutions. All study participants will provide written informed consent prior to study enrollment. Participants can voluntarily withdraw from the study at any time. Participants will be withdrawn from the study at the time of symptomatic disease progression. Any protocol amendments will be approved by the research ethics boards and communicated to investigators as well as to study participants as directed by the research ethics board. The trial is registered at <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">clinicaltrials.gov</ext-link> (registration number: NCT02834416) and the SPIRIT figure is shown in Additional file <xref rid="MOESM1" ref-type="media">1</xref>.<fig id="Fig1"><label>Fig. 1</label><caption><p>Study flow diagram</p></caption><graphic xlink:href="12885_2018_4937_Fig1_HTML" id="MO1"/></fig></p>
              </sec>
              <sec id="Sec4">
                <title>Study participants</title>
                <p id="Par62">The trial will include men with histologically confirmed PC who are fluent in English, able to provide consent, live close to a study centre and are either starting or continuing on ADT for at least 6 months or those in an androgen-deprived (or castrate) state for the duration of the intervention (total testosterone &lt; 1.7 nmol/L). Men are ineligible if they are already meeting guidelines for moderate to vigorous physical activity (MVPA) or have conditions that would interfere with ability to participate. Details are listed in Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Table S1.</p>
              </sec>
              <sec id="Sec5">
                <title>Recruitment</title>
                <p id="Par63">Each study site will feature a dedicated research coordinator (RC) who is a Certified Exercise Physiologist (CEP) or Registered Kinesiologist (RKin). Attending PC specialists (urologists, radiation oncologists, and medical oncologists) in PC clinics will identify potentially eligible patients and notify the RC. The RC will approach potential patients and a study information package will be provided. For patients interested in participating, written informed consent will be obtained and a baseline assessment will be scheduled. Based on patient volumes per centre and prior trial experience, we estimate recruiting 200 patients in approximately 24 months.</p>
              </sec>
              <sec id="Sec6">
                <title>Assessments</title>
                <p id="Par64">Participants will complete 5 assessments over the course of the trial (baseline, 3, 6 (end of intervention), 9, and 12 months). The 9- and 12-month assessments are completed following the end of the intervention and will provide information following the active intervention period. Outcome assessments are completed by a trained outcome assessor. Although neither the patient nor the exercise leader can be blinded to treatment allocation, outcome assessors will be blinded. At each assessment time point, participants will receive compensation to subsidize parking costs and to acknowledge their ongoing commitment to the trial.</p>
              </sec>
              <sec id="Sec7">
                <title>Baseline assessment</title>
                <p id="Par65">The baseline assessment consists of obtaining socio-demographic and clinical data as well as assessing fitness using measures of resting heart rate (HR), blood pressure (BP), oxygen saturation, body composition, upper and lower body strength testing, and a measure of functional endurance. Participants will also complete a series of questionnaires (to assess QOL, fatigue, and exercise adherence, including prior exercise program participation [<xref ref-type="bibr" rid="CR114">114</xref>]) and will be scheduled to complete both a BMD test (if one has not been completed within the past year as per standard of care) and blood work. All measures are detailed below and summarized in Table <xref rid="Tab1" ref-type="table">1</xref>. First aid and emergency equipment and supplies will be on hand for all testing and training sessions.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Summary of Study Measures at Specified Time Points</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Domain/Measure</th><th>Time required</th><th>T<sub>0</sub>: (Baseline)</th><th>T<sub>1</sub>: (3 mo.)</th><th>T<sub>2</sub>:6 mo. (End Int.)</th><th>T<sub>3</sub>: 9 mo. (3 mo. f/u)</th><th>T<sub>4</sub>:12 mo. (6 mo. f/u)</th></tr></thead><tbody><tr><td colspan="7">Quality of life</td></tr><tr><td> FACT-P</td><td>4–5 min</td><td>●</td><td>●</td><td>●</td><td>●</td><td>●</td></tr><tr><td> FACT-G</td><td>8–10 min</td><td>●</td><td>●</td><td>●</td><td>●</td><td>●</td></tr><tr><td> FACT-F (co-primary)</td><td>5 min</td><td>●</td><td>●</td><td>●</td><td>●</td><td>●</td></tr><tr><td colspan="7">Physical Fitness</td></tr><tr><td> 6MWT (co-primary)</td><td>6 min</td><td>●</td><td>●</td><td>●</td><td>●</td><td>●</td></tr><tr><td> Sit-to-Stand Test</td><td>1 min</td><td>●</td><td>●</td><td>●</td><td>●</td><td>●</td></tr><tr><td> Grip Strength</td><td>1 min</td><td>●</td><td>●</td><td>●</td><td>●</td><td>●</td></tr><tr><td>Biological Outcomes<sup>a</sup></td><td>&lt; 5 min</td><td>●</td><td/><td>●</td><td/><td>●</td></tr><tr><td> Blood glucose</td><td/><td/><td/><td/><td/><td/></tr><tr><td> Cholesterol profile</td><td/><td/><td/><td/><td/><td/></tr><tr><td> PSA (safety)</td><td/><td/><td/><td/><td/><td/></tr><tr><td> Testosterone<sup>c</sup></td><td/><td/><td/><td/><td/><td/></tr><tr><td> Haemoglobin (covariate)</td><td/><td/><td/><td/><td/><td/></tr><tr><td> HbA1c (covariate)</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan="7">Body Composition</td></tr><tr><td> Bone mineral density</td><td>30 min<sup>b</sup></td><td>●</td><td/><td/><td/><td>●</td></tr><tr><td> Body composition<sup>d</sup></td><td>5 min</td><td>●</td><td/><td>●</td><td/><td>●</td></tr><tr><td>Adherence</td><td/><td/><td/><td/><td/><td/></tr><tr><td> Accelerometer</td><td>–</td><td>●</td><td>●</td><td>●</td><td>●</td><td>●</td></tr><tr><td> GLTEQ</td><td>&lt; 5 min</td><td>●</td><td>●</td><td>●</td><td>●</td><td>●</td></tr><tr><td> Sessional attendance<sup>e</sup></td><td>–</td><td/><td/><td/><td/><td/></tr><tr><td colspan="7">Adherence Predictor Variables</td></tr><tr><td> HCCQ</td><td>5 min</td><td>●</td><td/><td/><td/><td/></tr><tr><td> BREQ2</td><td>5 min</td><td>●</td><td/><td>●</td><td/><td>●</td></tr><tr><td> PNSF</td><td>5 min</td><td>●</td><td/><td>●</td><td/><td>●</td></tr><tr><td> PAB</td><td>5 min</td><td>●</td><td/><td>●</td><td/><td>●</td></tr><tr><td> Sedentary Behaviours</td><td>5 min</td><td>●</td><td/><td>●</td><td/><td>●</td></tr><tr><td colspan="7">Cost-Effectiveness</td></tr><tr><td> Health questionnaire</td><td>5 min</td><td>●</td><td>●</td><td>●</td><td>●</td><td>●</td></tr><tr><td> EQ-5D</td><td>5 min</td><td>●</td><td>●</td><td>●</td><td>●</td><td>●</td></tr><tr><td>Study Completion</td><td>5 min</td><td/><td/><td/><td/><td>●</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup> All biological measures are considered to be standard of care at baseline and 12 months. PSA is considered to be standard of care at all 3 time points. Blood glucose, cholesterol profile, and haemoglobin tests at 6 months are NOT standard of care</p><p><sup>b</sup> Can be done on separate day to reduce participant burden</p><p><sup>c</sup> Will only be measured in participants who are not on continuous ADT for the duration of the intervention</p><p><sup>d</sup> Includes BIA, waist circumference, and waist circumference: height ratio</p><p><sup>e</sup> Only for those in supervised groups (done weekly)</p><p><italic>Abbreviations</italic><bold>:</bold><italic>6MWT</italic> 6 min walk test, <italic>BREQ2</italic> Behavioral Regulations in Exercise Questionnaire – 2, <italic>EQ-5D</italic> EuroQol 5 dimensions of health scale, <italic>FACT-G</italic> Functional Assessment of Cancer Therapy General, <italic>FACT-F</italic> Fatigue subscale, <italic>FACT-P</italic> Prostate subscale, <italic>GLTEQ</italic> Godin Leisure Time Exercise Questionnaire, <italic>HbA1c</italic> glycated hemoglobin, <italic>HCCQ</italic> Health Care Climate Questionnaire, <italic>Int</italic> Intervention, <italic>PAB</italic> Planning, Attitudes, &amp; Behaviour questionnaire, <italic>PSA</italic> prostate-specific antigen, <italic>PNSF</italic> Psychological Need Support and Frustration Scale – Relatedness Items</p></table-wrap-foot></table-wrap></p>
              </sec>
              <sec id="Sec8">
                <title>Randomization</title>
                <p id="Par66">Patients will be allocated in a 1:1 ratio to treatment groups through a web-based central randomization scheme, with stratification on centre and prior duration of ADT (<bold>&lt;</bold> 3 months vs. 3+ months). We are stratifying on duration of prior ADT as this has been shown to impact on subsequent declines in physical function and QOL as well as response to exercise [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR115">115</xref>]. Randomization will occur following the baseline assessment. Once randomized, group-supervised participants will be scheduled to attend their first exercise session and home-based participants will be scheduled to attend an orientation session conducted by the RC and health coach. All participants will receive a study manual and basic exercise equipment (stability ball, mat, and resistance bands) to support program adherence.</p>
              </sec>
              <sec id="Sec9">
                <title>Follow-up assessments</title>
                <p id="Par67">All follow-up assessments will include documentation of any change in clinical status as well as completion of the fitness measures described above and self-report questionnaires. BMD testing will occur only at baseline and 12 months and body composition measures and blood work will be collected at baseline, 6, and 12 months (Table <xref rid="Tab1" ref-type="table">1</xref>).</p>
              </sec>
              <sec id="Sec10">
                <title>Intervention</title>
                <p id="Par68">The 6-month intervention consists of two delivery arms, a group-supervised arm and a home-based arm. Both programs are designed with evidence from previous research by our team [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR70">70</xref>, <xref ref-type="bibr" rid="CR72">72</xref>, <xref ref-type="bibr" rid="CR76">76</xref>, <xref ref-type="bibr" rid="CR77">77</xref>, <xref ref-type="bibr" rid="CR116">116</xref>] and will be individualized using baseline fitness results. Prior to starting the intervention, the CEP/RKin will meet with participants to provide instruction regarding the exercise program. All participants will be asked to complete 4–5 days per week of mixed modality exercise incorporating flexibility (stretching for 5–10 min at the end of each session), aerobic exercise (approximately 30 min targeting 60–70% heart rate reserve (HR<sub>reserve</sub>) assessed by heart rate monitor), and resistance training (using body weight, resistance bands and/or free weights, a stability ball, and/or an exercise mat with prescribed exercises that target the major muscle groups), encouraging participants to work toward a target of 150 min per week as per established guidelines [<xref ref-type="bibr" rid="CR117">117</xref>]. The absolute workload (60–70% HR<sub>reserve</sub>), and time is standard across all interventions. Program adaptation and progression are described below and summarized in Table <xref rid="Tab2" ref-type="table">2</xref>.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Exercise Program Details</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Group-Supervised Exercise</th><th>Home-Based Exercise</th></tr></thead><tbody><tr><td>Frequency of exercise</td><td colspan="2">4–5 days per week (see also Delivery Location below)</td></tr><tr><td>Intensity</td><td colspan="2">AET: RPE of 11–14/20; HR of 60–70% of HRR RET: RPE of 11–14/20; 60–75% of 1RM ×  8–12 repetitions × 2–3 sets; 5 exercises/session alternating each day (10 different RET exercises in total)<sup>a</sup></td></tr><tr><td>Session Duration</td><td colspan="2">Identical</td></tr><tr><td colspan="3">Delivery Location of exercise</td></tr><tr><td> <italic>Facility-based</italic></td><td>3 x/week</td><td>Not applicable</td></tr><tr><td> <italic>Home-based</italic></td><td>1–2 x/week</td><td>4–5 x/week</td></tr><tr><td>Trainer Presence</td><td>Group Exercise Leader</td><td>Unsupervised; remote support from health coach</td></tr></tbody></table><table-wrap-foot><p><italic>1RM</italic> one-repetition maximum (maximum amount of weight that can be lifted), <italic>AET</italic> aerobic exercise training, <italic>HRR</italic> heart rate reserve, <italic>RPE</italic> Rating of perceived exertion, <italic>RET</italic> resistance exercise training</p><p><sup>a</sup>All resistance exercises are conducted using body weight or resistance bands. A stability ball and yoga mat will also be available for use. RET exercises will target different major muscle groups delivered in two alternating programs. Day 1: Chest, upper back, shoulders, and arms. Day 2: Legs, gluteals, mid back, and core</p></table-wrap-foot></table-wrap></p>
                <p id="Par69">Each program also includes an education component of 12 topics that focus on common concerns facing new exercisers (Table <xref rid="Tab3" ref-type="table">3</xref>). Education sessions will occur during in-centre group classes for group-based participants and over the phone or during monthly in-person sessions for participants in the home-based arm of the intervention.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Education Topics</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Education Topics</th><th>Key Points</th></tr></thead><tbody><tr><td> 1) Introduction to Exercise</td><td>● Benefits of Physical Activity<break/>● Program targets 3 areas of PA (aerobic, resistance, and flexibility)<break/>● PA is safe, feasible and has shown to provide benefits</td></tr><tr><td> 2) Goal Setting</td><td>● Goal setting will assist with your dedication and motivation to complete the exercises<break/>● SMART Goals - Specific, Measurable, Attainable, Realistic, Timely<break/>● Use the goal worksheet in the manual<break/>● Make long term and short term goals</td></tr><tr><td> 3) Behavior Change</td><td>● The plan you set out may not be followed 100%<break/>● Anticipate obstacles that may come as you are changing a behaviour and develop strategies for dealing with it before it arises.<break/>● Monitor your progress, Reward yourself, Visualize your success</td></tr><tr><td> 4) Planning for Barriers</td><td>● Biggest perceived obstacles<break/> ○ Lack of time, self-discipline, partner and ability<break/>● Plan ahead for periods of inactivity</td></tr><tr><td> 5) Social Support</td><td>● You are more likely to be successful if your family, friends and even co-workers are supportive of you<break/>● Social support can occur in many forms – encouragement, completing activities with you, etc.</td></tr><tr><td> 6) Monitoring Behavior</td><td>● Mix up your activities to stay motivated<break/>● Try something new, or something you have done prev.<break/>● It is very easy to enter an exercise rut</td></tr><tr><td> 7) Maintaining Motivation</td><td>● Greatest source of motivation: Fun/enjoyment/stimulation, feeling of accomplishment, pleasure of learning and benefits (i.e. improved sleeping)<break/>● Pursue something that you enjoy, that is convenient to your schedule.<break/>● Take opportunities to be active</td></tr><tr><td> 8) Personal Control</td><td>● Believing that you are in control of your own life give you reinforced motivation and further commitment to make changes</td></tr><tr><td> 9) Self- Discipline, Reward &amp; Attitude</td><td>● Self-discipline can result in increased productivity, improved self-esteem and confidence<break/>● Rewards – use workbook in manual<break/>● Attitudes toward change can determine whether you will be successful</td></tr><tr><td> 10) Adapting your Program</td><td>● Adapting your program – FITT principle</td></tr><tr><td> 11) Health and the Media</td><td>● Be mindful of the ‘Get fit quick’ media marketing – Healthy eating and regular PA will help maintain a long-term healthy lifestyle</td></tr><tr><td> 12) Lifelong Active Living</td><td>● Use some of the tips and tricks in the manual to assist with continuing your active life.<break/>● Change things up, work towards small goals, work with a friend, etc.</td></tr></tbody></table></table-wrap></p>
                <p id="Par70">Group-based exercise program delivery will be standardized across sites using several approaches. Training staff (CEPs/RKins) will be required to attend an introductory training session covering participant testing and training parameters, safety precautions, and emergency procedures. An exercise manual will be developed for training staff outlining specific exercises and appropriate progression of intensity. Monthly conference calls will be held with CEPs/RKins and RCs across all sites to ensure standardization and solve problems. Finally, trainers will record weekly exercise plans and logs for each participant or group. These will be audited by the site PIs and randomly audited by the study PI and central RC monthly for the first 6 months and then every 3 months if compliance is &gt; 90% with the training manual.</p>
                <sec id="Sec11">
                  <title>Monitoring intensity and progression</title>
                  <p id="Par71">The 10-point Rating of Perceived Exertion (RPE) scale will be used to monitor exercise intensity during each exercise session [<xref ref-type="bibr" rid="CR118">118</xref>]. Participants will be instructed to exercise at a level of 3–6 on the 10-point RPE scale (12–16 on the 15-point scale). This corresponds to the target HR range detailed above and is a suitable alternative to regular HR monitoring [<xref ref-type="bibr" rid="CR119">119</xref>]. In addition, HR monitors (Polar, NY, USA) will be used at 3-week intervals throughout the intervention to ensure that the intensity of aerobic exercise being performed aligns with the absolute workload prescribed and to monitor individual exercise progression. If a participant’s HR is outside of his target HR range, exercise intensity will be modified to ensure training within the target HR zone. Participants who need to increase their aerobic exercise workload will first increase exercise duration (e.g. walking minutes), followed by the intensity of exercise (e.g., walking speed). If a participant is able to perform ≥12 repetitions and 3 sets of any given resistance training exercise, the resistance level used for that exercise will be increased (e.g., from a medium to a heavy band). Participants in the group-supervised arm of the intervention will wear a HR monitor during group exercise classes as indicated. Participants in the home-based arm of the intervention will be given a HR monitor to use for the duration of the intervention and will be taught how to use and read their HR response, wearing the monitor as instructed by their health coach.</p>
                </sec>
                <sec id="Sec12">
                  <title>Group-supervised program</title>
                  <p id="Par72">Participants in the group-supervised program will take part in classes led by a CEP/RKin 3 times per week for a period of 6 months. At each site, groups will commence as soon as 2 men have been randomized to a group and will grow to include 4–8 participants to ensure adequate supervision and progression. Participants will be provided with a set of resistance bands to support additional independent exercise.</p>
                </sec>
                <sec id="Sec13">
                  <title>Home-based program</title>
                  <p id="Par73">Participants in this arm will receive equipment (exercise bands, ball, mat, heart rate monitor) free of charge to support home exercise. The frequency, intensity, time, and type of exercise are the same as in the group-supervised program although specific exercises in the aerobic component may be modified to incorporate participant preference and interest.</p>
                  <p id="Par74">Since the strongest evidence in terms of exercise delivery appears to support supervised programs [<xref ref-type="bibr" rid="CR78">78</xref>, <xref ref-type="bibr" rid="CR100">100</xref>], we have incorporated enhancements to prior home-based programs [<xref ref-type="bibr" rid="CR66">66</xref>, <xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR72">72</xref>] based on emerging data in the field of behavioural interventions [<xref ref-type="bibr" rid="CR120">120</xref>–<xref ref-type="bibr" rid="CR122">122</xref>] as well as data from our phase II trial [<xref ref-type="bibr" rid="CR101">101</xref>]. In particular, we will employ cutting-edge smartphone technology and the use of Fitbits as well as remote ‘health coaches’ to provide support to patients during the intervention phase and ideally optimize participation and adherence.</p>
                </sec>
                <sec id="Sec14">
                  <title>Health coaching</title>
                  <p id="Par75">A growing body of research supports the effectiveness of the role a ‘health coach’ in chronic disease management [<xref ref-type="bibr" rid="CR121">121</xref>, <xref ref-type="bibr" rid="CR123">123</xref>]. A health coach is a clinic-based health promoter trained to specifically stimulate and support initiation of and adherence to health behaviours (e.g., exercise, improved nutrition). Participants in the home-based arm of the intervention will work with a remote health coach, following a protocol adapted from Spring et al.’s successful trials in improving physical activity and weight loss [<xref ref-type="bibr" rid="CR120">120</xref>, <xref ref-type="bibr" rid="CR121">121</xref>, <xref ref-type="bibr" rid="CR124">124</xref>, <xref ref-type="bibr" rid="CR125">125</xref>] as well as our prior experience in the phase II trial [<xref ref-type="bibr" rid="CR101">101</xref>] and other trials by members of our group [<xref ref-type="bibr" rid="CR126">126</xref>–<xref ref-type="bibr" rid="CR129">129</xref>] (Additional file <xref rid="MOESM3" ref-type="media">3</xref>: Table S2). The health coach will meet with each home-based participant at study entry to help set goals and will make contact with participants every week to review uploaded exercise data in relation to goals. In addition to weekly contacts made via phone or electronic device, health coaches will meet face to face with participants once a month during the intervention period. This will support the development of alliance between participant and health coach and will include items that may not be possible in phone or electronic-based contact.</p>
                  <p id="Par76">To enhance health coach-participant interactions, we will use specialized health promotion software for smartphones (an ‘app’) from NexJ Systems, Inc. (Toronto, Canada). Home-based study participants will receive smartphones, loaded with health monitoring and communication software and a wearable activity tracker (Fitbit) to use for the duration of the intervention. NexJ software effectively interfaces with Fitbit activity trackers to capture all of the features that the Fitbit tracks. Previous research demonstrates that Fitbit results are reliable, valid measurements of exercise adherence [<xref ref-type="bibr" rid="CR130">130</xref>, <xref ref-type="bibr" rid="CR131">131</xref>]. These data will allow health coaches to better support participants, providing them with tools and suggestions for maintaining or increasing adherence based on Fitbit results.</p>
                </sec>
                <sec id="Sec15">
                  <title>Tapering</title>
                  <p id="Par77">Tapering is designed to enable participants to achieve weekly exercise goals in an increasingly independent manner. Ultimately this will prepare participants to continue with regular exercise following the active intervention. To aid with this transition to independent exercise in the group arm, the number of weekly supervised exercise sessions offered to participants will be reduced from 3 to 2 in the fifth month and to 1 in the final month of the intervention. Participants will be asked to increase the number of independent exercise sessions to maintain a total of 4 to 5 sessions of exercise per week. In the home-based program, the frequency of contact with health coaches will be reduced from every week to every 2 weeks in months five and six and text message support will be reduced to 24-h turnaround time.</p>
                </sec>
              </sec>
              <sec id="Sec16">
                <title>Outcomes and measures</title>
                <sec id="Sec17">
                  <title>Co-primary outcomes</title>
                  <p id="Par78">Our co-primary outcomes are fatigue, as measured by the Functional Assessment of Cancer Therapy–Fatigue (FACT-F) [<xref ref-type="bibr" rid="CR132">132</xref>], and functional endurance, assessed with the 6-min walk test (6MWT). The FACT-F includes 13 items measuring cancer-related fatigue. It has excellent reliability and validity and published normative data [<xref ref-type="bibr" rid="CR133">133</xref>]. Fatigue is a common symptom in men on ADT and fatigue in cancer patients is negatively correlated with many components of QOL [<xref ref-type="bibr" rid="CR134">134</xref>–<xref ref-type="bibr" rid="CR136">136</xref>]. It has been shown to improve consistently with exercise in prior trials in men on ADT [<xref ref-type="bibr" rid="CR78">78</xref>, <xref ref-type="bibr" rid="CR79">79</xref>, <xref ref-type="bibr" rid="CR100">100</xref>]. The 6MWT is a commonly used, validated measure that assesses functional endurance [<xref ref-type="bibr" rid="CR137">137</xref>, <xref ref-type="bibr" rid="CR138">138</xref>]. Physical fitness commonly declines with ADT use and improves with exercise [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR68">68</xref>–<xref ref-type="bibr" rid="CR70">70</xref>, <xref ref-type="bibr" rid="CR72">72</xref>, <xref ref-type="bibr" rid="CR73">73</xref>].</p>
                </sec>
                <sec id="Sec18">
                  <title>Secondary outcomes</title>
                  <sec id="FPar1">
                    <title>Quality of life – General</title>
                    <p id="Par79">General QOL will be assessed using the Functional Assessment of Cancer Therapy – General (FACT-G). It is a well-validated and widely used QOL measure that has been an outcome in major PC exercise trials [<xref ref-type="bibr" rid="CR80">80</xref>, <xref ref-type="bibr" rid="CR139">139</xref>]. It can be completed in 8–10 min and has published normative data [<xref ref-type="bibr" rid="CR140">140</xref>, <xref ref-type="bibr" rid="CR141">141</xref>].</p>
                  </sec>
                  <sec id="FPar2">
                    <title>Quality of life – Prostate-specific</title>
                    <p id="Par80">Prostate-specific QOL will be assessed using the Functional Assessment of Cancer Therapy – Prostate (FACT-P) [<xref ref-type="bibr" rid="CR142">142</xref>] which supplements the FACT-G with 12 prostate-specific items covering domains of urinary function, sexual function, pain, and related symptoms. It is also well-validated and has been used in multiple prior exercise trials [<xref ref-type="bibr" rid="CR80">80</xref>, <xref ref-type="bibr" rid="CR142">142</xref>].</p>
                  </sec>
                  <sec id="FPar3">
                    <title>Physical fitness</title>
                    <p id="Par81">Prior to the start of fitness testing, resting HR, BP, and oxygen saturation will be measured. Musculoskeletal fitness will be assessed using the 5-times sit-to-stand test, a common, simple, and validated measure of functional lower body performance and strength [<xref ref-type="bibr" rid="CR143">143</xref>–<xref ref-type="bibr" rid="CR145">145</xref>]. In addition to this, grip strength will be assessed as a measure of upper body strength [<xref ref-type="bibr" rid="CR146">146</xref>] using a Jamar dynamometer and recording the highest of three readings for each hand. This measure is responsive to ADT use [<xref ref-type="bibr" rid="CR12">12</xref>], and predicts long-term disability and mortality in middle-aged and older adults [<xref ref-type="bibr" rid="CR147">147</xref>].</p>
                  </sec>
                  <sec id="FPar4">
                    <title>Body composition</title>
                    <p id="Par82">Body fat percentage, fat-free mass, and fat mass will be measured using bioelectrical impedance analysis (BIA) with the Tanita TBF-300A device (Illinois, USA). Additional anthropometric measurements include waist circumference (WC), WC:hip ratio, and body mass index, following the standardized CSEP-PATH protocol [<xref ref-type="bibr" rid="CR148">148</xref>]. In addition, BMD will be measured at lumbar spine, total hip, and femoral neck using dual x-ray absorptiometry (DXA).</p>
                  </sec>
                  <sec id="FPar5">
                    <title>Biological outcomes</title>
                    <p id="Par83">Blood will be collected at three time points (baseline, 6 months, and 12 months) to analyze fasting blood glucose, lipid profile (total cholesterol, low density lipoprotein, high density lipoprotein, triglycerides), hemoglobin, glycosylated hemoglobin (HbA1c), total testosterone, as well as prostate-specific antigen (PSA) levels. These outcomes are being measured given the impact of ADT and exercise on various biological endpoints. More specifically, ADT leads to deleterious effects on blood glucose and cholesterol levels, whereas exercise may be associated with their improvement. Hemoglobin levels will be assessed since ADT leads to mild declines in hemoglobin that may affect fatigue, QOL, physical fitness, and adherence [<xref ref-type="bibr" rid="CR70">70</xref>, <xref ref-type="bibr" rid="CR149">149</xref>, <xref ref-type="bibr" rid="CR150">150</xref>]. Glycosylated hemoglobin will be collected since regular exercise has been shown to reduce HbA1c levels whereas ADT is associated with worse insulin resistance and diabetic control [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR151">151</xref>]. Total testosterone levels will be collected to confirm that participants who are not actively on ADT during the intervention period are in an androgen-deprived state for the duration of the intervention. PSA is a standard safety measure, since there is theoretical evidence that exercise leads to an acute increase in testosterone that could aggravate PC [<xref ref-type="bibr" rid="CR152">152</xref>]. In multiple prior exercise studies in men on ADT, PSA has been found to be unaffected following bouts of training or over the course of an intervention [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR70">70</xref>, <xref ref-type="bibr" rid="CR73">73</xref>].</p>
                  </sec>
                  <sec id="FPar6">
                    <title>Costing and utility outcomes</title>
                    <p id="Par84">To allow cost-effectiveness analysis, both the EQ-5D-5 L and a patient costs diary will be used. The EQ-5D-5 L is a well-validated, widely used, generic, off-the-shelf preference instrument that measures patient utilities across 5 dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) [<xref ref-type="bibr" rid="CR153">153</xref>, <xref ref-type="bibr" rid="CR154">154</xref>]. It was originally known as the EuroQol, and has been widely used throughout the world in both clinical investigations and health policy determinations [<xref ref-type="bibr" rid="CR155">155</xref>]. A total of 3125 unique combinations of scores across the 5 levels of each of 5 dimensions can be generated, each of which can be converted into a utility score based on population-weighted responses from either a United Kingdom-based population cohort or a United States-based cohort [<xref ref-type="bibr" rid="CR154">154</xref>]. It can be completed in 5 min.</p>
                    <p id="Par85">Resource utilization, out-of-pocket costs, and productivity costs will be estimated using a patient cost diary that we have used in prior PC studies, adapted for this study based on patient feedback and response analysis in the phase II trial. More specifically, the patient cost diary will capture: i) hospitalizations/medical events; ii) physician/other health professional services including hospitalizations and outpatient diagnostic tests; iii) drugs, including drug costs unrelated to ADT; iv) equipment costs; v) community services and home care; vi) productivity costs; vii) exercise-specific costs; and viii) out-of-pocket costs.</p>
                  </sec>
                  <sec id="FPar7">
                    <title>Adherence</title>
                    <p id="Par86">Program adherence and predictors of adherence will also be assessed. We recognize there is no perfect, all-inclusive definition of adherence. We will therefore measure different elements of adherence in this trial. Our primary adherence measure is the proportion of individuals in each arm who achieve at least 150 min of MVPA at both the three-month and six-month time points based on objective measurements via accelerometry. A target of 150 min is recommended by both Cancer Care Ontario’s guideline for cancer survivors [<xref ref-type="bibr" rid="CR117">117</xref>] and the revised Canadian Society for Exercise Physiology (CSEP) guideline for adults and older adults [<xref ref-type="bibr" rid="CR156">156</xref>]. Recognizing limitations of accelerometry (e.g. technical malfunction, incomplete wearing, not capturing all activities) we will also capture self-reported MVPA with the Godin Leisure Time Exercise Questionnaire (GLTEQ) at each time point. The GLTEQ is a brief, self-administered validated questionnaire that records light, moderate, and vigorous exercise performed each week in 15-min increments [<xref ref-type="bibr" rid="CR157">157</xref>, <xref ref-type="bibr" rid="CR158">158</xref>]. For those in the group supervised arm, we will capture weekly attendance at exercise sessions. For those in the home-based program, we will measure three elements of adherence/engagement: a) Fitbit step counts; b) frequency of health coach contacts; c) frequency of use of the smartphone app.</p>
                    <p id="Par87">Study participants will be asked to wear Actigraph GT3X (Pensacola, FL) accelerometers daily from awakening to bedtime for 1 week at each assessment time point (including baseline). Accelerometers are reliable [<xref ref-type="bibr" rid="CR159">159</xref>] and non-obtrusive, and capture all physical activity during waking hours, thereby providing information on total physical activity during the time period of observation [<xref ref-type="bibr" rid="CR160">160</xref>]. Accelerometer data will be extracted in 60-s epochs and screened using standard methods for: (i) at least 4 days of valid data, including (ii) at least 10 h of wear time per day; (iii) continuous non-wear time (periods of time with zero movement counts per minute) of more than 1 h. Total time spent in MVPA (&gt; 1952 movement counts per minute [<xref ref-type="bibr" rid="CR161">161</xref>]) will be calculated for the week. Additionally, accelerometer data enables the capture of sedentary behaviour using a protocol of time spent in activities with &lt; 100 counts per minute and time spent inclined (using the inclinometer setting).</p>
                    <p id="Par88">Predictors of adherence were selected based on a social ecological framework (Fig. <xref rid="Fig2" ref-type="fig">2</xref>). Potential determinants of exercise adherence and the relationship between these determinants will be examined using validated measures at each level: exosystem, mesosystem, and microsystem. Exosystem will be examined via participant postal codes, which will be collected to map where participants live in order to obtain information about neighbourhood resources and environment. This will provide details about the walkability and access to recreation in participant neighbourhoods [<xref ref-type="bibr" rid="CR162">162</xref>]. Mesosystem variables include assessment of autonomy support and social relatedness. We will use the Health Care Climate Questionnaire (HCCQ short form) [<xref ref-type="bibr" rid="CR163">163</xref>], a 6-item self-report measure that assesses patients’ perceptions of the degree to which their health care ‘network’ is autonomy supportive. The modified HCCQ, which allows the assessment of provision of autonomy support from appropriate: (1) group members; (2) exercise instructors, and (3) health check ‘system’ [<xref ref-type="bibr" rid="CR164">164</xref>] (i.e. 3 scales) will be used. Relatedness to Other Exercisers will be used as a social connectedness indicator of adherence using the Psychological Need Support and Frustration Scale – Relatedness Items [<xref ref-type="bibr" rid="CR165">165</xref>]. This is an 8-item scale with good psychometric properties that assesses how individuals feel connected to other exercisers. The microsystem includes a measure of motivation, which will be assessed using the Behavioral Regulations in Exercise Questionnaire-2 (BREQ-2) [<xref ref-type="bibr" rid="CR166">166</xref>, <xref ref-type="bibr" rid="CR167">167</xref>]. A modified version of this questionnaire that does not include the amotivation scale (4 items) will be used since participants who have consented to an exercise trial are likely not to be amotivated. The BREQ-2 is a 15-item inventory assessing extrinsic, introjected, identified, and intrinsic regulations. Planning, Attitudes, &amp; Barriers will be assessed using a scale validated for cancer patients [<xref ref-type="bibr" rid="CR168">168</xref>, <xref ref-type="bibr" rid="CR169">169</xref>].<fig id="Fig2"><label>Fig. 2</label><caption><p>Social Ecological Framework for Understanding Exercise Determinants</p></caption><graphic xlink:href="12885_2018_4937_Fig2_HTML" id="MO2"/></fig></p>
                  </sec>
                  <sec id="FPar8">
                    <title>Sedentary behaviour</title>
                    <p id="Par89">An exploratory outcome will be change in sedentary behaviour, which is defined as <bold>any waking activity characterized by an energy expenditure ≤ 1.5 metabolic equivalents</bold>
<italic>and</italic>
<bold>a sitting or reclining posture.</bold> There are currently no data on men on ADT on levels of sedentary behaviour. These data will be obtained from accelerometry at the assessment time points.</p>
                  </sec>
                </sec>
              </sec>
              <sec id="Sec19">
                <title>Safety</title>
                <p id="Par90">The CEP/RKin will review exercise precautions and safety during the intervention orientation. In addition, participants are encouraged to review the manual prior to commencing independent exercise sessions. All exercise personnel are trained in cardiopulmonary resuscitation (CPR) and automated external defibrillator (AED) use and have received safety training at each site. Possible adverse events during intervention and post-intervention phases will be captured using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v4.0. There is no independent data monitoring committee given the lack of anticipated safety concerns based on multiple prior trials of both interventions.</p>
              </sec>
              <sec id="Sec20">
                <title>Sample size calculation</title>
                <p id="Par91">A total of 200 participants (100 per arm) gives an estimated 81% power for analysis of the FACT-F and 6MWT for non-inferiority and will also provide accurate estimates of parameters related to secondary outcomes. Details are shown in Additional file <xref rid="MOESM4" ref-type="media">4</xref>: Methods. There are no planned interim analyses or early stopping rules.</p>
              </sec>
              <sec id="Sec21">
                <title>Statistical analysis</title>
                <sec id="Sec22">
                  <title>Co-primary outcomes</title>
                  <p id="Par92">The primary analysis will use a Bayesian analysis of covariance (ANCOVA) model to regress the change in FACT-F and 6MWT values between baseline and 6 months against the baseline value, the treatment group variable and variables representing stratification by centre and length-of-ADT. We will treat the high-intensity group (group supervised; higher level of supervision and greater resources) as the reference.</p>
                  <p id="Par93">For each primary outcome, we will compute the Bayesian posterior probability that the low intensity group is non-inferior to the high intensity group (i.e., that the mean difference between groups is larger than the non-inferiority margin -<bold>δ</bold>). If either of these probabilities is large enough (i.e. &gt; 97.5%) then we will declare the home-based group to be non-inferior for that outcome. One advantage of a Bayesian approach is that it allows us to assign posterior probabilities to the 4 possible outcomes of the study (illustrated in Fig. <xref rid="Fig3" ref-type="fig">3</xref>): (1) Home-based inferior only for 6MWT; (2) Home-based inferior only for FACT-F; (3) Home-based inferior for both outcomes; and (4) both non-inferior. Another advantage is that it allows a more useful presentation of individual results than a simple confidence interval or <italic>p</italic>-value: for example, we will be able to say that the mean difference lies below –<bold>δ</bold> (i.e., home-based is inferior) with probability X%, that it lies between –<bold>δ</bold> and 0 (i.e., home-based is worse but non-inferior) with probability Y% and that it is above 0 (i.e., home-based is better) with probability Z%. Finally, the outputs of the Bayesian model can be used as probabilistic inputs for the economic analysis. The Bayesian analyses will use non-informative priors, allowing the results to be data-driven and make direct probability statements about non-inferiority.<fig id="Fig3"><label>Fig. 3</label><caption><p>Illustration of Four Possible Scenarios in Non-Inferiority Testing for Proposed 2-Arm Trial. We will compare groups by means of ANCOVA using the baseline score as the covariate. After fitting a Bayesian model to each outcome, we will evaluate the probability in each of the 4 regions in the figure above. We can calculate the probability that: 1. Both the 6MWT and FACT-F fatigue scores are non-inferior in the home-based arm. This is the green region (<bold>b</bold>). 2. Both the 6MWT and FACT-F fatigue scores are inferior in the home-based arm. This is the grey region (<bold>c</bold>). 3. The 6MWT score is non-inferior in the home-based arm. This is the green region (<bold>b</bold>) plus the blue region (<bold>a</bold>). 4. The FACT-F Fatigue score is non-inferior in the home-based arm. This is the green region (<bold>b</bold>) plus the gold region (<bold>d</bold>). If either probability in (3) or (4) is above 97.5%, then we will declare non-inferiority of the home-based intervention.</p></caption><graphic xlink:href="12885_2018_4937_Fig3_HTML" id="MO3"/></fig></p>
                  <p id="Par94">Since this is a non-inferiority trial, the primary analysis will be per protocol, which in the presence of non-adherence to exercise is more conservative than intention-to-treat (i.e., less likely to conclude groups are similar when they are not). Two secondary analyses of the primary outcomes will be conducted. First, we will make the above between-group comparison of the changes in FACT-F and 6MWT scores from baseline to each follow-up time point. Secondly, we will perform an intention-to-treat analysis, including outcomes on subjects who were non-adherent to their exercise program. We will also conduct within-group analyses of change over time for the co-primary outcomes to understand the effects of each exercise modality on these outcomes and to facilitate comparisons with published studies.</p>
                </sec>
                <sec id="Sec23">
                  <title>Secondary outcomes</title>
                  <p id="Par95">Analyses for each of our secondary outcomes (QOL, fitness, biological, and body composition) will use mixed effects models for data at all time points incorporating within-person correlation. Within-person correlation of residuals will be handled by an autoregressive (AR1) error structure and factors will also be added for the 2 stratification variables (centre, ADT duration). All of these secondary outcomes will be analyzed as continuous variables after examining distributions to ensure symmetrical (approximately normal) distributions. Skewed data will be transformed as appropriate.</p>
                </sec>
                <sec id="Sec24">
                  <title>Post-intervention period outcomes</title>
                  <p id="Par96">Using similar mixed effects models, we will estimate changes over time and differences between exercise delivery groups in FACT-F and 6MWT during the 6-month post-intervention period, covering 3 assessment points (end of intervention, 3 months post-intervention, and 6 months post-intervention).</p>
                  <p id="Par97">To give a quantitative overview of changes between and within groups over the entire 12 months, all study outcomes will be assessed using these same types of linear mixed effects models. By examination of estimated model parameters and their 95% confidence intervals, we can assess whether changes over time are similar between groups and whether differences between groups at any given time are clinically important.</p>
                </sec>
                <sec id="Sec25">
                  <title>Adherence</title>
                  <p id="Par98">Several analyses will be used to assess adherence to the exercise programs and the relationship of adherence to both time and potential predictors. Adherence will be defined as a binary variable for the primary analysis, which uses accelerometry to measure MVPA. We will assess adherence over 4 distinct periods: 0–3 months, 3–6 months, 6–9 months and 9–12 months, so that each subject has up to 4 observation periods for adherence-based analyses. Our first analysis of adherence will simply be the calculation of percentages adhering in each group in each of the 4 time windows. Chi-squared or Fisher’s exact tests will compare adherence across groups within each of the time windows. All further analyses will be done on the sequence of 4 adherence measures on each subject using a generalized estimating equation (GEE) logistic regression model with an AR1 correlation structure.</p>
                  <p id="Par99">Predictors of adherence will be examined at the exosystem, mesosystem, and microsystem levels using specific questionnaires as detailed earlier. These will be considered for inclusion in models examining each of the adherence variables separately. Mediation/moderation analyses will be explored based on the primary findings.</p>
                </sec>
                <sec id="Sec26">
                  <title>Cost-effectiveness</title>
                  <p id="Par100">We will conduct a within-trial cost utility analysis using standard methods, focusing on interventions directly evaluated in the trial from both payer and societal perspectives. We will adopt two time horizons: the trial (12 months) and the lifetime of the trial cohort. Outcomes will be reported as quality-adjusted life years (QALYs) and cumulative costs, in undiscounted 2017 Canadian dollars.</p>
                </sec>
                <sec id="Sec27">
                  <title>Costs</title>
                  <p id="Par101">We will estimate costs for all health care use in both arms, including:<list list-type="simple"><list-item><label>i).</label><p id="Par102">hospitalizations/medical events;</p></list-item><list-item><label>ii).</label><p id="Par103">physician/other health professional services including outpatient diagnostic tests;</p></list-item><list-item><label>iii).</label><p id="Par104">drugs, including drug costs unrelated to ADT;</p></list-item><list-item><label>iv).</label><p id="Par105">equipment costs;</p></list-item><list-item><label>v).</label><p id="Par106">community services and home care;</p></list-item><list-item><label>vi).</label><p id="Par107">productivity costs;</p></list-item><list-item><label>vii).</label><p id="Par108"> exercise-specific costs;</p></list-item><list-item><label>viii).</label><p id="Par109"> out-of-pocket costs.</p></list-item></list></p>
                  <p id="Par110">The intervention will be costed by estimating the value of time of those administering the intervention, facility-use costs, and device/ equipment costs, amortized over an appropriate period. Resource utilization, out-of-pocket costs, and productivity costs will be estimated using a patient cost diary. We will assess economically relevant health status using the EQ-5D-5 L at each time point [<xref ref-type="bibr" rid="CR153">153</xref>, <xref ref-type="bibr" rid="CR154">154</xref>]. Valuation will be conducted using province-specific estimates when possible (e.g. schedule of physician benefits, cost per weighted case) and standard methods (e.g. provincial schedule of benefits, resource intensity weights and average cost per weighted case) [<xref ref-type="bibr" rid="CR170">170</xref>–<xref ref-type="bibr" rid="CR172">172</xref>]. Productivity losses will be valued both by the human capital (with adjustment for labour force participation) and friction cost methods [<xref ref-type="bibr" rid="CR173">173</xref>].</p>
                </sec>
                <sec id="Sec28">
                  <title>Outcomes</title>
                  <p id="Par111">Quality-adjusted life years (QALYs) will be estimated based on patients’ responses to the EQ-5D-5 L questionnaire [<xref ref-type="bibr" rid="CR174">174</xref>] collected at each assessment. The EQ-5D-5 L provides a description of a patient’s health state, to which a utility score derived from a set of preference weights measured in a representative sample of the Canadian population can be applied. The EQ-5D-5 L weighted utility scores at each time-point will be used to estimate QALYs following standard procedures [<xref ref-type="bibr" rid="CR175">175</xref>–<xref ref-type="bibr" rid="CR177">177</xref>].</p>
                </sec>
                <sec id="Sec29">
                  <title>Analysis</title>
                  <p id="Par112">Cumulative costs and QALYs for each trial arm will be estimated and compared in order to calculate the incremental cost utility ratio, and incremental Net Health Benefit. Censoring for both outcomes will be handled through inverse probability weighting [<xref ref-type="bibr" rid="CR178">178</xref>, <xref ref-type="bibr" rid="CR179">179</xref>].</p>
                  <p id="Par113">We will evaluate uncertainty and estimate confidence intervals around the estimates, using both deterministic and probabilistic methods. We will account for correlation between costs and health outcomes using appropriate bivariate methods. Cost-effectiveness acceptability curves (CEACs) will be used to graphically represent the probability that the intervention would be cost-effective for thresholds of $20,000, $50,000, and $100,000 per QALY gained (multiple thresholds for sensitivity analyses). Reporting will follow the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement [<xref ref-type="bibr" rid="CR180">180</xref>].</p>
                </sec>
              </sec>
            </sec>
            <sec id="Sec30">
              <title>Discussion</title>
              <p id="Par114">PC is the most common cancer in men. ADT is widely used to treat men with PC. It prolongs survival and slows disease progression but at the cost of numerous adverse effects. Exercise has been shown to mitigate and reverse many ADT-associated adverse effects, yet it is not widely available or implemented. To date, no study has examined which delivery model of exercise is most effective at producing these results or which are sustainable in the longer term, nor have studies examined the costs of these delivery approaches. These gaps in translational research must be addressed before exercise can be integrated into standard care for this population. The proposed multi-centre phase III trial aims to definitively answer these 3 questions (efficacy, long-term adherence, cost-effectiveness). Thus, this trial has tremendous empirical and practical relevance for men receiving ADT, and its findings should provide clear data on the value of implementing exercise programs for men on ADT. Additionally, our findings on psychological predictors of adherence will serve as the basis for future theory-based intervention studies designed to enhance long-term adherence to exercise. As such, the findings from the proposed study will serve as a foundation in the evidence-based clinical integration of exercise in this population.</p>
              <p id="Par115">As detailed elsewhere [<xref ref-type="bibr" rid="CR113">113</xref>] (manuscript submitted), the current protocol is similar to our prior phase II trial in many ways, but with four key differences as informed by the results of the phase II trial [<xref ref-type="bibr" rid="CR101">101</xref>]. First, the 1:1 supervised exercise arm has been eliminated. Second, all participants in the home-based arm will receive Fitbits to provide real-time, practical feedback on step counts as an easy to understand summary of physical activity performed. Fitbits were not provided in the phase II trial. Third, health coaches will meet once monthly in person with each participant in the home-based arm. In the prior trial, there was no in-person meeting. Fourth, to reduce participant burden in terms of outcome measures, and to incorporate emerging data on neighborhood walkability measures, our outcomes were streamlined with the Neighborhood Walkability Scale being substituted by postal code capture to facilite neighborhood walkability analysis, substitution of the PNSF for Relatedness to Others in Physical Activity Scale (ROPAS), and administration of the HCCQ at baseline only. These modifications should ensure the trial incorporates current evidence from published studies and our own phase II RCT, and positions it to provide invaluable data addressing the value of different exercise delivery models, determine the cost-effectiveness of exercise among men on ADT, as well as generate important insights into long-term adherence and predictors of adherence.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Additional files</title>
              <sec id="Sec31">
                <p>
                  <supplementary-material content-type="local-data" id="MOESM1">
                    <media xlink:href="12885_2018_4937_MOESM1_ESM.doc">
                      <label>Additional file 1:</label>
                      <caption>
                        <p>CIHR ADT Ex RCT Protocol Paper SPIRIT Figure. Figure of study timelines (DOC 54 kb)</p>
                      </caption>
                    </media>
                  </supplementary-material>
                  <supplementary-material content-type="local-data" id="MOESM2">
                    <media xlink:href="12885_2018_4937_MOESM2_ESM.docx">
                      <label>Additional file 2:</label>
                      <caption>
                        <p><bold>Table S1.</bold> Study Participant Inclusion and Exclusion Criteria. Table describing study participant inclusion and exclusion criteria (DOCX 16 kb)</p>
                      </caption>
                    </media>
                  </supplementary-material>
                  <supplementary-material content-type="local-data" id="MOESM3">
                    <media xlink:href="12885_2018_4937_MOESM3_ESM.docx">
                      <label>Additional file 3:</label>
                      <caption>
                        <p><bold>Table S2.</bold> Elements of Health Coaching (adapted from Spring et al.). Table describing elements of health coaching. (DOCX 20 kb)</p>
                      </caption>
                    </media>
                  </supplementary-material>
                  <supplementary-material content-type="local-data" id="MOESM4">
                    <media xlink:href="12885_2018_4937_MOESM4_ESM.pdf">
                      <label>Additional file 4:</label>
                      <caption>
                        <p>CIHR ADT Ex RCT Protocol Paper Supplemental Methods. Sample size for 2-arm non-inferiority study with dual primary outcome. Methods used to determine trial sample size. (PDF 137 kb)</p>
                      </caption>
                    </media>
                  </supplementary-material>
                </p>
              </sec>
            </sec>
          </body>
          <back>
            <glossary>
              <title>Abbreviations</title>
              <def-list>
                <def-item>
                  <term>6MWT</term>
                  <def>
                    <p id="Par5">Six-minute walk test</p>
                  </def>
                </def-item>
                <def-item>
                  <term>ADT</term>
                  <def>
                    <p id="Par6">Androgen Deprivation Therapy</p>
                  </def>
                </def-item>
                <def-item>
                  <term>AED</term>
                  <def>
                    <p id="Par7">Automated external defibrillator</p>
                  </def>
                </def-item>
                <def-item>
                  <term>BIA</term>
                  <def>
                    <p id="Par8">Bioelectrical impedance analysis</p>
                  </def>
                </def-item>
                <def-item>
                  <term>BMD</term>
                  <def>
                    <p id="Par9">Bone mineral density</p>
                  </def>
                </def-item>
                <def-item>
                  <term>BP</term>
                  <def>
                    <p id="Par10">Blood Pressure</p>
                  </def>
                </def-item>
                <def-item>
                  <term>BREQ-2</term>
                  <def>
                    <p id="Par11">Behavioral Regulations in Exercise Questionnaire – 2</p>
                  </def>
                </def-item>
                <def-item>
                  <term>CEP</term>
                  <def>
                    <p id="Par12">Certified Exercise Physiologist</p>
                  </def>
                </def-item>
                <def-item>
                  <term>CHEERS</term>
                  <def>
                    <p id="Par13">Consolidated Health Economic Evaluation Reporting Standards</p>
                  </def>
                </def-item>
                <def-item>
                  <term>CPR</term>
                  <def>
                    <p id="Par14">Cardiopulmonary resuscitation</p>
                  </def>
                </def-item>
                <def-item>
                  <term>CSEP</term>
                  <def>
                    <p id="Par15">Canadian Society for Exercise Physiology</p>
                  </def>
                </def-item>
                <def-item>
                  <term>CSEP-PATH</term>
                  <def>
                    <p id="Par16">Canadian Society for Exercise Physiology – Physical Activity Training for Health</p>
                  </def>
                </def-item>
                <def-item>
                  <term>CTCAE</term>
                  <def>
                    <p id="Par17">Common Terminology Criteria for Adverse Events</p>
                  </def>
                </def-item>
                <def-item>
                  <term>DXA</term>
                  <def>
                    <p id="Par18">dual x-ray absorptiometry</p>
                  </def>
                </def-item>
                <def-item>
                  <term>EQ-5D</term>
                  <def>
                    <p id="Par19">EuroQol 5 dimensions of health scale;</p>
                  </def>
                </def-item>
                <def-item>
                  <term>FACT-F</term>
                  <def>
                    <p id="Par20">Functional Assessment of Cancer Therapy - Fatigue</p>
                  </def>
                </def-item>
                <def-item>
                  <term>FACT-G</term>
                  <def>
                    <p id="Par21">Functional Assessment of Cancer Therapy - General</p>
                  </def>
                </def-item>
                <def-item>
                  <term>FACT-P</term>
                  <def>
                    <p id="Par22">Functional Assessment of Cancer Therapy - Prostate</p>
                  </def>
                </def-item>
                <def-item>
                  <term>FITT</term>
                  <def>
                    <p id="Par23">Frequency, Intensity, Time, Type</p>
                  </def>
                </def-item>
                <def-item>
                  <term>GEE</term>
                  <def>
                    <p id="Par24">Generalized estimating equation</p>
                  </def>
                </def-item>
                <def-item>
                  <term>GLTEQ</term>
                  <def>
                    <p id="Par25">Godin Leisure Time Exercise Questionnaire</p>
                  </def>
                </def-item>
                <def-item>
                  <term>HbA1c</term>
                  <def>
                    <p id="Par26">Glycosylated hemoglobin</p>
                  </def>
                </def-item>
                <def-item>
                  <term>HCCQ</term>
                  <def>
                    <p id="Par27">Health Care Climate Questionnaire</p>
                  </def>
                </def-item>
                <def-item>
                  <term>HR</term>
                  <def>
                    <p id="Par28">Heart Rate</p>
                  </def>
                </def-item>
                <def-item>
                  <term>HRreserve</term>
                  <def>
                    <p id="Par29">Heart rate reserve</p>
                  </def>
                </def-item>
                <def-item>
                  <term>MVPA</term>
                  <def>
                    <p id="Par30">Moderate to Vigorous Physical Activity</p>
                  </def>
                </def-item>
                <def-item>
                  <term>PAB</term>
                  <def>
                    <p id="Par31">Planning, Attitudes, &amp; Behaviour questionnaire</p>
                  </def>
                </def-item>
                <def-item>
                  <term>PC</term>
                  <def>
                    <p id="Par32">Prostate Cancer</p>
                  </def>
                </def-item>
                <def-item>
                  <term>PM</term>
                  <def>
                    <p id="Par33">Princess Margaret Cancer Centre</p>
                  </def>
                </def-item>
                <def-item>
                  <term>PNSF</term>
                  <def>
                    <p id="Par34">Psychological Need Support and Frustration Scale – Relatedness Items</p>
                  </def>
                </def-item>
                <def-item>
                  <term>PSA</term>
                  <def>
                    <p id="Par35">Prostate-specific antigen</p>
                  </def>
                </def-item>
                <def-item>
                  <term>QALY</term>
                  <def>
                    <p id="Par36">Quality-adjusted life years</p>
                  </def>
                </def-item>
                <def-item>
                  <term>QOL</term>
                  <def>
                    <p id="Par37">Quality of Life</p>
                  </def>
                </def-item>
                <def-item>
                  <term>RC</term>
                  <def>
                    <p id="Par38">Research Coordinator</p>
                  </def>
                </def-item>
                <def-item>
                  <term>RCT</term>
                  <def>
                    <p id="Par39">Randomized Controlled Trial</p>
                  </def>
                </def-item>
                <def-item>
                  <term>RKin</term>
                  <def>
                    <p id="Par40">Registered Kinesiologist</p>
                  </def>
                </def-item>
                <def-item>
                  <term>RPE</term>
                  <def>
                    <p id="Par41">Rated perceived exertion</p>
                  </def>
                </def-item>
                <def-item>
                  <term>SRH</term>
                  <def>
                    <p id="Par42">Scarborough and Rouge Hospital – Centenary site</p>
                  </def>
                </def-item>
                <def-item>
                  <term>SRHC</term>
                  <def>
                    <p id="Par43">Southlake Regional Health Centre</p>
                  </def>
                </def-item>
                <def-item>
                  <term>TBCC</term>
                  <def>
                    <p id="Par44">Tom Baker Cancer Centre</p>
                  </def>
                </def-item>
                <def-item>
                  <term>WC</term>
                  <def>
                    <p id="Par45">Waist circumference</p>
                  </def>
                </def-item>
              </def-list>
            </glossary>
            <ack>
              <title>Acknowledgements</title>
              <p>Dr. James Chiarotto is the site lead for the SRH site. The authors would like to thank the Canadian Institutes of Health Research for graciously sponsoring the trial.</p>
              <sec id="FPar9">
                <title>Funding</title>
                <p id="Par116">This trial is sponsored by the Canadian Institutes of Health Research (CIHR).</p>
                <p id="Par117">CIHR has no direct role in the design, conduct, or analysis of the trial.</p>
              </sec>
              <sec id="FPar10">
                <title>Availability of data and materials</title>
                <p id="Par118">Not applicable.</p>
              </sec>
            </ack>
            <notes notes-type="author-contribution">
              <title>Authors’ contributions</title>
              <p>SMHA, DSM, PR, CS, MK, GT, AM, HL, PW, and SNCR contributed to the study design and protocol. SD assisted with further study protocol refinement. SMHA, SNCR, and PR, are study-site leads at their respective institutions. SD and MO implement and oversee the protocol and data collection. All authors contributed to the writing and approval of the final manuscript.</p>
            </notes>
            <notes notes-type="COI-statement">
              <sec id="FPar11">
                <title>Ethics approval and consent to participate</title>
                <p>This trial has been approved by the Research Ethics Board of University Health Network, University of Calgary, Southlake Regional Health Centre, and Scarborough and Rouge Hospital. Written informed consent will be obtained for each participant upon enrollment.</p>
              </sec>
              <sec id="FPar12">
                <title>Consent for publication</title>
                <p>Not applicable.</p>
              </sec>
              <sec id="FPar13">
                <title>Competing interests</title>
                <p>The authors declare that they have no competing interests.</p>
              </sec>
              <sec id="FPar14">
                <title>Publisher’s Note</title>
                <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
              </sec>
            </notes>
            <ref-list id="Bib1">
              <title>References</title>
              <ref id="CR1">
                <label>1.</label>
                <mixed-citation publication-type="other">Canadian Cancer Society’s Steering Committee on Cancer Statistics. Canadian Cancer Statistics 2012. Toronto, ON: Canadian Cancer Society; 2012.</mixed-citation>
              </ref>
              <ref id="CR2">
                <label>2.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Siegel</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Naishadham</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Jemal</surname>
                      <given-names>A</given-names>
                    </name>
                  </person-group>
                  <article-title>Cancer statistics, 2012</article-title>
                  <source>CA Cancer J Clin</source>
                  <year>2012</year>
                  <volume>62</volume>
                  <issue>1</issue>
                  <fpage>10</fpage>
                  <lpage>29</lpage>
                  <pub-id pub-id-type="doi">10.3322/caac.20138</pub-id>
                  <?supplied-pmid 22237781?>
                  <pub-id pub-id-type="pmid">22237781</pub-id>
                </element-citation>
              </ref>
              <ref id="CR3">
                <label>3.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Huggins</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Hodges</surname>
                      <given-names>CV</given-names>
                    </name>
                  </person-group>
                  <article-title>Studies on prostate cancer, I: the effect of castration and estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate</article-title>
                  <source>Cancer Res</source>
                  <year>1941</year>
                  <volume>1</volume>
                  <issue>4</issue>
                  <fpage>293</fpage>
                  <lpage>297</lpage>
                </element-citation>
              </ref>
              <ref id="CR4">
                <label>4.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Meng</surname>
                      <given-names>MV</given-names>
                    </name>
                    <name>
                      <surname>Grossfeld</surname>
                      <given-names>GD</given-names>
                    </name>
                    <name>
                      <surname>Sadetsky</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Mehta</surname>
                      <given-names>SS</given-names>
                    </name>
                    <name>
                      <surname>Lubeck</surname>
                      <given-names>DP</given-names>
                    </name>
                    <name>
                      <surname>Carroll</surname>
                      <given-names>PR</given-names>
                    </name>
                  </person-group>
                  <article-title>Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer</article-title>
                  <source>Urology</source>
                  <year>2002</year>
                  <volume>60</volume>
                  <issue>3 Suppl 1</issue>
                  <fpage>7</fpage>
                  <lpage>11</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0090-4295(02)01560-1</pub-id>
                  <?supplied-pmid 12231037?>
                  <pub-id pub-id-type="pmid">12231037</pub-id>
                </element-citation>
              </ref>
              <ref id="CR5">
                <label>5.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cooperberg</surname>
                      <given-names>MR</given-names>
                    </name>
                    <name>
                      <surname>Grossfeld</surname>
                      <given-names>GD</given-names>
                    </name>
                    <name>
                      <surname>Lubeck</surname>
                      <given-names>DP</given-names>
                    </name>
                    <name>
                      <surname>Carroll</surname>
                      <given-names>PR</given-names>
                    </name>
                  </person-group>
                  <article-title>National practice patterns and time trends in androgen ablation for localized prostate cancer</article-title>
                  <source>J Natl Cancer Inst</source>
                  <year>2003</year>
                  <volume>95</volume>
                  <issue>13</issue>
                  <fpage>981</fpage>
                  <lpage>989</lpage>
                  <pub-id pub-id-type="doi">10.1093/jnci/95.13.981</pub-id>
                  <?supplied-pmid 12837834?>
                  <pub-id pub-id-type="pmid">12837834</pub-id>
                </element-citation>
              </ref>
              <ref id="CR6">
                <label>6.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Shahinian</surname>
                      <given-names>VB</given-names>
                    </name>
                    <name>
                      <surname>Kuo</surname>
                      <given-names>YF</given-names>
                    </name>
                    <name>
                      <surname>Freeman</surname>
                      <given-names>JL</given-names>
                    </name>
                    <name>
                      <surname>Orihuela</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Goodwin</surname>
                      <given-names>JS</given-names>
                    </name>
                  </person-group>
                  <article-title>Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma</article-title>
                  <source>Cancer</source>
                  <year>2005</year>
                  <volume>103</volume>
                  <issue>8</issue>
                  <fpage>1615</fpage>
                  <lpage>1624</lpage>
                  <pub-id pub-id-type="doi">10.1002/cncr.20955</pub-id>
                  <?supplied-pmid 15742331?>
                  <pub-id pub-id-type="pmid">15742331</pub-id>
                </element-citation>
              </ref>
              <ref id="CR7">
                <label>7.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bolla</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Collette</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Blank</surname>
                      <given-names>L</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial</article-title>
                  <source>Lancet</source>
                  <year>2002</year>
                  <volume>360</volume>
                  <issue>9327</issue>
                  <fpage>103</fpage>
                  <lpage>106</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0140-6736(02)09408-4</pub-id>
                  <?supplied-pmid 12126818?>
                  <pub-id pub-id-type="pmid">12126818</pub-id>
                </element-citation>
              </ref>
              <ref id="CR8">
                <label>8.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Isbarn</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Boccon-Gibod</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Carroll</surname>
                      <given-names>PR</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Androgen deprivation therapy for the treatment of prostate Cancer: consider both benefits and risks</article-title>
                  <source>Eur Urol</source>
                  <year>2009</year>
                  <volume>55</volume>
                  <issue>1</issue>
                  <fpage>62</fpage>
                  <lpage>75</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.eururo.2008.10.008</pub-id>
                  <?supplied-pmid 18945543?>
                  <pub-id pub-id-type="pmid">18945543</pub-id>
                </element-citation>
              </ref>
              <ref id="CR9">
                <label>9.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Loblaw</surname>
                      <given-names>DA</given-names>
                    </name>
                    <name>
                      <surname>Virgo</surname>
                      <given-names>KS</given-names>
                    </name>
                    <name>
                      <surname>Nam</surname>
                      <given-names>R</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline</article-title>
                  <source>J Clin Oncol</source>
                  <year>2007</year>
                  <volume>25</volume>
                  <issue>12</issue>
                  <fpage>1596</fpage>
                  <lpage>1605</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.2006.10.1949</pub-id>
                  <?supplied-pmid 17404365?>
                  <pub-id pub-id-type="pmid">17404365</pub-id>
                </element-citation>
              </ref>
              <ref id="CR10">
                <label>10.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sharifi</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Gulley</surname>
                      <given-names>JL</given-names>
                    </name>
                    <name>
                      <surname>Dahut</surname>
                      <given-names>WL</given-names>
                    </name>
                  </person-group>
                  <article-title>Androgen deprivation therapy for prostate cancer</article-title>
                  <source>JAMA</source>
                  <year>2005</year>
                  <volume>294</volume>
                  <issue>2</issue>
                  <fpage>238</fpage>
                  <lpage>244</lpage>
                  <pub-id pub-id-type="doi">10.1001/jama.294.2.238</pub-id>
                  <pub-id pub-id-type="pmid">16014598</pub-id>
                </element-citation>
              </ref>
              <ref id="CR11">
                <label>11.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Alibhai</surname>
                      <given-names>SM</given-names>
                    </name>
                    <name>
                      <surname>Gogov</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Allibhai</surname>
                      <given-names>Z</given-names>
                    </name>
                  </person-group>
                  <article-title>Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review</article-title>
                  <source>Crit Rev Oncol Hematol</source>
                  <year>2006</year>
                  <volume>60</volume>
                  <issue>3</issue>
                  <fpage>201</fpage>
                  <lpage>215</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.critrevonc.2006.06.006</pub-id>
                  <?supplied-pmid 16860998?>
                  <pub-id pub-id-type="pmid">16860998</pub-id>
                </element-citation>
              </ref>
              <ref id="CR12">
                <label>12.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Alibhai</surname>
                      <given-names>SMH</given-names>
                    </name>
                    <name>
                      <surname>Breunis</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Timilshina</surname>
                      <given-names>N</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Impact of androgen-deprivation therapy on physical function and quality of life in men with non-metastatic prostate cancer</article-title>
                  <source>J Clin Oncol</source>
                  <year>2010</year>
                  <volume>28</volume>
                  <issue>34</issue>
                  <fpage>5038</fpage>
                  <lpage>5045</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.2010.29.8091</pub-id>
                  <?supplied-pmid 21041715?>
                  <pub-id pub-id-type="pmid">21041715</pub-id>
                </element-citation>
              </ref>
              <ref id="CR13">
                <label>13.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Alibhai</surname>
                      <given-names>SM</given-names>
                    </name>
                    <name>
                      <surname>Duong-Hua</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Sutradhar</surname>
                      <given-names>R</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Impact of androgen deprivation therapy on cardiovascular disease and diabetes</article-title>
                  <source>J Clin Oncol</source>
                  <year>2009</year>
                  <volume>27</volume>
                  <issue>21</issue>
                  <fpage>3452</fpage>
                  <lpage>3458</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.2008.20.0923</pub-id>
                  <?supplied-pmid 19506162?>
                  <pub-id pub-id-type="pmid">19506162</pub-id>
                </element-citation>
              </ref>
              <ref id="CR14">
                <label>14.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Fossa</surname>
                      <given-names>SD</given-names>
                    </name>
                    <name>
                      <surname>Woehre</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Kurth</surname>
                      <given-names>K-H</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Influence of urological morbidity on quality of life in patients with prostate cancer</article-title>
                  <source>Eur Urol</source>
                  <year>1997</year>
                  <volume>31</volume>
                  <issue>Suppl 3</issue>
                  <fpage>3</fpage>
                  <lpage>8</lpage>
                  <pub-id pub-id-type="doi">10.1159/000474553</pub-id>
                  <?supplied-pmid 9101208?>
                  <pub-id pub-id-type="pmid">9101208</pub-id>
                </element-citation>
              </ref>
              <ref id="CR15">
                <label>15.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Smith</surname>
                      <given-names>DS</given-names>
                    </name>
                    <name>
                      <surname>Carvalhal</surname>
                      <given-names>GF</given-names>
                    </name>
                    <name>
                      <surname>Schneider</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Krygiel</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Yan</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Catalona</surname>
                      <given-names>WJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Quality-of-life outcomes for men with prostate carcinoma detected by screening</article-title>
                  <source>Cancer</source>
                  <year>2000</year>
                  <volume>88</volume>
                  <issue>6</issue>
                  <fpage>1454</fpage>
                  <lpage>1463</lpage>
                  <pub-id pub-id-type="doi">10.1002/(SICI)1097-0142(20000315)88:6&lt;1454::AID-CNCR25&gt;3.0.CO;2-S</pub-id>
                  <?supplied-pmid 10717630?>
                  <pub-id pub-id-type="pmid">10717630</pub-id>
                </element-citation>
              </ref>
              <ref id="CR16">
                <label>16.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Potosky</surname>
                      <given-names>AL</given-names>
                    </name>
                    <name>
                      <surname>Reeve</surname>
                      <given-names>BB</given-names>
                    </name>
                    <name>
                      <surname>Clegg</surname>
                      <given-names>LX</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy</article-title>
                  <source>J Natl Cancer Inst</source>
                  <year>2002</year>
                  <volume>94</volume>
                  <issue>6</issue>
                  <fpage>430</fpage>
                  <lpage>437</lpage>
                  <pub-id pub-id-type="doi">10.1093/jnci/94.6.430</pub-id>
                  <?supplied-pmid 11904315?>
                  <pub-id pub-id-type="pmid">11904315</pub-id>
                </element-citation>
              </ref>
              <ref id="CR17">
                <label>17.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wei</surname>
                      <given-names>JT</given-names>
                    </name>
                    <name>
                      <surname>Dunn</surname>
                      <given-names>RL</given-names>
                    </name>
                    <name>
                      <surname>Sandler</surname>
                      <given-names>HM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer</article-title>
                  <source>J Clin Oncol</source>
                  <year>2002</year>
                  <volume>20</volume>
                  <issue>2</issue>
                  <fpage>557</fpage>
                  <lpage>566</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.2002.20.2.557</pub-id>
                  <?supplied-pmid 11786586?>
                  <pub-id pub-id-type="pmid">11786586</pub-id>
                </element-citation>
              </ref>
              <ref id="CR18">
                <label>18.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Fowler</surname>
                      <given-names>FJ</given-names>
                      <suffix>Jr</suffix>
                    </name>
                    <name>
                      <surname>McNaughton Collins</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Walker Corkery</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Elliott</surname>
                      <given-names>DB</given-names>
                    </name>
                    <name>
                      <surname>Barry</surname>
                      <given-names>MJ</given-names>
                    </name>
                  </person-group>
                  <article-title>The impact of androgen deprivation on quality of life after radical prostatectomy for prostate carcinoma</article-title>
                  <source>Cancer</source>
                  <year>2002</year>
                  <volume>95</volume>
                  <issue>2</issue>
                  <fpage>287</fpage>
                  <lpage>295</lpage>
                  <pub-id pub-id-type="doi">10.1002/cncr.10656</pub-id>
                  <?supplied-pmid 12124828?>
                  <pub-id pub-id-type="pmid">12124828</pub-id>
                </element-citation>
              </ref>
              <ref id="CR19">
                <label>19.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lubeck</surname>
                      <given-names>DP</given-names>
                    </name>
                    <name>
                      <surname>Litwin</surname>
                      <given-names>MS</given-names>
                    </name>
                    <name>
                      <surname>Henning</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Stoddard</surname>
                      <given-names>ML</given-names>
                    </name>
                    <name>
                      <surname>Flanders</surname>
                      <given-names>SC</given-names>
                    </name>
                    <name>
                      <surname>Carroll</surname>
                      <given-names>PR</given-names>
                    </name>
                  </person-group>
                  <article-title>Changes in health-related quality of life in the first year after treatment for prostate cancer: results from CaPSURE</article-title>
                  <source>Urology</source>
                  <year>1999</year>
                  <volume>53</volume>
                  <issue>1</issue>
                  <fpage>180</fpage>
                  <lpage>186</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0090-4295(98)00408-7</pub-id>
                  <?supplied-pmid 9886609?>
                  <pub-id pub-id-type="pmid">9886609</pub-id>
                </element-citation>
              </ref>
              <ref id="CR20">
                <label>20.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Herr</surname>
                      <given-names>HW</given-names>
                    </name>
                    <name>
                      <surname>O'Sullivan</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <article-title>Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy</article-title>
                  <source>J Urol</source>
                  <year>2000</year>
                  <volume>163</volume>
                  <issue>6</issue>
                  <fpage>1743</fpage>
                  <lpage>1746</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0022-5347(05)67533-7</pub-id>
                  <?supplied-pmid 10799173?>
                  <pub-id pub-id-type="pmid">10799173</pub-id>
                </element-citation>
              </ref>
              <ref id="CR21">
                <label>21.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lubeck</surname>
                      <given-names>DP</given-names>
                    </name>
                    <name>
                      <surname>Grossfeld</surname>
                      <given-names>GD</given-names>
                    </name>
                    <name>
                      <surname>Carroll</surname>
                      <given-names>PR</given-names>
                    </name>
                  </person-group>
                  <article-title>The effect of androgen deprivation therapy on health-related quality of life in men with prostate cancer</article-title>
                  <source>Urology</source>
                  <year>2001</year>
                  <volume>58</volume>
                  <issue>2 Suppl 1</issue>
                  <fpage>94</fpage>
                  <lpage>100</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0090-4295(01)01250-X</pub-id>
                  <?supplied-pmid 11502459?>
                  <pub-id pub-id-type="pmid">11502459</pub-id>
                </element-citation>
              </ref>
              <ref id="CR22">
                <label>22.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Green</surname>
                      <given-names>HJ</given-names>
                    </name>
                    <name>
                      <surname>Pakenham</surname>
                      <given-names>KI</given-names>
                    </name>
                    <name>
                      <surname>Headley</surname>
                      <given-names>BC</given-names>
                    </name>
                    <name>
                      <surname>Gardiner</surname>
                      <given-names>RA</given-names>
                    </name>
                  </person-group>
                  <article-title>Coping and health-related quality of life in men with prostate cancer randomly assigned to hormonal medication or close monitoring</article-title>
                  <source>Psychooncology</source>
                  <year>2002</year>
                  <volume>11</volume>
                  <issue>5</issue>
                  <fpage>401</fpage>
                  <lpage>414</lpage>
                  <pub-id pub-id-type="doi">10.1002/pon.599</pub-id>
                  <?supplied-pmid 12228873?>
                  <pub-id pub-id-type="pmid">12228873</pub-id>
                </element-citation>
              </ref>
              <ref id="CR23">
                <label>23.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>van Andel</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Kurth</surname>
                      <given-names>KH</given-names>
                    </name>
                  </person-group>
                  <article-title>The impact of androgen deprivation therapy on health related quality of life in asymptomatic men with lymph node positive prostate cancer</article-title>
                  <source>Eur Urol</source>
                  <year>2003</year>
                  <volume>44</volume>
                  <issue>2</issue>
                  <fpage>209</fpage>
                  <lpage>214</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0302-2838(03)00208-2</pub-id>
                  <?supplied-pmid 12875940?>
                  <pub-id pub-id-type="pmid">12875940</pub-id>
                </element-citation>
              </ref>
              <ref id="CR24">
                <label>24.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Stone</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Hardy</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Huddart</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>A'Hern</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Richards</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <article-title>Fatigue in patients with prostate cancer receiving hormone therapy</article-title>
                  <source>Eur J Cancer</source>
                  <year>2000</year>
                  <volume>36</volume>
                  <issue>9</issue>
                  <fpage>1134</fpage>
                  <lpage>1141</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0959-8049(00)00084-8</pub-id>
                  <?supplied-pmid 10854947?>
                  <pub-id pub-id-type="pmid">10854947</pub-id>
                </element-citation>
              </ref>
              <ref id="CR25">
                <label>25.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Alibhai</surname>
                      <given-names>Shabbir M. H.</given-names>
                    </name>
                    <name>
                      <surname>Breunis</surname>
                      <given-names>Henriette</given-names>
                    </name>
                    <name>
                      <surname>Timilshina</surname>
                      <given-names>Narhari</given-names>
                    </name>
                    <name>
                      <surname>Naglie</surname>
                      <given-names>Gary</given-names>
                    </name>
                    <name>
                      <surname>Tannock</surname>
                      <given-names>Ian</given-names>
                    </name>
                    <name>
                      <surname>Krahn</surname>
                      <given-names>Murray</given-names>
                    </name>
                    <name>
                      <surname>Warde</surname>
                      <given-names>Padraig</given-names>
                    </name>
                    <name>
                      <surname>Fleshner</surname>
                      <given-names>Neil E.</given-names>
                    </name>
                    <name>
                      <surname>Canning</surname>
                      <given-names>Sarah Duff</given-names>
                    </name>
                    <name>
                      <surname>Tomlinson</surname>
                      <given-names>George</given-names>
                    </name>
                  </person-group>
                  <article-title>Long-term impact of androgen-deprivation therapy on physical function and quality of life</article-title>
                  <source>Cancer</source>
                  <year>2015</year>
                  <volume>121</volume>
                  <issue>14</issue>
                  <fpage>2350</fpage>
                  <lpage>2357</lpage>
                  <pub-id pub-id-type="doi">10.1002/cncr.29355</pub-id>
                  <?supplied-pmid 25809861?>
                  <pub-id pub-id-type="pmid">25809861</pub-id>
                </element-citation>
              </ref>
              <ref id="CR26">
                <label>26.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gray</surname>
                      <given-names>RE</given-names>
                    </name>
                    <name>
                      <surname>Wassersug</surname>
                      <given-names>RJ</given-names>
                    </name>
                    <name>
                      <surname>Sinding</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Barbara</surname>
                      <given-names>AM</given-names>
                    </name>
                    <name>
                      <surname>Trosztmer</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Fleshner</surname>
                      <given-names>N</given-names>
                    </name>
                  </person-group>
                  <article-title>The experiences of men receiving androgen deprivation treatment for prostate cancer: a qualitative study</article-title>
                  <source>Can J Urol</source>
                  <year>2005</year>
                  <volume>12</volume>
                  <issue>4</issue>
                  <fpage>2755</fpage>
                  <lpage>2763</lpage>
                  <?supplied-pmid 16197599?>
                  <pub-id pub-id-type="pmid">16197599</pub-id>
                </element-citation>
              </ref>
              <ref id="CR27">
                <label>27.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Zeliadt</surname>
                      <given-names>SB</given-names>
                    </name>
                    <name>
                      <surname>Ramsey</surname>
                      <given-names>SD</given-names>
                    </name>
                    <name>
                      <surname>Penson</surname>
                      <given-names>DF</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Why do men choose one treatment over another?: a review of patient decision making for localized prostate cancer</article-title>
                  <source>Cancer</source>
                  <year>2006</year>
                  <volume>106</volume>
                  <issue>9</issue>
                  <fpage>1865</fpage>
                  <lpage>1874</lpage>
                  <pub-id pub-id-type="doi">10.1002/cncr.21822</pub-id>
                  <?supplied-pmid 16568450?>
                  <pub-id pub-id-type="pmid">16568450</pub-id>
                </element-citation>
              </ref>
              <ref id="CR28">
                <label>28.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Taylor</surname>
                      <given-names>LG</given-names>
                    </name>
                    <name>
                      <surname>Canfield</surname>
                      <given-names>SE</given-names>
                    </name>
                    <name>
                      <surname>Du</surname>
                      <given-names>XL</given-names>
                    </name>
                  </person-group>
                  <article-title>Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer</article-title>
                  <source>Cancer</source>
                  <year>2009</year>
                  <volume>115</volume>
                  <issue>11</issue>
                  <fpage>2388</fpage>
                  <lpage>2399</lpage>
                  <pub-id pub-id-type="doi">10.1002/cncr.24283</pub-id>
                  <?supplied-pmid 19399748?>
                  <pub-id pub-id-type="pmid">19399748</pub-id>
                </element-citation>
              </ref>
              <ref id="CR29">
                <label>29.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Basaria</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Lieb</surname>
                      <given-names>J</given-names>
                      <suffix>2nd</suffix>
                    </name>
                    <name>
                      <surname>Tang</surname>
                      <given-names>AM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Long-term effects of androgen deprivation therapy in prostate cancer patients</article-title>
                  <source>Clin Endocrinol (Oxford)</source>
                  <year>2002</year>
                  <volume>56</volume>
                  <issue>6</issue>
                  <fpage>779</fpage>
                  <lpage>786</lpage>
                  <pub-id pub-id-type="doi">10.1046/j.1365-2265.2002.01551.x</pub-id>
                </element-citation>
              </ref>
              <ref id="CR30">
                <label>30.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Segal</surname>
                      <given-names>RJ</given-names>
                    </name>
                    <name>
                      <surname>Reid</surname>
                      <given-names>RD</given-names>
                    </name>
                    <name>
                      <surname>Courneya</surname>
                      <given-names>KS</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Resistance exercise in men receiving androgen deprivation therapy for prostate cancer</article-title>
                  <source>J Clin Oncol</source>
                  <year>2003</year>
                  <volume>21</volume>
                  <issue>9</issue>
                  <fpage>1653</fpage>
                  <lpage>1659</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.2003.09.534</pub-id>
                  <?supplied-pmid 12721238?>
                  <pub-id pub-id-type="pmid">12721238</pub-id>
                </element-citation>
              </ref>
              <ref id="CR31">
                <label>31.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Potosky</surname>
                      <given-names>AL</given-names>
                    </name>
                    <name>
                      <surname>Knopf</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Clegg</surname>
                      <given-names>LX</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Quality-of-life outcomes after primary androgen deprivation therapy: results from the prostate Cancer outcomes study</article-title>
                  <source>J Clin Oncol</source>
                  <year>2001</year>
                  <volume>19</volume>
                  <issue>17</issue>
                  <fpage>3750</fpage>
                  <lpage>3757</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.2001.19.17.3750</pub-id>
                  <?supplied-pmid 11533098?>
                  <pub-id pub-id-type="pmid">11533098</pub-id>
                </element-citation>
              </ref>
              <ref id="CR32">
                <label>32.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Galvão</surname>
                      <given-names>Daniel A.</given-names>
                    </name>
                    <name>
                      <surname>Spry</surname>
                      <given-names>Nigel A.</given-names>
                    </name>
                    <name>
                      <surname>Taaffe</surname>
                      <given-names>Dennis R.</given-names>
                    </name>
                    <name>
                      <surname>Newton</surname>
                      <given-names>Robert U.</given-names>
                    </name>
                    <name>
                      <surname>Stanley</surname>
                      <given-names>John</given-names>
                    </name>
                    <name>
                      <surname>Shannon</surname>
                      <given-names>Tom</given-names>
                    </name>
                    <name>
                      <surname>Rowling</surname>
                      <given-names>Chris</given-names>
                    </name>
                    <name>
                      <surname>Prince</surname>
                      <given-names>Richard</given-names>
                    </name>
                  </person-group>
                  <article-title>Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer</article-title>
                  <source>BJU International</source>
                  <year>2008</year>
                  <volume>102</volume>
                  <issue>1</issue>
                  <fpage>44</fpage>
                  <lpage>47</lpage>
                  <pub-id pub-id-type="doi">10.1111/j.1464-410X.2008.07539.x</pub-id>
                  <?supplied-pmid 18336606?>
                  <pub-id pub-id-type="pmid">18336606</pub-id>
                </element-citation>
              </ref>
              <ref id="CR33">
                <label>33.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Galvao</surname>
                      <given-names>DA</given-names>
                    </name>
                    <name>
                      <surname>Taaffe</surname>
                      <given-names>DR</given-names>
                    </name>
                    <name>
                      <surname>Spry</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Joseph</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Turner</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Newton</surname>
                      <given-names>RU</given-names>
                    </name>
                  </person-group>
                  <article-title>Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation</article-title>
                  <source>Prostate Cancer Prostatic Dis</source>
                  <year>2009</year>
                  <volume>12</volume>
                  <issue>2</issue>
                  <fpage>198</fpage>
                  <lpage>203</lpage>
                  <pub-id pub-id-type="doi">10.1038/pcan.2008.51</pub-id>
                  <?supplied-pmid 18852703?>
                  <pub-id pub-id-type="pmid">18852703</pub-id>
                </element-citation>
              </ref>
              <ref id="CR34">
                <label>34.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Smith</surname>
                      <given-names>MR</given-names>
                    </name>
                  </person-group>
                  <article-title>Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer</article-title>
                  <source>Urology</source>
                  <year>2004</year>
                  <volume>63</volume>
                  <issue>4</issue>
                  <fpage>742</fpage>
                  <lpage>745</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.urology.2003.10.063</pub-id>
                  <?supplied-pmid 15072892?>
                  <pub-id pub-id-type="pmid">15072892</pub-id>
                </element-citation>
              </ref>
              <ref id="CR35">
                <label>35.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Smith</surname>
                      <given-names>MR</given-names>
                    </name>
                    <name>
                      <surname>Finkelstein</surname>
                      <given-names>JS</given-names>
                    </name>
                    <name>
                      <surname>McGovern</surname>
                      <given-names>FJ</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Changes in body composition during androgen deprivation therapy for prostate cancer</article-title>
                  <source>J Clin Endo Metab</source>
                  <year>2002</year>
                  <volume>87</volume>
                  <issue>2</issue>
                  <fpage>599</fpage>
                  <lpage>603</lpage>
                  <pub-id pub-id-type="doi">10.1210/jcem.87.2.8299</pub-id>
                </element-citation>
              </ref>
              <ref id="CR36">
                <label>36.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Smith</surname>
                      <given-names>MR</given-names>
                    </name>
                    <name>
                      <surname>Saad</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Egerdie</surname>
                      <given-names>B</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Sarcopenia during androgen-deprivation therapy for prostate cancer</article-title>
                  <source>J Clin Oncol</source>
                  <year>2012</year>
                  <volume>30</volume>
                  <issue>26</issue>
                  <fpage>3271</fpage>
                  <lpage>3276</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.2011.38.8850</pub-id>
                  <?supplied-pmid 22649143?>
                  <pub-id pub-id-type="pmid">22649143</pub-id>
                </element-citation>
              </ref>
              <ref id="CR37">
                <label>37.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bylow</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Dale</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Mustian</surname>
                      <given-names>K</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Falls and physical performance deficits in older patients with prostate cancer undergoing androgen deprivation therapy</article-title>
                  <source>Urology</source>
                  <year>2008</year>
                  <volume>72</volume>
                  <issue>2</issue>
                  <fpage>422</fpage>
                  <lpage>427</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.urology.2008.03.032</pub-id>
                  <?supplied-pmid 18561991?>
                  <pub-id pub-id-type="pmid">18561991</pub-id>
                </element-citation>
              </ref>
              <ref id="CR38">
                <label>38.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hussain</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Breunis</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Timilshina</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Alibhai</surname>
                      <given-names>SMH</given-names>
                    </name>
                  </person-group>
                  <article-title>Falls in men on androgen deprivation therapy for prostate cancer</article-title>
                  <source>J Geriatr Oncol</source>
                  <year>2010</year>
                  <volume>1</volume>
                  <issue>1</issue>
                  <fpage>32</fpage>
                  <lpage>39</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.jgo.2010.03.004</pub-id>
                </element-citation>
              </ref>
              <ref id="CR39">
                <label>39.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Body</surname>
                      <given-names>JJ</given-names>
                    </name>
                    <name>
                      <surname>Bergmann</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Boonen</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Management of cancer treatment-induced bone loss in early breast and prostate cancer -- a consensus paper of the Belgian bone Club</article-title>
                  <source>Osteoporos Int</source>
                  <year>2007</year>
                  <volume>18</volume>
                  <issue>11</issue>
                  <fpage>1439</fpage>
                  <lpage>1450</lpage>
                  <pub-id pub-id-type="doi">10.1007/s00198-007-0439-4</pub-id>
                  <?supplied-pmid 17690930?>
                  <pub-id pub-id-type="pmid">17690930</pub-id>
                </element-citation>
              </ref>
              <ref id="CR40">
                <label>40.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Diamond</surname>
                      <given-names>TH</given-names>
                    </name>
                    <name>
                      <surname>Higano</surname>
                      <given-names>CS</given-names>
                    </name>
                    <name>
                      <surname>Smith</surname>
                      <given-names>MR</given-names>
                    </name>
                    <name>
                      <surname>Guise</surname>
                      <given-names>TA</given-names>
                    </name>
                    <name>
                      <surname>Singer</surname>
                      <given-names>FR</given-names>
                    </name>
                  </person-group>
                  <article-title>Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies</article-title>
                  <source>Cancer</source>
                  <year>2004</year>
                  <volume>100</volume>
                  <issue>5</issue>
                  <fpage>892</fpage>
                  <lpage>899</lpage>
                  <pub-id pub-id-type="doi">10.1002/cncr.20056</pub-id>
                  <?supplied-pmid 14983482?>
                  <pub-id pub-id-type="pmid">14983482</pub-id>
                </element-citation>
              </ref>
              <ref id="CR41">
                <label>41.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Greenspan</surname>
                      <given-names>SL</given-names>
                    </name>
                    <name>
                      <surname>Coates</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Sereika</surname>
                      <given-names>SM</given-names>
                    </name>
                    <name>
                      <surname>Nelson</surname>
                      <given-names>JB</given-names>
                    </name>
                    <name>
                      <surname>Trump</surname>
                      <given-names>DL</given-names>
                    </name>
                    <name>
                      <surname>Resnick</surname>
                      <given-names>NM</given-names>
                    </name>
                  </person-group>
                  <article-title>Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer</article-title>
                  <source>J Clin Endo Metab</source>
                  <year>2005</year>
                  <volume>90</volume>
                  <issue>12</issue>
                  <fpage>6410</fpage>
                  <lpage>6417</lpage>
                  <pub-id pub-id-type="doi">10.1210/jc.2005-0183</pub-id>
                </element-citation>
              </ref>
              <ref id="CR42">
                <label>42.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kiratli</surname>
                      <given-names>BJ</given-names>
                    </name>
                    <name>
                      <surname>Srinivas</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Perkash</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Terris</surname>
                      <given-names>MK</given-names>
                    </name>
                  </person-group>
                  <article-title>Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer</article-title>
                  <source>Urology</source>
                  <year>2001</year>
                  <volume>57</volume>
                  <issue>1</issue>
                  <fpage>127</fpage>
                  <lpage>132</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0090-4295(00)00895-5</pub-id>
                  <?supplied-pmid 11164157?>
                  <pub-id pub-id-type="pmid">11164157</pub-id>
                </element-citation>
              </ref>
              <ref id="CR43">
                <label>43.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Krupski</surname>
                      <given-names>TL</given-names>
                    </name>
                    <name>
                      <surname>Smith</surname>
                      <given-names>MR</given-names>
                    </name>
                    <name>
                      <surname>Chan Lee</surname>
                      <given-names>W</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy</article-title>
                  <source>Cancer</source>
                  <year>2004</year>
                  <volume>101</volume>
                  <issue>3</issue>
                  <fpage>541</fpage>
                  <lpage>549</lpage>
                  <pub-id pub-id-type="doi">10.1002/cncr.20388</pub-id>
                  <?supplied-pmid 15274067?>
                  <pub-id pub-id-type="pmid">15274067</pub-id>
                </element-citation>
              </ref>
              <ref id="CR44">
                <label>44.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Morote</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Orsola</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Abascal</surname>
                      <given-names>JM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression</article-title>
                  <source>J Urol</source>
                  <year>2006</year>
                  <volume>175</volume>
                  <issue>5</issue>
                  <fpage>1679</fpage>
                  <lpage>1683</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0022-5347(05)00999-7</pub-id>
                  <?supplied-pmid 16600728?>
                  <pub-id pub-id-type="pmid">16600728</pub-id>
                </element-citation>
              </ref>
              <ref id="CR45">
                <label>45.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Saad</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Adachi</surname>
                      <given-names>JD</given-names>
                    </name>
                    <name>
                      <surname>Brown</surname>
                      <given-names>JP</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Cancer treatment-induced bone loss in breast and prostate cancer</article-title>
                  <source>J Clin Oncol</source>
                  <year>2008</year>
                  <volume>26</volume>
                  <issue>33</issue>
                  <fpage>5465</fpage>
                  <lpage>5476</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.2008.18.4184</pub-id>
                  <?supplied-pmid 18955443?>
                  <pub-id pub-id-type="pmid">18955443</pub-id>
                </element-citation>
              </ref>
              <ref id="CR46">
                <label>46.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wadhwa</surname>
                      <given-names>VK</given-names>
                    </name>
                    <name>
                      <surname>Weston</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Mistry</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Parr</surname>
                      <given-names>NJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values</article-title>
                  <source>BJU Int</source>
                  <year>2009</year>
                  <volume>104</volume>
                  <issue>6</issue>
                  <fpage>800</fpage>
                  <lpage>805</lpage>
                  <pub-id pub-id-type="doi">10.1111/j.1464-410X.2009.08483.x</pub-id>
                  <?supplied-pmid 19338564?>
                  <pub-id pub-id-type="pmid">19338564</pub-id>
                </element-citation>
              </ref>
              <ref id="CR47">
                <label>47.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Shahinian</surname>
                      <given-names>VB</given-names>
                    </name>
                    <name>
                      <surname>Kuo</surname>
                      <given-names>YF</given-names>
                    </name>
                    <name>
                      <surname>Freeman</surname>
                      <given-names>JL</given-names>
                    </name>
                    <name>
                      <surname>Goodwin</surname>
                      <given-names>JS</given-names>
                    </name>
                  </person-group>
                  <article-title>Risk of fracture after androgen deprivation for prostate cancer</article-title>
                  <source>N Engl J Med</source>
                  <year>2005</year>
                  <volume>352</volume>
                  <issue>2</issue>
                  <fpage>154</fpage>
                  <lpage>164</lpage>
                  <pub-id pub-id-type="doi">10.1056/NEJMoa041943</pub-id>
                  <?supplied-pmid 15647578?>
                  <pub-id pub-id-type="pmid">15647578</pub-id>
                </element-citation>
              </ref>
              <ref id="CR48">
                <label>48.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Alibhai</surname>
                      <given-names>SM</given-names>
                    </name>
                    <name>
                      <surname>Duong-Hua</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Cheung</surname>
                      <given-names>AM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Fracture types and risk factors in men with prostate Cancer on androgen deprivation therapy: a matched cohort study of 19,079 men</article-title>
                  <source>J Urol</source>
                  <year>2010</year>
                  <volume>184</volume>
                  <issue>3</issue>
                  <fpage>918</fpage>
                  <lpage>924</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.juro.2010.04.068</pub-id>
                  <?supplied-pmid 20643458?>
                  <pub-id pub-id-type="pmid">20643458</pub-id>
                </element-citation>
              </ref>
              <ref id="CR49">
                <label>49.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lopez</surname>
                      <given-names>AM</given-names>
                    </name>
                    <name>
                      <surname>Pena</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Hernandez</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Val</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Martin</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Riancho</surname>
                      <given-names>JA</given-names>
                    </name>
                  </person-group>
                  <article-title>Fracture risk in patients with prostate cancer on androgen deprivation therapy</article-title>
                  <source>Osteoporos Int</source>
                  <year>2005</year>
                  <volume>16</volume>
                  <issue>6</issue>
                  <fpage>707</fpage>
                  <lpage>711</lpage>
                  <pub-id pub-id-type="doi">10.1007/s00198-004-1799-7</pub-id>
                  <?supplied-pmid 15714259?>
                  <pub-id pub-id-type="pmid">15714259</pub-id>
                </element-citation>
              </ref>
              <ref id="CR50">
                <label>50.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Malcolm</surname>
                      <given-names>JB</given-names>
                    </name>
                    <name>
                      <surname>Derweesh</surname>
                      <given-names>IH</given-names>
                    </name>
                    <name>
                      <surname>Kincade</surname>
                      <given-names>MC</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Osteoporosis and fractures after androgen deprivation initiation for prostate cancer</article-title>
                  <source>Can J Urol</source>
                  <year>2007</year>
                  <volume>14</volume>
                  <issue>3</issue>
                  <fpage>3551</fpage>
                  <lpage>3559</lpage>
                  <?supplied-pmid 17594745?>
                  <pub-id pub-id-type="pmid">17594745</pub-id>
                </element-citation>
              </ref>
              <ref id="CR51">
                <label>51.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Smith</surname>
                      <given-names>MR</given-names>
                    </name>
                    <name>
                      <surname>Malkowicz</surname>
                      <given-names>SB</given-names>
                    </name>
                    <name>
                      <surname>Chu</surname>
                      <given-names>F</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study</article-title>
                  <source>J Clin Oncol</source>
                  <year>2008</year>
                  <volume>26</volume>
                  <issue>11</issue>
                  <fpage>1824</fpage>
                  <lpage>1829</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.2007.13.5517</pub-id>
                  <?supplied-pmid 18398147?>
                  <pub-id pub-id-type="pmid">18398147</pub-id>
                </element-citation>
              </ref>
              <ref id="CR52">
                <label>52.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mohamedali</surname>
                      <given-names>HZ</given-names>
                    </name>
                    <name>
                      <surname>Breunis</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Timilshina</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Alibhai</surname>
                      <given-names>SM</given-names>
                    </name>
                  </person-group>
                  <article-title>Changes in blood glucose and cholesterol levels due to androgen deprivation therapy in men with non-metastatic prostate cancer</article-title>
                  <source>Can Urol Assoc J</source>
                  <year>2011</year>
                  <volume>5</volume>
                  <issue>1</issue>
                  <fpage>28</fpage>
                  <lpage>32</lpage>
                  <pub-id pub-id-type="doi">10.5489/cuaj.556</pub-id>
                  <?supplied-pmid 21470509?>
                  <pub-id pub-id-type="pmid">21470509</pub-id>
                </element-citation>
              </ref>
              <ref id="CR53">
                <label>53.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Smith</surname>
                      <given-names>MR</given-names>
                    </name>
                    <name>
                      <surname>Lee</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Fallon</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Nathan</surname>
                      <given-names>DM</given-names>
                    </name>
                  </person-group>
                  <article-title>Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer</article-title>
                  <source>Urology</source>
                  <year>2008</year>
                  <volume>71</volume>
                  <issue>2</issue>
                  <fpage>318</fpage>
                  <lpage>322</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.urology.2007.08.035</pub-id>
                  <?supplied-pmid 18308111?>
                  <pub-id pub-id-type="pmid">18308111</pub-id>
                </element-citation>
              </ref>
              <ref id="CR54">
                <label>54.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Smith</surname>
                      <given-names>MR</given-names>
                    </name>
                    <name>
                      <surname>Lee</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>McGovern</surname>
                      <given-names>F</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome</article-title>
                  <source>Cancer</source>
                  <year>2008</year>
                  <volume>112</volume>
                  <issue>10</issue>
                  <fpage>2188</fpage>
                  <lpage>2194</lpage>
                  <pub-id pub-id-type="doi">10.1002/cncr.23440</pub-id>
                  <?supplied-pmid 18348297?>
                  <pub-id pub-id-type="pmid">18348297</pub-id>
                </element-citation>
              </ref>
              <ref id="CR55">
                <label>55.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Smith</surname>
                      <given-names>MR</given-names>
                    </name>
                    <name>
                      <surname>Lee</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Nathan</surname>
                      <given-names>DM</given-names>
                    </name>
                  </person-group>
                  <article-title>Insulin sensitivity during combined androgen blockade for prostate cancer</article-title>
                  <source>J Clin Endo Metab</source>
                  <year>2006</year>
                  <volume>91</volume>
                  <issue>4</issue>
                  <fpage>1305</fpage>
                  <lpage>1308</lpage>
                  <pub-id pub-id-type="doi">10.1210/jc.2005-2507</pub-id>
                </element-citation>
              </ref>
              <ref id="CR56">
                <label>56.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Keating</surname>
                      <given-names>NL</given-names>
                    </name>
                    <name>
                      <surname>O'Malley</surname>
                      <given-names>AJ</given-names>
                    </name>
                    <name>
                      <surname>Freedland</surname>
                      <given-names>SJ</given-names>
                    </name>
                    <name>
                      <surname>Smith</surname>
                      <given-names>MR</given-names>
                    </name>
                  </person-group>
                  <article-title>Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer</article-title>
                  <source>J Natl Cancer Inst</source>
                  <year>2010</year>
                  <volume>102</volume>
                  <issue>1</issue>
                  <fpage>39</fpage>
                  <lpage>46</lpage>
                  <pub-id pub-id-type="doi">10.1093/jnci/djp404</pub-id>
                  <?supplied-pmid 19996060?>
                  <pub-id pub-id-type="pmid">19996060</pub-id>
                </element-citation>
              </ref>
              <ref id="CR57">
                <label>57.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Keating</surname>
                      <given-names>NL</given-names>
                    </name>
                    <name>
                      <surname>O'Malley</surname>
                      <given-names>AJ</given-names>
                    </name>
                    <name>
                      <surname>Smith</surname>
                      <given-names>MR</given-names>
                    </name>
                  </person-group>
                  <article-title>Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer</article-title>
                  <source>J Clin Oncol</source>
                  <year>2006</year>
                  <volume>24</volume>
                  <issue>27</issue>
                  <fpage>4448</fpage>
                  <lpage>4456</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.2006.06.2497</pub-id>
                  <?supplied-pmid 16983113?>
                  <pub-id pub-id-type="pmid">16983113</pub-id>
                </element-citation>
              </ref>
              <ref id="CR58">
                <label>58.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lage</surname>
                      <given-names>MJ</given-names>
                    </name>
                    <name>
                      <surname>Barber</surname>
                      <given-names>BL</given-names>
                    </name>
                    <name>
                      <surname>Markus</surname>
                      <given-names>RA</given-names>
                    </name>
                  </person-group>
                  <article-title>Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer</article-title>
                  <source>Urology</source>
                  <year>2007</year>
                  <volume>70</volume>
                  <issue>6</issue>
                  <fpage>1104</fpage>
                  <lpage>1108</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.urology.2007.08.012</pub-id>
                  <?supplied-pmid 18158027?>
                  <pub-id pub-id-type="pmid">18158027</pub-id>
                </element-citation>
              </ref>
              <ref id="CR59">
                <label>59.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>D'Amico</surname>
                      <given-names>AV</given-names>
                    </name>
                    <name>
                      <surname>Denham</surname>
                      <given-names>JW</given-names>
                    </name>
                    <name>
                      <surname>Crook</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions</article-title>
                  <source>J Clin Oncol</source>
                  <year>2007</year>
                  <volume>25</volume>
                  <issue>17</issue>
                  <fpage>2420</fpage>
                  <lpage>2425</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.2006.09.3369</pub-id>
                  <?supplied-pmid 17557956?>
                  <pub-id pub-id-type="pmid">17557956</pub-id>
                </element-citation>
              </ref>
              <ref id="CR60">
                <label>60.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Tsai</surname>
                      <given-names>HK</given-names>
                    </name>
                    <name>
                      <surname>D'Amico</surname>
                      <given-names>AV</given-names>
                    </name>
                    <name>
                      <surname>Sadetsky</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Chen</surname>
                      <given-names>MH</given-names>
                    </name>
                    <name>
                      <surname>Carroll</surname>
                      <given-names>PR</given-names>
                    </name>
                  </person-group>
                  <article-title>Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality</article-title>
                  <source>J Natl Cancer Inst</source>
                  <year>2007</year>
                  <volume>99</volume>
                  <issue>20</issue>
                  <fpage>1516</fpage>
                  <lpage>1524</lpage>
                  <pub-id pub-id-type="doi">10.1093/jnci/djm168</pub-id>
                  <?supplied-pmid 17925537?>
                  <pub-id pub-id-type="pmid">17925537</pub-id>
                </element-citation>
              </ref>
              <ref id="CR61">
                <label>61.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Efstathiou</surname>
                      <given-names>JA</given-names>
                    </name>
                    <name>
                      <surname>Bae</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Shipley</surname>
                      <given-names>WU</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02</article-title>
                  <source>Eur Urol</source>
                  <year>2008</year>
                  <volume>54</volume>
                  <issue>4</issue>
                  <fpage>816</fpage>
                  <lpage>823</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.eururo.2008.01.021</pub-id>
                  <?supplied-pmid 18243498?>
                  <pub-id pub-id-type="pmid">18243498</pub-id>
                </element-citation>
              </ref>
              <ref id="CR62">
                <label>62.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Efstathiou</surname>
                      <given-names>JA</given-names>
                    </name>
                    <name>
                      <surname>Bae</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Shipley</surname>
                      <given-names>WU</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31</article-title>
                  <source>J Clin Oncol</source>
                  <year>2009</year>
                  <volume>27</volume>
                  <issue>1</issue>
                  <fpage>92</fpage>
                  <lpage>99</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.2007.12.3752</pub-id>
                  <?supplied-pmid 19047297?>
                  <pub-id pub-id-type="pmid">19047297</pub-id>
                </element-citation>
              </ref>
              <ref id="CR63">
                <label>63.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Saigal</surname>
                      <given-names>CS</given-names>
                    </name>
                    <name>
                      <surname>Gore</surname>
                      <given-names>JL</given-names>
                    </name>
                    <name>
                      <surname>Krupski</surname>
                      <given-names>TL</given-names>
                    </name>
                    <name>
                      <surname>Hanley</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Schonlau</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Litwin</surname>
                      <given-names>MS</given-names>
                    </name>
                  </person-group>
                  <article-title>Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer</article-title>
                  <source>Cancer</source>
                  <year>2007</year>
                  <volume>110</volume>
                  <issue>7</issue>
                  <fpage>1493</fpage>
                  <lpage>1500</lpage>
                  <pub-id pub-id-type="doi">10.1002/cncr.22933</pub-id>
                  <?supplied-pmid 17657815?>
                  <pub-id pub-id-type="pmid">17657815</pub-id>
                </element-citation>
              </ref>
              <ref id="CR64">
                <label>64.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Alibhai</surname>
                      <given-names>SM</given-names>
                    </name>
                  </person-group>
                  <article-title>Cardiovascular toxicity of androgen deprivation therapy: a new door opens</article-title>
                  <source>J Clin Oncol</source>
                  <year>2011</year>
                  <volume>29</volume>
                  <issue>26</issue>
                  <fpage>3500</fpage>
                  <lpage>3502</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.2011.37.5741</pub-id>
                  <?supplied-pmid 21844507?>
                  <pub-id pub-id-type="pmid">21844507</pub-id>
                </element-citation>
              </ref>
              <ref id="CR65">
                <label>65.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Alibhai</surname>
                      <given-names>SM</given-names>
                    </name>
                    <name>
                      <surname>Mohamedali</surname>
                      <given-names>HZ</given-names>
                    </name>
                  </person-group>
                  <article-title>Cardiac and cognitive effects of androgen deprivation therapy: are they real?</article-title>
                  <source>Curr Oncol</source>
                  <year>2010</year>
                  <volume>17</volume>
                  <issue>Suppl 2</issue>
                  <fpage>S55</fpage>
                  <lpage>S64</lpage>
                  <?supplied-pmid 20882135?>
                  <pub-id pub-id-type="pmid">20882135</pub-id>
                </element-citation>
              </ref>
              <ref id="CR66">
                <label>66.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Windsor</surname>
                      <given-names>PM</given-names>
                    </name>
                    <name>
                      <surname>Nicol</surname>
                      <given-names>KF</given-names>
                    </name>
                    <name>
                      <surname>Potter</surname>
                      <given-names>J</given-names>
                    </name>
                  </person-group>
                  <article-title>A randomized, controlled trial of aerobic exercise for treatment-related fatigue in men receiving radical external beam radiotherapy for localized prostate carcinoma</article-title>
                  <source>Cancer</source>
                  <year>2004</year>
                  <volume>101</volume>
                  <issue>3</issue>
                  <fpage>550</fpage>
                  <lpage>557</lpage>
                  <pub-id pub-id-type="doi">10.1002/cncr.20378</pub-id>
                  <?supplied-pmid 15274068?>
                  <pub-id pub-id-type="pmid">15274068</pub-id>
                </element-citation>
              </ref>
              <ref id="CR67">
                <label>67.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Carmack Taylor</surname>
                      <given-names>CL</given-names>
                    </name>
                    <name>
                      <surname>Demoor</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Smith</surname>
                      <given-names>MA</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Active for life after Cancer: a randomized trial examining a lifestyle physical activity program for prostate cancer patients</article-title>
                  <source>Psychooncology</source>
                  <year>2006</year>
                  <volume>15</volume>
                  <issue>10</issue>
                  <fpage>847</fpage>
                  <lpage>862</lpage>
                  <pub-id pub-id-type="doi">10.1002/pon.1023</pub-id>
                  <?supplied-pmid 16447306?>
                  <pub-id pub-id-type="pmid">16447306</pub-id>
                </element-citation>
              </ref>
              <ref id="CR68">
                <label>68.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Galvao</surname>
                      <given-names>DA</given-names>
                    </name>
                    <name>
                      <surname>Nosaka</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Taaffe</surname>
                      <given-names>DR</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Resistance training and reduction of treatment side effects in prostate cancer patients</article-title>
                  <source>Med Sci Sports Exerc</source>
                  <year>2006</year>
                  <volume>38</volume>
                  <issue>12</issue>
                  <fpage>2045</fpage>
                  <lpage>2052</lpage>
                  <pub-id pub-id-type="doi">10.1249/01.mss.0000233803.48691.8b</pub-id>
                  <?supplied-pmid 17146309?>
                  <pub-id pub-id-type="pmid">17146309</pub-id>
                </element-citation>
              </ref>
              <ref id="CR69">
                <label>69.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Culos-Reed</surname>
                      <given-names>SN</given-names>
                    </name>
                    <name>
                      <surname>Robinson</surname>
                      <given-names>JL</given-names>
                    </name>
                    <name>
                      <surname>Lau</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>O'Connor</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Keats</surname>
                      <given-names>MR</given-names>
                    </name>
                  </person-group>
                  <article-title>Benefits of a physical activity intervention for men with prostate cancer</article-title>
                  <source>J Sport Exerc Psychol</source>
                  <year>2007</year>
                  <volume>29</volume>
                  <issue>1</issue>
                  <fpage>118</fpage>
                  <lpage>127</lpage>
                  <pub-id pub-id-type="doi">10.1123/jsep.29.1.118</pub-id>
                  <?supplied-pmid 17556779?>
                  <pub-id pub-id-type="pmid">17556779</pub-id>
                </element-citation>
              </ref>
              <ref id="CR70">
                <label>70.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Segal</surname>
                      <given-names>RJ</given-names>
                    </name>
                    <name>
                      <surname>Reid</surname>
                      <given-names>RD</given-names>
                    </name>
                    <name>
                      <surname>Courneya</surname>
                      <given-names>KS</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer</article-title>
                  <source>J Clin Oncol</source>
                  <year>2009</year>
                  <volume>27</volume>
                  <issue>3</issue>
                  <fpage>344</fpage>
                  <lpage>351</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.2007.15.4963</pub-id>
                  <?supplied-pmid 19064985?>
                  <pub-id pub-id-type="pmid">19064985</pub-id>
                </element-citation>
              </ref>
              <ref id="CR71">
                <label>71.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hansen</surname>
                      <given-names>PA</given-names>
                    </name>
                    <name>
                      <surname>Dechet</surname>
                      <given-names>CB</given-names>
                    </name>
                    <name>
                      <surname>Porucznik</surname>
                      <given-names>CA</given-names>
                    </name>
                    <name>
                      <surname>LaStayo</surname>
                      <given-names>PC</given-names>
                    </name>
                  </person-group>
                  <article-title>Comparing eccentric resistance exercise in prostate cancer survivors on and off hormone therapy: a pilot study</article-title>
                  <source>Phys Med Rehabil</source>
                  <year>2009</year>
                  <volume>1</volume>
                  <issue>11</issue>
                  <fpage>1019</fpage>
                  <lpage>1024</lpage>
                </element-citation>
              </ref>
              <ref id="CR72">
                <label>72.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Culos-Reed</surname>
                      <given-names>SN</given-names>
                    </name>
                    <name>
                      <surname>Robinson</surname>
                      <given-names>JW</given-names>
                    </name>
                    <name>
                      <surname>Lau</surname>
                      <given-names>H</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Physical activity for men receiving androgen deprivation therapy for prostate Cancer: benefits from a 16-week intervention</article-title>
                  <source>Support Care Cancer</source>
                  <year>2010</year>
                  <volume>18</volume>
                  <issue>5</issue>
                  <fpage>591</fpage>
                  <lpage>599</lpage>
                  <pub-id pub-id-type="doi">10.1007/s00520-009-0694-3</pub-id>
                  <?supplied-pmid 19609570?>
                  <pub-id pub-id-type="pmid">19609570</pub-id>
                </element-citation>
              </ref>
              <ref id="CR73">
                <label>73.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Galvao</surname>
                      <given-names>DA</given-names>
                    </name>
                    <name>
                      <surname>Taaffe</surname>
                      <given-names>DR</given-names>
                    </name>
                    <name>
                      <surname>Spry</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Joseph</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Newton</surname>
                      <given-names>RU</given-names>
                    </name>
                  </person-group>
                  <article-title>Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial</article-title>
                  <source>J Clin Oncol</source>
                  <year>2010</year>
                  <volume>28</volume>
                  <issue>2</issue>
                  <fpage>340</fpage>
                  <lpage>347</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.2009.23.2488</pub-id>
                  <?supplied-pmid 19949016?>
                  <pub-id pub-id-type="pmid">19949016</pub-id>
                </element-citation>
              </ref>
              <ref id="CR74">
                <label>74.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bourke</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Doll</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Crank</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Daley</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Rosario</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Saxton</surname>
                      <given-names>JM</given-names>
                    </name>
                  </person-group>
                  <article-title>Lifestyle intervention in men with advanced prostate cancer receiving androgen suppression therapy: a feasibility study</article-title>
                  <source>Cancer Epidemiol Biomark Prev</source>
                  <year>2011</year>
                  <volume>20</volume>
                  <issue>4</issue>
                  <fpage>647</fpage>
                  <lpage>657</lpage>
                  <pub-id pub-id-type="doi">10.1158/1055-9965.EPI-10-1143</pub-id>
                </element-citation>
              </ref>
              <ref id="CR75">
                <label>75.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Truong</surname>
                      <given-names>PT</given-names>
                    </name>
                    <name>
                      <surname>Gaul</surname>
                      <given-names>CA</given-names>
                    </name>
                    <name>
                      <surname>McDonald</surname>
                      <given-names>RE</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Prospective evaluation of a 12-week walking exercise program and its effect on fatigue in prostate Cancer patients undergoing radical external beam radiotherapy</article-title>
                  <source>Am J Clin Oncol</source>
                  <year>2011</year>
                  <volume>34</volume>
                  <issue>4</issue>
                  <fpage>350</fpage>
                  <lpage>355</lpage>
                  <pub-id pub-id-type="doi">10.1097/COC.0b013e3181e841ec</pub-id>
                  <?supplied-pmid 20686404?>
                  <pub-id pub-id-type="pmid">20686404</pub-id>
                </element-citation>
              </ref>
              <ref id="CR76">
                <label>76.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Santa Mina</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Alibhai</surname>
                      <given-names>SMH</given-names>
                    </name>
                    <name>
                      <surname>Matthew</surname>
                      <given-names>AG</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>A randomized trial of aerobic versus resistance exercise in prostate cancer survivors</article-title>
                  <source>J Aging Phys Act</source>
                  <year>2013</year>
                  <volume>21</volume>
                  <issue>4</issue>
                  <fpage>455</fpage>
                  <lpage>478</lpage>
                  <pub-id pub-id-type="doi">10.1123/japa.21.4.455</pub-id>
                  <?supplied-pmid 23238110?>
                  <pub-id pub-id-type="pmid">23238110</pub-id>
                </element-citation>
              </ref>
              <ref id="CR77">
                <label>77.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Santa Mina</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Ritvo</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Matthew</surname>
                      <given-names>AG</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Group exercise versus personal training for prostate Cancer patients: a pilot randomized trial</article-title>
                  <source>J Cancer Ther</source>
                  <year>2012</year>
                  <volume>3</volume>
                  <issue>2</issue>
                  <fpage>146</fpage>
                  <lpage>156</lpage>
                  <pub-id pub-id-type="doi">10.4236/jct.2012.32020</pub-id>
                </element-citation>
              </ref>
              <ref id="CR78">
                <label>78.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Murphy</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Wassersug</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Dechman</surname>
                      <given-names>G</given-names>
                    </name>
                  </person-group>
                  <article-title>The role of exercise in managing the adverse effects of androgen deprivation therapy in men with prostate cancer</article-title>
                  <source>Phys Ther Rev</source>
                  <year>2011</year>
                  <volume>16</volume>
                  <issue>4</issue>
                  <fpage>269</fpage>
                  <lpage>277</lpage>
                  <pub-id pub-id-type="doi">10.1179/1743288X11Y.0000000029</pub-id>
                </element-citation>
              </ref>
              <ref id="CR79">
                <label>79.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Baumann</surname>
                      <given-names>FT</given-names>
                    </name>
                    <name>
                      <surname>Zopf</surname>
                      <given-names>EM</given-names>
                    </name>
                    <name>
                      <surname>Bloch</surname>
                      <given-names>W</given-names>
                    </name>
                  </person-group>
                  <article-title>Clinical exercise interventions in prostate cancer patients--a systematic review of randomized controlled trials</article-title>
                  <source>Support Care Cancer</source>
                  <year>2012</year>
                  <volume>20</volume>
                  <issue>2</issue>
                  <fpage>221</fpage>
                  <lpage>233</lpage>
                  <pub-id pub-id-type="doi">10.1007/s00520-011-1271-0</pub-id>
                  <?supplied-pmid 21989678?>
                  <pub-id pub-id-type="pmid">21989678</pub-id>
                </element-citation>
              </ref>
              <ref id="CR80">
                <label>80.</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="author">
                    <name>
                      <surname>SMH</surname>
                      <given-names>A</given-names>
                    </name>
                  </person-group>
                  <person-group person-group-type="editor">
                    <name>
                      <surname>Santa Mina</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Ritvo</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Segal</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Culos-Reed</surname>
                      <given-names>SN</given-names>
                    </name>
                    <name>
                      <surname>Saxton</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Daley</surname>
                      <given-names>A</given-names>
                    </name>
                  </person-group>
                  <article-title>Exercise After Prostate Cancer Diagnosis</article-title>
                  <source>Exercise and Cancer Survivorship: Impact on Health Outcomes and Quality of Life</source>
                  <year>2010</year>
                  <publisher-loc>New York</publisher-loc>
                  <publisher-name>Springer</publisher-name>
                  <fpage>113</fpage>
                  <lpage>140</lpage>
                </element-citation>
              </ref>
              <ref id="CR81">
                <label>81.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gardner</surname>
                      <given-names>JR</given-names>
                    </name>
                    <name>
                      <surname>Livingston</surname>
                      <given-names>PM</given-names>
                    </name>
                    <name>
                      <surname>Fraser</surname>
                      <given-names>SF</given-names>
                    </name>
                  </person-group>
                  <article-title>Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: a systematic review</article-title>
                  <source>J Clin Oncol</source>
                  <year>2014</year>
                  <volume>32</volume>
                  <issue>4</issue>
                  <fpage>335</fpage>
                  <lpage>346</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.2013.49.5523</pub-id>
                  <?supplied-pmid 24344218?>
                  <pub-id pub-id-type="pmid">24344218</pub-id>
                </element-citation>
              </ref>
              <ref id="CR82">
                <label>82.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bourke</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Smith</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Steed</surname>
                      <given-names>L</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Exercise for men with prostate Cancer: a systematic review and meta-analysis</article-title>
                  <source>Eur Urol</source>
                  <year>2016</year>
                  <volume>69</volume>
                  <issue>4</issue>
                  <fpage>693</fpage>
                  <lpage>703</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.eururo.2015.10.047</pub-id>
                  <?supplied-pmid 26632144?>
                  <pub-id pub-id-type="pmid">26632144</pub-id>
                </element-citation>
              </ref>
              <ref id="CR83">
                <label>83.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Santa Mina</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Connor</surname>
                      <given-names>MK</given-names>
                    </name>
                    <name>
                      <surname>Alibhai</surname>
                      <given-names>SM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Exercise effects on adipokines and the IGF axis in men with prostate cancer treated with androgen deprivation: a randomized study</article-title>
                  <source>Can Urol Assoc J</source>
                  <year>2013</year>
                  <volume>7</volume>
                  <issue>11–12</issue>
                  <fpage>E692</fpage>
                  <lpage>E698</lpage>
                  <pub-id pub-id-type="doi">10.5489/cuaj.235</pub-id>
                  <?supplied-pmid 24282459?>
                  <pub-id pub-id-type="pmid">24282459</pub-id>
                </element-citation>
              </ref>
              <ref id="CR84">
                <label>84.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Albertsen</surname>
                      <given-names>PC</given-names>
                    </name>
                    <name>
                      <surname>Moore</surname>
                      <given-names>DF</given-names>
                    </name>
                    <name>
                      <surname>Shih</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Lin</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Li</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Lu-Yao</surname>
                      <given-names>GL</given-names>
                    </name>
                  </person-group>
                  <article-title>Impact of comorbidity on survival among men with localized prostate cancer</article-title>
                  <source>J Clin Oncol</source>
                  <year>2011</year>
                  <volume>29</volume>
                  <issue>10</issue>
                  <fpage>1335</fpage>
                  <lpage>1341</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.2010.31.2330</pub-id>
                  <?supplied-pmid 21357791?>
                  <pub-id pub-id-type="pmid">21357791</pub-id>
                </element-citation>
              </ref>
              <ref id="CR85">
                <label>85.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Brassell</surname>
                      <given-names>SA</given-names>
                    </name>
                    <name>
                      <surname>Rice</surname>
                      <given-names>KR</given-names>
                    </name>
                    <name>
                      <surname>Parker</surname>
                      <given-names>PM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Prostate cancer in men 70 years old or older, indolent or aggressive: clinicopathological analysis and outcomes</article-title>
                  <source>J Urol</source>
                  <year>2011</year>
                  <volume>185</volume>
                  <issue>1</issue>
                  <fpage>132</fpage>
                  <lpage>137</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.juro.2010.09.014</pub-id>
                  <?supplied-pmid 21074211?>
                  <pub-id pub-id-type="pmid">21074211</pub-id>
                </element-citation>
              </ref>
              <ref id="CR86">
                <label>86.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cooperberg</surname>
                      <given-names>MR</given-names>
                    </name>
                    <name>
                      <surname>Broering</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Carroll</surname>
                      <given-names>PR</given-names>
                    </name>
                  </person-group>
                  <article-title>Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis</article-title>
                  <source>J Natl Cancer Inst</source>
                  <year>2009</year>
                  <volume>101</volume>
                  <issue>12</issue>
                  <fpage>878</fpage>
                  <lpage>887</lpage>
                  <pub-id pub-id-type="doi">10.1093/jnci/djp122</pub-id>
                  <?supplied-pmid 2697208?>
                  <pub-id pub-id-type="pmid">19509351</pub-id>
                </element-citation>
              </ref>
              <ref id="CR87">
                <label>87.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Crawford</surname>
                      <given-names>ED</given-names>
                    </name>
                    <name>
                      <surname>Grubb</surname>
                      <given-names>R</given-names>
                      <suffix>3rd</suffix>
                    </name>
                    <name>
                      <surname>Black</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Comorbidity and mortality results from a randomized prostate cancer screening trial</article-title>
                  <source>J Clin Oncol</source>
                  <year>2011</year>
                  <volume>29</volume>
                  <issue>4</issue>
                  <fpage>355</fpage>
                  <lpage>361</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.2010.30.5979</pub-id>
                  <?supplied-pmid 21041707?>
                  <pub-id pub-id-type="pmid">21041707</pub-id>
                </element-citation>
              </ref>
              <ref id="CR88">
                <label>88.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>D'Amico</surname>
                      <given-names>AV</given-names>
                    </name>
                    <name>
                      <surname>Chen</surname>
                      <given-names>MH</given-names>
                    </name>
                    <name>
                      <surname>Renshaw</surname>
                      <given-names>AA</given-names>
                    </name>
                    <name>
                      <surname>Loffredo</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Kantoff</surname>
                      <given-names>PW</given-names>
                    </name>
                  </person-group>
                  <article-title>Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer</article-title>
                  <source>Cancer</source>
                  <year>2008</year>
                  <volume>113</volume>
                  <issue>12</issue>
                  <fpage>3290</fpage>
                  <lpage>3297</lpage>
                  <pub-id pub-id-type="doi">10.1002/cncr.23970</pub-id>
                  <?supplied-pmid 18980297?>
                  <pub-id pub-id-type="pmid">18980297</pub-id>
                </element-citation>
              </ref>
              <ref id="CR89">
                <label>89.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>D'Amico</surname>
                      <given-names>AV</given-names>
                    </name>
                    <name>
                      <surname>Cote</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Loffredo</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Renshaw</surname>
                      <given-names>AA</given-names>
                    </name>
                    <name>
                      <surname>Schultz</surname>
                      <given-names>D</given-names>
                    </name>
                  </person-group>
                  <article-title>Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer</article-title>
                  <source>J Clin Oncol</source>
                  <year>2002</year>
                  <volume>20</volume>
                  <issue>23</issue>
                  <fpage>4567</fpage>
                  <lpage>4573</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.2002.03.061</pub-id>
                  <?supplied-pmid 12454114?>
                  <pub-id pub-id-type="pmid">12454114</pub-id>
                </element-citation>
              </ref>
              <ref id="CR90">
                <label>90.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Daskivich</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Sadetsky</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Kaplan</surname>
                      <given-names>SH</given-names>
                    </name>
                    <name>
                      <surname>Greenfield</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Litwin</surname>
                      <given-names>MS</given-names>
                    </name>
                  </person-group>
                  <article-title>Severity of comorbidity and non-prostate cancer mortality in men with early-stage prostate cancer</article-title>
                  <source>Arch Intern Med</source>
                  <year>2010</year>
                  <volume>170</volume>
                  <issue>15</issue>
                  <fpage>1396</fpage>
                  <lpage>1397</lpage>
                  <pub-id pub-id-type="doi">10.1001/archinternmed.2010.251</pub-id>
                  <?supplied-pmid 20696968?>
                  <pub-id pub-id-type="pmid">20696968</pub-id>
                </element-citation>
              </ref>
              <ref id="CR91">
                <label>91.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Dosoretz</surname>
                      <given-names>AM</given-names>
                    </name>
                    <name>
                      <surname>Chen</surname>
                      <given-names>MH</given-names>
                    </name>
                    <name>
                      <surname>Salenius</surname>
                      <given-names>SA</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Mortality in men with localized prostate cancer treated with brachytherapy with or without neoadjuvant hormone therapy</article-title>
                  <source>Cancer</source>
                  <year>2010</year>
                  <volume>116</volume>
                  <issue>4</issue>
                  <fpage>837</fpage>
                  <lpage>842</lpage>
                  <pub-id pub-id-type="doi">10.1002/cncr.24750</pub-id>
                  <?supplied-pmid 20052734?>
                  <pub-id pub-id-type="pmid">20052734</pub-id>
                </element-citation>
              </ref>
              <ref id="CR92">
                <label>92.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ades</surname>
                      <given-names>PA</given-names>
                    </name>
                  </person-group>
                  <article-title>Cardiac rehabilitation and secondary prevention of coronary heart disease</article-title>
                  <source>N Engl J Med</source>
                  <year>2001</year>
                  <volume>345</volume>
                  <issue>12</issue>
                  <fpage>892</fpage>
                  <lpage>902</lpage>
                  <pub-id pub-id-type="doi">10.1056/NEJMra001529</pub-id>
                  <?supplied-pmid 11565523?>
                  <pub-id pub-id-type="pmid">11565523</pub-id>
                </element-citation>
              </ref>
              <ref id="CR93">
                <label>93.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Knowler</surname>
                      <given-names>WC</given-names>
                    </name>
                    <name>
                      <surname>Barrett-Connor</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Fowler</surname>
                      <given-names>SE</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin</article-title>
                  <source>N Engl J Med</source>
                  <year>2002</year>
                  <volume>346</volume>
                  <issue>6</issue>
                  <fpage>393</fpage>
                  <lpage>403</lpage>
                  <pub-id pub-id-type="doi">10.1056/NEJMoa012512</pub-id>
                  <pub-id pub-id-type="pmid">11832527</pub-id>
                </element-citation>
              </ref>
              <ref id="CR94">
                <label>94.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gillies</surname>
                      <given-names>CL</given-names>
                    </name>
                    <name>
                      <surname>Abrams</surname>
                      <given-names>KR</given-names>
                    </name>
                    <name>
                      <surname>Lambert</surname>
                      <given-names>PC</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis</article-title>
                  <source>BMJ</source>
                  <year>2007</year>
                  <volume>334</volume>
                  <issue>7588</issue>
                  <fpage>299</fpage>
                  <pub-id pub-id-type="doi">10.1136/bmj.39063.689375.55</pub-id>
                  <?supplied-pmid 17237299?>
                  <pub-id pub-id-type="pmid">17237299</pub-id>
                </element-citation>
              </ref>
              <ref id="CR95">
                <label>95.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Taylor</surname>
                      <given-names>RS</given-names>
                    </name>
                    <name>
                      <surname>Brown</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Ebrahim</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials</article-title>
                  <source>Am J Med</source>
                  <year>2004</year>
                  <volume>116</volume>
                  <issue>10</issue>
                  <fpage>682</fpage>
                  <lpage>692</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.amjmed.2004.01.009</pub-id>
                  <?supplied-pmid 15121495?>
                  <pub-id pub-id-type="pmid">15121495</pub-id>
                </element-citation>
              </ref>
              <ref id="CR96">
                <label>96.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Papaioannou</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Morin</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Cheung</surname>
                      <given-names>AM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary</article-title>
                  <source>CMAJ</source>
                  <year>2010</year>
                  <volume>182</volume>
                  <issue>17</issue>
                  <fpage>1864</fpage>
                  <lpage>1873</lpage>
                  <pub-id pub-id-type="doi">10.1503/cmaj.100771</pub-id>
                  <?supplied-pmid 2988535?>
                  <pub-id pub-id-type="pmid">20940232</pub-id>
                </element-citation>
              </ref>
              <ref id="CR97">
                <label>97.</label>
                <mixed-citation publication-type="other">Klibanski A, Adams-Campbell L, Bassford T, et al. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285(6):785–95.</mixed-citation>
              </ref>
              <ref id="CR98">
                <label>98.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Nikander</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Sievanen</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Heinonen</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Daly</surname>
                      <given-names>RM</given-names>
                    </name>
                    <name>
                      <surname>Uusi-Rasi</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Kannus</surname>
                      <given-names>P</given-names>
                    </name>
                  </person-group>
                  <article-title>Targeted exercise against osteoporosis: a systematic review and meta-analysis for optimising bone strength throughout life</article-title>
                  <source>BMC Med</source>
                  <year>2010</year>
                  <volume>8</volume>
                  <fpage>47</fpage>
                  <pub-id pub-id-type="doi">10.1186/1741-7015-8-47</pub-id>
                  <?supplied-pmid 20663158?>
                  <pub-id pub-id-type="pmid">20663158</pub-id>
                </element-citation>
              </ref>
              <ref id="CR99">
                <label>99.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kenfield</surname>
                      <given-names>SA</given-names>
                    </name>
                    <name>
                      <surname>Stampfer</surname>
                      <given-names>MJ</given-names>
                    </name>
                    <name>
                      <surname>Giovannucci</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Chan</surname>
                      <given-names>JM</given-names>
                    </name>
                  </person-group>
                  <article-title>Physical activity and survival after prostate cancer diagnosis in the health professionals follow-up study</article-title>
                  <source>J Clin Oncol</source>
                  <year>2011</year>
                  <volume>29</volume>
                  <issue>6</issue>
                  <fpage>726</fpage>
                  <lpage>732</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.2010.31.5226</pub-id>
                  <?supplied-pmid 21205749?>
                  <pub-id pub-id-type="pmid">21205749</pub-id>
                </element-citation>
              </ref>
              <ref id="CR100">
                <label>100.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Keogh</surname>
                      <given-names>JW</given-names>
                    </name>
                    <name>
                      <surname>MacLeod</surname>
                      <given-names>RD</given-names>
                    </name>
                  </person-group>
                  <article-title>Body composition, physical fitness, functional performance, quality of life, and fatigue benefits of exercise for prostate cancer patients: a systematic review</article-title>
                  <source>J Pain Symptom Manag</source>
                  <year>2012</year>
                  <volume>43</volume>
                  <issue>1</issue>
                  <fpage>96</fpage>
                  <lpage>110</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.jpainsymman.2011.03.006</pub-id>
                </element-citation>
              </ref>
              <ref id="CR101">
                <label>101.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Alibhai</surname>
                      <given-names>SM</given-names>
                    </name>
                    <name>
                      <surname>Santa Mina</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Ritvo</surname>
                      <given-names>P</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>A phase II RCT and economic analysis of three exercise delivery methods in men with prostate cancer on androgen deprivation therapy</article-title>
                  <source>BMC Cancer</source>
                  <year>2015</year>
                  <volume>15</volume>
                  <issue>1</issue>
                  <fpage>312</fpage>
                  <pub-id pub-id-type="doi">10.1186/s12885-015-1316-8</pub-id>
                  <?supplied-pmid 25908311?>
                  <pub-id pub-id-type="pmid">25908311</pub-id>
                </element-citation>
              </ref>
              <ref id="CR102">
                <label>102.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Antonelli</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Freedland</surname>
                      <given-names>SJ</given-names>
                    </name>
                    <name>
                      <surname>Jones</surname>
                      <given-names>LW</given-names>
                    </name>
                  </person-group>
                  <article-title>Exercise therapy across the prostate cancer continuum</article-title>
                  <source>Prostate Cancer Prostatic Dis</source>
                  <year>2009</year>
                  <volume>12</volume>
                  <issue>2</issue>
                  <fpage>110</fpage>
                  <lpage>115</lpage>
                  <pub-id pub-id-type="doi">10.1038/pcan.2009.4</pub-id>
                  <?supplied-pmid 19274062?>
                  <pub-id pub-id-type="pmid">19274062</pub-id>
                </element-citation>
              </ref>
              <ref id="CR103">
                <label>103.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Demark-Wahnefried</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Clipp</surname>
                      <given-names>EC</given-names>
                    </name>
                    <name>
                      <surname>Lipkus</surname>
                      <given-names>IM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Main outcomes of the FRESH START trial: a sequentially tailored, diet and exercise mailed print intervention among breast and prostate cancer survivors</article-title>
                  <source>J Clin Oncol</source>
                  <year>2007</year>
                  <volume>25</volume>
                  <issue>19</issue>
                  <fpage>2709</fpage>
                  <lpage>2718</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.2007.10.7094</pub-id>
                  <?supplied-pmid 17602076?>
                  <pub-id pub-id-type="pmid">17602076</pub-id>
                </element-citation>
              </ref>
              <ref id="CR104">
                <label>104.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Meyerhardt</surname>
                      <given-names>JA</given-names>
                    </name>
                    <name>
                      <surname>Ma</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Courneya</surname>
                      <given-names>KS</given-names>
                    </name>
                  </person-group>
                  <article-title>Energetics in colorectal and prostate cancer</article-title>
                  <source>J Clin Oncol</source>
                  <year>2010</year>
                  <volume>28</volume>
                  <issue>26</issue>
                  <fpage>4066</fpage>
                  <lpage>4073</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.2009.26.8797</pub-id>
                  <?supplied-pmid 20644082?>
                  <pub-id pub-id-type="pmid">20644082</pub-id>
                </element-citation>
              </ref>
              <ref id="CR105">
                <label>105.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Richman</surname>
                      <given-names>EL</given-names>
                    </name>
                    <name>
                      <surname>Kenfield</surname>
                      <given-names>SA</given-names>
                    </name>
                    <name>
                      <surname>Stampfer</surname>
                      <given-names>MJ</given-names>
                    </name>
                    <name>
                      <surname>Paciorek</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Carroll</surname>
                      <given-names>PR</given-names>
                    </name>
                    <name>
                      <surname>Chan</surname>
                      <given-names>JM</given-names>
                    </name>
                  </person-group>
                  <article-title>Physical activity after diagnosis and risk of prostate cancer progression: data from the cancer of the prostate strategic urologic research endeavor</article-title>
                  <source>Cancer Res</source>
                  <year>2011</year>
                  <volume>71</volume>
                  <issue>11</issue>
                  <fpage>3889</fpage>
                  <lpage>3895</lpage>
                  <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-3932</pub-id>
                  <?supplied-pmid 21610110?>
                  <pub-id pub-id-type="pmid">21610110</pub-id>
                </element-citation>
              </ref>
              <ref id="CR106">
                <label>106.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Vallance</surname>
                      <given-names>JK</given-names>
                    </name>
                    <name>
                      <surname>Courneya</surname>
                      <given-names>KS</given-names>
                    </name>
                    <name>
                      <surname>Plotnikoff</surname>
                      <given-names>RC</given-names>
                    </name>
                    <name>
                      <surname>Dinu</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Mackey</surname>
                      <given-names>JR</given-names>
                    </name>
                  </person-group>
                  <article-title>Maintenance of physical activity in breast cancer survivors after a randomized trial</article-title>
                  <source>Med Sci Sports Exerc</source>
                  <year>2008</year>
                  <volume>40</volume>
                  <issue>1</issue>
                  <fpage>173</fpage>
                  <lpage>180</lpage>
                  <pub-id pub-id-type="doi">10.1249/mss.0b013e3181586b41</pub-id>
                  <?supplied-pmid 18091007?>
                  <pub-id pub-id-type="pmid">18091007</pub-id>
                </element-citation>
              </ref>
              <ref id="CR107">
                <label>107.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Courneya</surname>
                      <given-names>KS</given-names>
                    </name>
                    <name>
                      <surname>Segal</surname>
                      <given-names>RJ</given-names>
                    </name>
                    <name>
                      <surname>Gelmon</surname>
                      <given-names>K</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Six-month follow-up of patient-rated outcomes in a randomized controlled trial of exercise training during breast cancer chemotherapy</article-title>
                  <source>Cancer Epidemiol Biomark Prev</source>
                  <year>2007</year>
                  <volume>16</volume>
                  <issue>12</issue>
                  <fpage>2572</fpage>
                  <lpage>2578</lpage>
                  <pub-id pub-id-type="doi">10.1158/1055-9965.EPI-07-0413</pub-id>
                </element-citation>
              </ref>
              <ref id="CR108">
                <label>108.</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Dishman</surname>
                      <given-names>RK</given-names>
                    </name>
                  </person-group>
                  <source>Exercise adherence: its impact on public health</source>
                  <year>1988</year>
                  <publisher-loc>Champaign</publisher-loc>
                  <publisher-name>Human Kinetics</publisher-name>
                </element-citation>
              </ref>
              <ref id="CR109">
                <label>109.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Courneya</surname>
                      <given-names>KS</given-names>
                    </name>
                    <name>
                      <surname>Segal</surname>
                      <given-names>RJ</given-names>
                    </name>
                    <name>
                      <surname>Reid</surname>
                      <given-names>RD</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Three independent factors predicted adherence in a randomized controlled trial of resistance exercise training among prostate cancer survivors</article-title>
                  <source>J Clin Epidemiol</source>
                  <year>2004</year>
                  <volume>57</volume>
                  <issue>6</issue>
                  <fpage>571</fpage>
                  <lpage>579</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.jclinepi.2003.11.010</pub-id>
                  <?supplied-pmid 15246125?>
                  <pub-id pub-id-type="pmid">15246125</pub-id>
                </element-citation>
              </ref>
              <ref id="CR110">
                <label>110.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Oldridge</surname>
                      <given-names>NB</given-names>
                    </name>
                    <name>
                      <surname>Guyatt</surname>
                      <given-names>GH</given-names>
                    </name>
                    <name>
                      <surname>Fischer</surname>
                      <given-names>ME</given-names>
                    </name>
                    <name>
                      <surname>Rimm</surname>
                      <given-names>AA</given-names>
                    </name>
                  </person-group>
                  <article-title>Cardiac rehabilitation after myocardial infarction. Combined experience of randomized clinical trials</article-title>
                  <source>JAMA</source>
                  <year>1988</year>
                  <volume>260</volume>
                  <issue>7</issue>
                  <fpage>945</fpage>
                  <lpage>950</lpage>
                  <pub-id pub-id-type="doi">10.1001/jama.1988.03410070073031</pub-id>
                  <?supplied-pmid 3398199?>
                  <pub-id pub-id-type="pmid">3398199</pub-id>
                </element-citation>
              </ref>
              <ref id="CR111">
                <label>111.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Fong</surname>
                      <given-names>DY</given-names>
                    </name>
                    <name>
                      <surname>Ho</surname>
                      <given-names>JW</given-names>
                    </name>
                    <name>
                      <surname>Hui</surname>
                      <given-names>BP</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Physical activity for cancer survivors: meta-analysis of randomised controlled trials</article-title>
                  <source>BMJ</source>
                  <year>2012</year>
                  <volume>344</volume>
                  <fpage>e70</fpage>
                  <pub-id pub-id-type="doi">10.1136/bmj.e70</pub-id>
                  <?supplied-pmid 22294757?>
                  <pub-id pub-id-type="pmid">22294757</pub-id>
                </element-citation>
              </ref>
              <ref id="CR112">
                <label>112.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Dalal</surname>
                      <given-names>HM</given-names>
                    </name>
                    <name>
                      <surname>Zawada</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Jolly</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Moxham</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Taylor</surname>
                      <given-names>RS</given-names>
                    </name>
                  </person-group>
                  <article-title>Home based versus Centre based cardiac rehabilitation: Cochrane systematic review and meta-analysis</article-title>
                  <source>BMJ</source>
                  <year>2010</year>
                  <volume>340</volume>
                  <fpage>b5631</fpage>
                  <pub-id pub-id-type="doi">10.1136/bmj.b5631</pub-id>
                  <?supplied-pmid 20085991?>
                  <pub-id pub-id-type="pmid">20085991</pub-id>
                </element-citation>
              </ref>
              <ref id="CR113">
                <label>113.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Alibhai</surname>
                      <given-names>SMH</given-names>
                    </name>
                    <name>
                      <surname>Santa Mina</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Ritvo</surname>
                      <given-names>P</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>A phase II RCT of three exercise delivery methods in older men with prostate cancer on adtrogen deprivation therapy (abstract)</article-title>
                  <source>J Geriatr Oncol</source>
                  <year>2016</year>
                  <volume>7</volume>
                  <issue>Suppl. 1</issue>
                  <fpage>58</fpage>
                  <lpage>59</lpage>
                </element-citation>
              </ref>
              <ref id="CR114">
                <label>114.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Friedenreich</surname>
                      <given-names>CM</given-names>
                    </name>
                    <name>
                      <surname>Courneya</surname>
                      <given-names>KS</given-names>
                    </name>
                    <name>
                      <surname>Bryant</surname>
                      <given-names>HE</given-names>
                    </name>
                  </person-group>
                  <article-title>The lifetime total physical activity questionnaire: development and reliability</article-title>
                  <source>Med Sci Sports Exerc</source>
                  <year>1998</year>
                  <volume>30</volume>
                  <issue>2</issue>
                  <fpage>266</fpage>
                  <lpage>274</lpage>
                  <pub-id pub-id-type="doi">10.1097/00005768-199802000-00015</pub-id>
                  <?supplied-pmid 9502356?>
                  <pub-id pub-id-type="pmid">9502356</pub-id>
                </element-citation>
              </ref>
              <ref id="CR115">
                <label>115.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Galvao</surname>
                      <given-names>DA</given-names>
                    </name>
                    <name>
                      <surname>Taaffe</surname>
                      <given-names>DR</given-names>
                    </name>
                    <name>
                      <surname>Spry</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Joseph</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Newton</surname>
                      <given-names>RU</given-names>
                    </name>
                  </person-group>
                  <article-title>Acute versus chronic exposure to androgen suppression for prostate cancer: impact on the exercise response</article-title>
                  <source>J Urol</source>
                  <year>2011</year>
                  <volume>186</volume>
                  <issue>4</issue>
                  <fpage>1291</fpage>
                  <lpage>1297</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.juro.2011.05.055</pub-id>
                  <?supplied-pmid 21849187?>
                  <pub-id pub-id-type="pmid">21849187</pub-id>
                </element-citation>
              </ref>
              <ref id="CR116">
                <label>116.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Santa Mina</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Alibhai</surname>
                      <given-names>SM</given-names>
                    </name>
                    <name>
                      <surname>Matthew</surname>
                      <given-names>AG</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Exercise in clinical cancer care: a call to action and program development description</article-title>
                  <source>Curr Oncol</source>
                  <year>2012</year>
                  <volume>19</volume>
                  <issue>3</issue>
                  <fpage>e136</fpage>
                  <lpage>e144</lpage>
                  <pub-id pub-id-type="doi">10.3747/co.19.912</pub-id>
                  <?supplied-pmid 22670103?>
                  <pub-id pub-id-type="pmid">22670103</pub-id>
                </element-citation>
              </ref>
              <ref id="CR117">
                <label>117.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Segal</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Zwaal</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Green</surname>
                      <given-names>E</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Exercise for people with cancer: a clinical practice guideline</article-title>
                  <source>Curr Oncol</source>
                  <year>2017</year>
                  <volume>24</volume>
                  <issue>1</issue>
                  <fpage>40</fpage>
                  <lpage>46</lpage>
                  <pub-id pub-id-type="doi">10.3747/co.24.3376</pub-id>
                  <?supplied-pmid 28270724?>
                  <pub-id pub-id-type="pmid">28270724</pub-id>
                </element-citation>
              </ref>
              <ref id="CR118">
                <label>118.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Borg</surname>
                      <given-names>GA</given-names>
                    </name>
                  </person-group>
                  <article-title>Psychophysical bases of perceived exertion</article-title>
                  <source>Med Sci Sports Exerc</source>
                  <year>1982</year>
                  <volume>14</volume>
                  <issue>5</issue>
                  <fpage>377</fpage>
                  <lpage>381</lpage>
                  <pub-id pub-id-type="doi">10.1249/00005768-198205000-00012</pub-id>
                  <?supplied-pmid 7154893?>
                  <pub-id pub-id-type="pmid">7154893</pub-id>
                </element-citation>
              </ref>
              <ref id="CR119">
                <label>119.</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Heyward</surname>
                      <given-names>VH</given-names>
                    </name>
                  </person-group>
                  <source>Advanced fitness assessment and exercise prescription, ed. 5th</source>
                  <year>2010</year>
                  <publisher-loc>Windsor</publisher-loc>
                  <publisher-name>Human Kinetics Publishers</publisher-name>
                </element-citation>
              </ref>
              <ref id="CR120">
                <label>120.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Spring</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Duncan</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Janke</surname>
                      <given-names>EA</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Integrating technology into standard weight loss treatment: a randomized controlled trial</article-title>
                  <source>JAMA Intern Med</source>
                  <year>2013</year>
                  <volume>173</volume>
                  <issue>2</issue>
                  <fpage>105</fpage>
                  <lpage>111</lpage>
                  <pub-id pub-id-type="doi">10.1001/jamainternmed.2013.1221</pub-id>
                  <?supplied-pmid 23229890?>
                  <pub-id pub-id-type="pmid">23229890</pub-id>
                </element-citation>
              </ref>
              <ref id="CR121">
                <label>121.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Spring</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Schneider</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>McFadden</surname>
                      <given-names>HG</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Multiple behavior changes in diet and activity: a randomized controlled trial using mobile technology</article-title>
                  <source>Arch Intern Med</source>
                  <year>2012</year>
                  <volume>172</volume>
                  <issue>10</issue>
                  <fpage>789</fpage>
                  <lpage>796</lpage>
                  <pub-id pub-id-type="doi">10.1001/archinternmed.2012.1044</pub-id>
                  <?supplied-pmid 22636824?>
                  <pub-id pub-id-type="pmid">22636824</pub-id>
                </element-citation>
              </ref>
              <ref id="CR122">
                <label>122.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Free</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Phillips</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Galli</surname>
                      <given-names>L</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>The effectiveness of mobile-health technology-based health behaviour change or disease management interventions for health care consumers: a systematic review</article-title>
                  <source>PLoS Med</source>
                  <year>2013</year>
                  <volume>10</volume>
                  <issue>1</issue>
                  <fpage>e1001362</fpage>
                  <pub-id pub-id-type="doi">10.1371/journal.pmed.1001362</pub-id>
                  <?supplied-pmid 23349621?>
                  <pub-id pub-id-type="pmid">23349621</pub-id>
                </element-citation>
              </ref>
              <ref id="CR123">
                <label>123.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Spring</surname>
                      <given-names>B</given-names>
                    </name>
                  </person-group>
                  <article-title>Health decision making: lynchpin of evidence-based practice</article-title>
                  <source>Med Decis Mak</source>
                  <year>2008</year>
                  <volume>28</volume>
                  <issue>6</issue>
                  <fpage>866</fpage>
                  <lpage>874</lpage>
                  <pub-id pub-id-type="doi">10.1177/0272989X08326146</pub-id>
                </element-citation>
              </ref>
              <ref id="CR124">
                <label>124.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Duncan</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Janke</surname>
                      <given-names>EA</given-names>
                    </name>
                    <name>
                      <surname>Kozak</surname>
                      <given-names>AT</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>PDA+: a personal digital assistant for obesity treatment - an RCT testing the use of technology to enhance weight loss treatment for veterans</article-title>
                  <source>BMC Public Health</source>
                  <year>2011</year>
                  <volume>11</volume>
                  <fpage>223</fpage>
                  <pub-id pub-id-type="doi">10.1186/1471-2458-11-223</pub-id>
                  <?supplied-pmid 21481253?>
                  <pub-id pub-id-type="pmid">21481253</pub-id>
                </element-citation>
              </ref>
              <ref id="CR125">
                <label>125.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Spring</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Schneider</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>McFadden</surname>
                      <given-names>HG</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Make better choices (MBC): study design of a randomized controlled trial testing optimal technology-supported change in multiple diet and physical activity risk behaviors</article-title>
                  <source>BMC Public Health</source>
                  <year>2010</year>
                  <volume>10</volume>
                  <fpage>586</fpage>
                  <pub-id pub-id-type="doi">10.1186/1471-2458-10-586</pub-id>
                  <?supplied-pmid 20920275?>
                  <pub-id pub-id-type="pmid">20920275</pub-id>
                </element-citation>
              </ref>
              <ref id="CR126">
                <label>126.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wayne</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Perez</surname>
                      <given-names>DF</given-names>
                    </name>
                    <name>
                      <surname>Kaplan</surname>
                      <given-names>DM</given-names>
                    </name>
                    <name>
                      <surname>Ritvo</surname>
                      <given-names>P</given-names>
                    </name>
                  </person-group>
                  <article-title>Health coaching reduces HbA1c in type 2 diabetic patients from a lower-socioeconomic status community: a randomized controlled trial</article-title>
                  <source>J Med Internet Res</source>
                  <year>2015</year>
                  <volume>17</volume>
                  <issue>10</issue>
                  <fpage>e224</fpage>
                  <pub-id pub-id-type="doi">10.2196/jmir.4871</pub-id>
                  <?supplied-pmid 4642794?>
                  <pub-id pub-id-type="pmid">26441467</pub-id>
                </element-citation>
              </ref>
              <ref id="CR127">
                <label>127.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wayne</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Ritvo</surname>
                      <given-names>P</given-names>
                    </name>
                  </person-group>
                  <article-title>Smartphone-enabled health coach intervention for people with diabetes from a modest socioeconomic strata community: single-arm longitudinal feasibility study</article-title>
                  <source>J Med Internet Res</source>
                  <year>2014</year>
                  <volume>16</volume>
                  <issue>6</issue>
                  <fpage>e149</fpage>
                  <pub-id pub-id-type="doi">10.2196/jmir.3180</pub-id>
                  <?supplied-pmid 24907918?>
                  <pub-id pub-id-type="pmid">24907918</pub-id>
                </element-citation>
              </ref>
              <ref id="CR128">
                <label>128.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Pludwinski</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Ahmad</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Wayne</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Ritvo</surname>
                      <given-names>P</given-names>
                    </name>
                  </person-group>
                  <article-title>Participant experiences in a smartphone-based health coaching intervention for type 2 diabetes: a qualitative inquiry</article-title>
                  <source>J Telemed Telecare</source>
                  <year>2016</year>
                  <volume>22</volume>
                  <issue>3</issue>
                  <fpage>172</fpage>
                  <lpage>178</lpage>
                  <pub-id pub-id-type="doi">10.1177/1357633X15595178</pub-id>
                  <?supplied-pmid 26199275?>
                  <pub-id pub-id-type="pmid">26199275</pub-id>
                </element-citation>
              </ref>
              <ref id="CR129">
                <label>129.</label>
                <mixed-citation publication-type="other">Ritvo P, Obadia M, Santa Mina D, et al. An Innovative smartphone-enabled health coaching intervention (iMOVE) to promote long-term maintenance of physical activity in breast cancer survivors: A protocol for a feasibility pilot randomized controlled trial. J Med Internet Res; in press.</mixed-citation>
              </ref>
              <ref id="CR130">
                <label>130.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Takacs</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Pollock</surname>
                      <given-names>CL</given-names>
                    </name>
                    <name>
                      <surname>Guenther</surname>
                      <given-names>JR</given-names>
                    </name>
                    <name>
                      <surname>Bahar</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Napier</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Hunt</surname>
                      <given-names>MA</given-names>
                    </name>
                  </person-group>
                  <article-title>Validation of the Fitbit one activity monitor device during treadmill walking</article-title>
                  <source>J Sci Med Sport</source>
                  <year>2014</year>
                  <volume>17</volume>
                  <issue>5</issue>
                  <fpage>496</fpage>
                  <lpage>500</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.jsams.2013.10.241</pub-id>
                  <?supplied-pmid 24268570?>
                  <pub-id pub-id-type="pmid">24268570</pub-id>
                </element-citation>
              </ref>
              <ref id="CR131">
                <label>131.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Noah</surname>
                      <given-names>JA</given-names>
                    </name>
                    <name>
                      <surname>Spierer</surname>
                      <given-names>DK</given-names>
                    </name>
                    <name>
                      <surname>Gu</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Bronner</surname>
                      <given-names>S</given-names>
                    </name>
                  </person-group>
                  <article-title>Comparison of steps and energy expenditure assessmetn in adults of Fitbit tracker and ultra to the Actical and indirect calorimetry</article-title>
                  <source>J Med Eng Technol</source>
                  <year>2013</year>
                  <volume>37</volume>
                  <issue>7</issue>
                  <fpage>456</fpage>
                  <lpage>462</lpage>
                  <pub-id pub-id-type="doi">10.3109/03091902.2013.831135</pub-id>
                  <pub-id pub-id-type="pmid">24007317</pub-id>
                </element-citation>
              </ref>
              <ref id="CR132">
                <label>132.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cella</surname>
                      <given-names>D</given-names>
                    </name>
                  </person-group>
                  <article-title>The functional assessment of Cancer therapy-Anemia (FACT-an) scale: a new tool for the assessment of outcomes in cancer anemia and fatigue</article-title>
                  <source>Semin Hematol</source>
                  <year>1997</year>
                  <volume>34</volume>
                  <issue>3 Suppl 2</issue>
                  <fpage>13</fpage>
                  <lpage>19</lpage>
                  <?supplied-pmid 9253779?>
                  <pub-id pub-id-type="pmid">9253779</pub-id>
                </element-citation>
              </ref>
              <ref id="CR133">
                <label>133.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cella</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Lai</surname>
                      <given-names>JS</given-names>
                    </name>
                    <name>
                      <surname>Chang</surname>
                      <given-names>CH</given-names>
                    </name>
                    <name>
                      <surname>Peterman</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Slavin</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <article-title>Fatigue in cancer patients compared with fatigue in the general United States population</article-title>
                  <source>Cancer</source>
                  <year>2002</year>
                  <volume>94</volume>
                  <issue>2</issue>
                  <fpage>528</fpage>
                  <lpage>538</lpage>
                  <pub-id pub-id-type="doi">10.1002/cncr.10245</pub-id>
                  <?supplied-pmid 11900238?>
                  <pub-id pub-id-type="pmid">11900238</pub-id>
                </element-citation>
              </ref>
              <ref id="CR134">
                <label>134.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Iop</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Manfredi</surname>
                      <given-names>AM</given-names>
                    </name>
                    <name>
                      <surname>Bonura</surname>
                      <given-names>S</given-names>
                    </name>
                  </person-group>
                  <article-title>Fatigue in cancer patients receiving chemotherapy: an analysis of published studies</article-title>
                  <source>Ann Oncol</source>
                  <year>2004</year>
                  <volume>15</volume>
                  <issue>5</issue>
                  <fpage>712</fpage>
                  <lpage>720</lpage>
                  <pub-id pub-id-type="doi">10.1093/annonc/mdh102</pub-id>
                  <?supplied-pmid 15111337?>
                  <pub-id pub-id-type="pmid">15111337</pub-id>
                </element-citation>
              </ref>
              <ref id="CR135">
                <label>135.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Minton</surname>
                      <given-names>O</given-names>
                    </name>
                    <name>
                      <surname>Richardson</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Sharpe</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Hotopf</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Stone</surname>
                      <given-names>P</given-names>
                    </name>
                  </person-group>
                  <article-title>A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue</article-title>
                  <source>J Natl Cancer Inst</source>
                  <year>2008</year>
                  <volume>100</volume>
                  <issue>16</issue>
                  <fpage>1155</fpage>
                  <lpage>1166</lpage>
                  <pub-id pub-id-type="doi">10.1093/jnci/djn250</pub-id>
                  <?supplied-pmid 18695134?>
                  <pub-id pub-id-type="pmid">18695134</pub-id>
                </element-citation>
              </ref>
              <ref id="CR136">
                <label>136.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Rao</surname>
                      <given-names>AV</given-names>
                    </name>
                    <name>
                      <surname>Cohen</surname>
                      <given-names>HJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Fatigue in older cancer patients: etiology, assessment, and treatment</article-title>
                  <source>Semin Oncol</source>
                  <year>2008</year>
                  <volume>35</volume>
                  <issue>6</issue>
                  <fpage>633</fpage>
                  <lpage>642</lpage>
                  <pub-id pub-id-type="doi">10.1053/j.seminoncol.2008.08.005</pub-id>
                  <?supplied-pmid 19027467?>
                  <pub-id pub-id-type="pmid">19027467</pub-id>
                </element-citation>
              </ref>
              <ref id="CR137">
                <label>137.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Enright</surname>
                      <given-names>PL</given-names>
                    </name>
                    <name>
                      <surname>McBurnie</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Bittner</surname>
                      <given-names>V</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>The 6-min walk test: a quick measure of functional status in elderly adults</article-title>
                  <source>Chest</source>
                  <year>2003</year>
                  <volume>123</volume>
                  <issue>2</issue>
                  <fpage>387</fpage>
                  <lpage>398</lpage>
                  <pub-id pub-id-type="doi">10.1378/chest.123.2.387</pub-id>
                  <?supplied-pmid 12576356?>
                  <pub-id pub-id-type="pmid">12576356</pub-id>
                </element-citation>
              </ref>
              <ref id="CR138">
                <label>138.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Solway</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Brooks</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Lacasse</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Thomas</surname>
                      <given-names>S</given-names>
                    </name>
                  </person-group>
                  <article-title>A qualitative systematic overview of the measurement properties of functional walk tests used in the cardiorespiratory domain</article-title>
                  <source>Chest</source>
                  <year>2001</year>
                  <volume>119</volume>
                  <issue>1</issue>
                  <fpage>256</fpage>
                  <lpage>270</lpage>
                  <pub-id pub-id-type="doi">10.1378/chest.119.1.256</pub-id>
                  <?supplied-pmid 11157613?>
                  <pub-id pub-id-type="pmid">11157613</pub-id>
                </element-citation>
              </ref>
              <ref id="CR139">
                <label>139.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cella</surname>
                      <given-names>DF</given-names>
                    </name>
                    <name>
                      <surname>Tulsky</surname>
                      <given-names>DS</given-names>
                    </name>
                    <name>
                      <surname>Gray</surname>
                      <given-names>G</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>The functional assessment of Cancer therapy scale: development and validation of the general measure</article-title>
                  <source>J Clin Oncol</source>
                  <year>1993</year>
                  <volume>11</volume>
                  <issue>3</issue>
                  <fpage>570</fpage>
                  <lpage>579</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.1993.11.3.570</pub-id>
                  <?supplied-pmid 8445433?>
                  <pub-id pub-id-type="pmid">8445433</pub-id>
                </element-citation>
              </ref>
              <ref id="CR140">
                <label>140.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cella</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Hahn</surname>
                      <given-names>EA</given-names>
                    </name>
                    <name>
                      <surname>Dineen</surname>
                      <given-names>K</given-names>
                    </name>
                  </person-group>
                  <article-title>Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening</article-title>
                  <source>Qual Life Res</source>
                  <year>2002</year>
                  <volume>11</volume>
                  <issue>3</issue>
                  <fpage>207</fpage>
                  <lpage>221</lpage>
                  <pub-id pub-id-type="doi">10.1023/A:1015276414526</pub-id>
                  <?supplied-pmid 12074259?>
                  <pub-id pub-id-type="pmid">12074259</pub-id>
                </element-citation>
              </ref>
              <ref id="CR141">
                <label>141.</label>
                <mixed-citation publication-type="other">Why FACIT. Benefits of the FACIT measurement system. <ext-link ext-link-type="uri" xlink:href="http://www.facit.org/FACITOrg/Overview/WhyFACIT/Benefits">http://www.facit.org/FACITOrg/Overview/WhyFACIT/Benefits</ext-link>. Accessed 12 July 2017.</mixed-citation>
              </ref>
              <ref id="CR142">
                <label>142.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Esper</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Mo</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Chodak</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Sinner</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Cella</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Pienta</surname>
                      <given-names>KJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument</article-title>
                  <source>Urology</source>
                  <year>1997</year>
                  <volume>50</volume>
                  <issue>6</issue>
                  <fpage>920</fpage>
                  <lpage>928</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0090-4295(97)00459-7</pub-id>
                  <?supplied-pmid 9426724?>
                  <pub-id pub-id-type="pmid">9426724</pub-id>
                </element-citation>
              </ref>
              <ref id="CR143">
                <label>143.</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="author">
                    <collab>Canadian Society of Exercise Physiology</collab>
                  </person-group>
                  <source>Certified fitness appraisers resource manual</source>
                  <year>1992</year>
                  <publisher-loc>Ottawa</publisher-loc>
                  <publisher-name>Canadian Society of Exercise Physiology</publisher-name>
                </element-citation>
              </ref>
              <ref id="CR144">
                <label>144.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bohannon</surname>
                      <given-names>RW</given-names>
                    </name>
                  </person-group>
                  <article-title>Sit-to-stand test for measuring performance of lower extremity muscles</article-title>
                  <source>Percept Mot Skills</source>
                  <year>1995</year>
                  <volume>80</volume>
                  <issue>1</issue>
                  <fpage>163</fpage>
                  <lpage>166</lpage>
                  <pub-id pub-id-type="doi">10.2466/pms.1995.80.1.163</pub-id>
                  <?supplied-pmid 7624188?>
                  <pub-id pub-id-type="pmid">7624188</pub-id>
                </element-citation>
              </ref>
              <ref id="CR145">
                <label>145.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Schaubert</surname>
                      <given-names>KL</given-names>
                    </name>
                    <name>
                      <surname>Bohannon</surname>
                      <given-names>RW</given-names>
                    </name>
                  </person-group>
                  <article-title>Reliability and validity of three strength measures obtained from community-dwelling elderly persons</article-title>
                  <source>J Strength Cond Res</source>
                  <year>2005</year>
                  <volume>19</volume>
                  <issue>3</issue>
                  <fpage>717</fpage>
                  <lpage>720</lpage>
                  <?supplied-pmid 16095431?>
                  <pub-id pub-id-type="pmid">16095431</pub-id>
                </element-citation>
              </ref>
              <ref id="CR146">
                <label>146.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mathiowetz</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Kashman</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Volland</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Weber</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Dowe</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Rogers</surname>
                      <given-names>S</given-names>
                    </name>
                  </person-group>
                  <article-title>Grip and pinch strength: normative data for adults</article-title>
                  <source>Arch Phys Med Rehabil</source>
                  <year>1985</year>
                  <volume>66</volume>
                  <issue>2</issue>
                  <fpage>69</fpage>
                  <lpage>74</lpage>
                  <?supplied-pmid 3970660?>
                  <pub-id pub-id-type="pmid">3970660</pub-id>
                </element-citation>
              </ref>
              <ref id="CR147">
                <label>147.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cooper</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Kuh</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Hardy</surname>
                      <given-names>R</given-names>
                    </name>
                  </person-group>
                  <article-title>Objectively measured physical capability levels and mortality: systematic review and meta-analysis</article-title>
                  <source>BMJ</source>
                  <year>2010</year>
                  <volume>341</volume>
                  <fpage>c4467</fpage>
                  <pub-id pub-id-type="doi">10.1136/bmj.c4467</pub-id>
                  <?supplied-pmid 20829298?>
                  <pub-id pub-id-type="pmid">20829298</pub-id>
                </element-citation>
              </ref>
              <ref id="CR148">
                <label>148.</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="author">
                    <collab>Canadian Society of Exercise Physiology</collab>
                  </person-group>
                  <source>Physical Activity Training for Health (CSEP-PATH)</source>
                  <year>2013</year>
                  <publisher-loc>Ottawa</publisher-loc>
                  <publisher-name>Health Canada</publisher-name>
                </element-citation>
              </ref>
              <ref id="CR149">
                <label>149.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Penninx</surname>
                      <given-names>BW</given-names>
                    </name>
                    <name>
                      <surname>Guralnik</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Onder</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Ferrucci</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Wallace</surname>
                      <given-names>RB</given-names>
                    </name>
                    <name>
                      <surname>Pahor</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <article-title>Anemia and decline in physical performance among older persons</article-title>
                  <source>Am J Med</source>
                  <year>2003</year>
                  <volume>115</volume>
                  <issue>2</issue>
                  <fpage>104</fpage>
                  <lpage>110</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0002-9343(03)00263-8</pub-id>
                  <?supplied-pmid 12893395?>
                  <pub-id pub-id-type="pmid">12893395</pub-id>
                </element-citation>
              </ref>
              <ref id="CR150">
                <label>150.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Timilshina</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Hussain</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Breunis</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Alibhai</surname>
                      <given-names>SM</given-names>
                    </name>
                  </person-group>
                  <article-title>Predictors of hemoglobin decline in non-metastatic prostate cancer patients on androgen deprivation therapy: a matched cohort study</article-title>
                  <source>Support Care Cancer</source>
                  <year>2011</year>
                  <volume>19</volume>
                  <issue>11</issue>
                  <fpage>1815</fpage>
                  <lpage>1821</lpage>
                  <pub-id pub-id-type="doi">10.1007/s00520-010-1023-6</pub-id>
                  <?supplied-pmid 20953801?>
                  <pub-id pub-id-type="pmid">20953801</pub-id>
                </element-citation>
              </ref>
              <ref id="CR151">
                <label>151.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Saylor</surname>
                      <given-names>PJ</given-names>
                    </name>
                    <name>
                      <surname>Smith</surname>
                      <given-names>MR</given-names>
                    </name>
                  </person-group>
                  <article-title>Metabolic complications of androgen deprivation therapy for prostate cancer</article-title>
                  <source>J Urol</source>
                  <year>2009</year>
                  <volume>181</volume>
                  <issue>5</issue>
                  <fpage>1998</fpage>
                  <lpage>2006</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.juro.2009.01.047</pub-id>
                  <?supplied-pmid 19286225?>
                  <pub-id pub-id-type="pmid">19286225</pub-id>
                </element-citation>
              </ref>
              <ref id="CR152">
                <label>152.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kraemer</surname>
                      <given-names>WJ</given-names>
                    </name>
                    <name>
                      <surname>Ratamess</surname>
                      <given-names>NA</given-names>
                    </name>
                  </person-group>
                  <article-title>Hormonal responses and adaptations to resistance exercise and training</article-title>
                  <source>Sports Med</source>
                  <year>2005</year>
                  <volume>35</volume>
                  <issue>4</issue>
                  <fpage>339</fpage>
                  <lpage>361</lpage>
                  <pub-id pub-id-type="doi">10.2165/00007256-200535040-00004</pub-id>
                  <?supplied-pmid 15831061?>
                  <pub-id pub-id-type="pmid">15831061</pub-id>
                </element-citation>
              </ref>
              <ref id="CR153">
                <label>153.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Roset</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Badia</surname>
                      <given-names>X</given-names>
                    </name>
                    <name>
                      <surname>Mayo</surname>
                      <given-names>NE</given-names>
                    </name>
                  </person-group>
                  <article-title>Sample size calculations in studies using the EuroQol 5D</article-title>
                  <source>Qual Life Res</source>
                  <year>1999</year>
                  <volume>8</volume>
                  <issue>6</issue>
                  <fpage>539</fpage>
                  <lpage>549</lpage>
                  <pub-id pub-id-type="doi">10.1023/A:1008973731515</pub-id>
                  <?supplied-pmid 10548869?>
                  <pub-id pub-id-type="pmid">10548869</pub-id>
                </element-citation>
              </ref>
              <ref id="CR154">
                <label>154.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Shaw</surname>
                      <given-names>JW</given-names>
                    </name>
                    <name>
                      <surname>Johnson</surname>
                      <given-names>JA</given-names>
                    </name>
                    <name>
                      <surname>Coons</surname>
                      <given-names>SJ</given-names>
                    </name>
                  </person-group>
                  <article-title>US valuation of the EQ-5D health states: development and testing of the D1 valuation model</article-title>
                  <source>Med Care</source>
                  <year>2005</year>
                  <volume>43</volume>
                  <issue>3</issue>
                  <fpage>203</fpage>
                  <lpage>220</lpage>
                  <pub-id pub-id-type="doi">10.1097/00005650-200503000-00003</pub-id>
                  <?supplied-pmid 15725977?>
                  <pub-id pub-id-type="pmid">15725977</pub-id>
                </element-citation>
              </ref>
              <ref id="CR155">
                <label>155.</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kattan</surname>
                      <given-names>MW</given-names>
                    </name>
                    <name>
                      <surname>Cowen</surname>
                      <given-names>ME</given-names>
                    </name>
                  </person-group>
                  <source>Encyclopedia of medical decision making</source>
                  <year>2009</year>
                  <publisher-loc>Thousand Oaks</publisher-loc>
                  <publisher-name>Sage Publications</publisher-name>
                </element-citation>
              </ref>
              <ref id="CR156">
                <label>156.</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="author">
                    <collab>Canadian Society of Exercise Physiology</collab>
                  </person-group>
                  <source>Canadian Physical Activity Guidelines</source>
                  <year>2011</year>
                  <publisher-loc>Ottawa</publisher-loc>
                  <publisher-name>Health Canada</publisher-name>
                </element-citation>
              </ref>
              <ref id="CR157">
                <label>157.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Godin</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Jobin</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Bouillon</surname>
                      <given-names>J</given-names>
                    </name>
                  </person-group>
                  <article-title>Assessment of leisure time exercise behavior by self-report: a concurrent validity study</article-title>
                  <source>Can J Public Health</source>
                  <year>1986</year>
                  <volume>77</volume>
                  <issue>5</issue>
                  <fpage>359</fpage>
                  <lpage>362</lpage>
                  <?supplied-pmid 3791117?>
                  <pub-id pub-id-type="pmid">3791117</pub-id>
                </element-citation>
              </ref>
              <ref id="CR158">
                <label>158.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Godin</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Shephard</surname>
                      <given-names>RJ</given-names>
                    </name>
                  </person-group>
                  <article-title>A simple method to assess exercise behavior in the community</article-title>
                  <source>Can J Appl Sport Sci</source>
                  <year>1985</year>
                  <volume>10</volume>
                  <issue>3</issue>
                  <fpage>141</fpage>
                  <lpage>146</lpage>
                  <?supplied-pmid 4053261?>
                  <pub-id pub-id-type="pmid">4053261</pub-id>
                </element-citation>
              </ref>
              <ref id="CR159">
                <label>159.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>McClain</surname>
                      <given-names>JJ</given-names>
                    </name>
                    <name>
                      <surname>Sisson</surname>
                      <given-names>SB</given-names>
                    </name>
                    <name>
                      <surname>Tudor-Locke</surname>
                      <given-names>C</given-names>
                    </name>
                  </person-group>
                  <article-title>Actigraph accelerometer interinstrument reliability during free-living in adults</article-title>
                  <source>Med Sci Sports Exerc</source>
                  <year>2007</year>
                  <volume>39</volume>
                  <issue>9</issue>
                  <fpage>1509</fpage>
                  <lpage>1514</lpage>
                  <pub-id pub-id-type="doi">10.1249/mss.0b013e3180dc9954</pub-id>
                  <?supplied-pmid 17805082?>
                  <pub-id pub-id-type="pmid">17805082</pub-id>
                </element-citation>
              </ref>
              <ref id="CR160">
                <label>160.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Prince</surname>
                      <given-names>SA</given-names>
                    </name>
                    <name>
                      <surname>Adamo</surname>
                      <given-names>KB</given-names>
                    </name>
                    <name>
                      <surname>Hamel</surname>
                      <given-names>ME</given-names>
                    </name>
                    <name>
                      <surname>Hardt</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Connor Gorber</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Tremblay</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <article-title>A comparison of direct versus self-report measures for assessing physical activity in adults: a systematic review</article-title>
                  <source>Int J Behav Nutr Phys Act</source>
                  <year>2008</year>
                  <volume>5</volume>
                  <fpage>56</fpage>
                  <pub-id pub-id-type="doi">10.1186/1479-5868-5-56</pub-id>
                  <?supplied-pmid 18990237?>
                  <pub-id pub-id-type="pmid">18990237</pub-id>
                </element-citation>
              </ref>
              <ref id="CR161">
                <label>161.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Freedson</surname>
                      <given-names>PS</given-names>
                    </name>
                    <name>
                      <surname>Melanson</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Sirard</surname>
                      <given-names>J</given-names>
                    </name>
                  </person-group>
                  <article-title>Calibration of the Computer Science and Applications, Inc. accelerometer</article-title>
                  <source>Med Sci Sports Exerc</source>
                  <year>1998</year>
                  <volume>30</volume>
                  <issue>5</issue>
                  <fpage>777</fpage>
                  <lpage>781</lpage>
                  <pub-id pub-id-type="doi">10.1097/00005768-199805000-00021</pub-id>
                  <?supplied-pmid 9588623?>
                  <pub-id pub-id-type="pmid">9588623</pub-id>
                </element-citation>
              </ref>
              <ref id="CR162">
                <label>162.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Creatore</surname>
                      <given-names>MI</given-names>
                    </name>
                    <name>
                      <surname>Glazier</surname>
                      <given-names>RH</given-names>
                    </name>
                    <name>
                      <surname>Moineddin</surname>
                      <given-names>R</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Association of Neighborhood Walkability With Change in Overweight, Obesity, and Diabetes</article-title>
                  <source>JAMA</source>
                  <year>2016</year>
                  <volume>315</volume>
                  <issue>20</issue>
                  <fpage>2211</fpage>
                  <lpage>20</lpage>
                  <pub-id pub-id-type="doi">10.1001/jama.2016.5898</pub-id>
                  <?supplied-pmid 27218630?>
                  <pub-id pub-id-type="pmid">27218630</pub-id>
                </element-citation>
              </ref>
              <ref id="CR163">
                <label>163.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Williams</surname>
                      <given-names>GC</given-names>
                    </name>
                    <name>
                      <surname>Grow</surname>
                      <given-names>VM</given-names>
                    </name>
                    <name>
                      <surname>Freedman</surname>
                      <given-names>ZR</given-names>
                    </name>
                    <name>
                      <surname>Ryan</surname>
                      <given-names>RM</given-names>
                    </name>
                    <name>
                      <surname>Deci</surname>
                      <given-names>EL</given-names>
                    </name>
                  </person-group>
                  <article-title>Motivational predictors of weight loss and weight-loss maintenance</article-title>
                  <source>J Pers Soc Psychol</source>
                  <year>1996</year>
                  <volume>70</volume>
                  <issue>1</issue>
                  <fpage>115</fpage>
                  <lpage>126</lpage>
                  <pub-id pub-id-type="doi">10.1037/0022-3514.70.1.115</pub-id>
                  <?supplied-pmid 8558405?>
                  <pub-id pub-id-type="pmid">8558405</pub-id>
                </element-citation>
              </ref>
              <ref id="CR164">
                <label>164.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Moustaka</surname>
                      <given-names>FC</given-names>
                    </name>
                    <name>
                      <surname>Vlachopoulos</surname>
                      <given-names>SP</given-names>
                    </name>
                    <name>
                      <surname>Kabitsis</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Theodorakis</surname>
                      <given-names>Y</given-names>
                    </name>
                  </person-group>
                  <article-title>Effects of an autonomy-supportive exercise instructing style on exercise motivation, psychological well-being, and exercise attendance in middle-age women</article-title>
                  <source>J Phys Act Health</source>
                  <year>2012</year>
                  <volume>9</volume>
                  <issue>1</issue>
                  <fpage>138</fpage>
                  <lpage>150</lpage>
                  <pub-id pub-id-type="doi">10.1123/jpah.9.1.138</pub-id>
                  <?supplied-pmid 22232500?>
                  <pub-id pub-id-type="pmid">22232500</pub-id>
                </element-citation>
              </ref>
              <ref id="CR165">
                <label>165.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chen</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Vansteenkiste</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Beyers</surname>
                      <given-names>W</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Basic psychological need satisfaction, need frustration, and need strength across four cultures</article-title>
                  <source>Motiv Emot</source>
                  <year>2015</year>
                  <volume>39</volume>
                  <fpage>216</fpage>
                  <lpage>236</lpage>
                  <pub-id pub-id-type="doi">10.1007/s11031-014-9450-1</pub-id>
                </element-citation>
              </ref>
              <ref id="CR166">
                <label>166.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Markland</surname>
                      <given-names>DA</given-names>
                    </name>
                    <name>
                      <surname>Tobin</surname>
                      <given-names>V</given-names>
                    </name>
                  </person-group>
                  <article-title>A modification to the Behavioural regulation in exercise questionnaire to include an assessment of amotivation</article-title>
                  <source>J Sport Exerc Psychol</source>
                  <year>2004</year>
                  <volume>26</volume>
                  <fpage>191</fpage>
                  <lpage>196</lpage>
                  <pub-id pub-id-type="doi">10.1123/jsep.26.2.191</pub-id>
                </element-citation>
              </ref>
              <ref id="CR167">
                <label>167.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Brunet</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Sabiston</surname>
                      <given-names>CM</given-names>
                    </name>
                  </person-group>
                  <article-title>Exploring motivation for physical activity across the adult lifespan</article-title>
                  <source>Psychol Sport Exerc</source>
                  <year>2011</year>
                  <volume>12</volume>
                  <issue>2</issue>
                  <fpage>99</fpage>
                  <lpage>105</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.psychsport.2010.09.006</pub-id>
                </element-citation>
              </ref>
              <ref id="CR168">
                <label>168.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Courneya</surname>
                      <given-names>KS</given-names>
                    </name>
                    <name>
                      <surname>Friedenreich</surname>
                      <given-names>CM</given-names>
                    </name>
                  </person-group>
                  <article-title>Utility of the theory of planned behavior for understanding exercise during breast cancer treatment</article-title>
                  <source>Psychooncology</source>
                  <year>1999</year>
                  <volume>8</volume>
                  <issue>2</issue>
                  <fpage>112</fpage>
                  <lpage>122</lpage>
                  <pub-id pub-id-type="doi">10.1002/(SICI)1099-1611(199903/04)8:2&lt;112::AID-PON341&gt;3.0.CO;2-L</pub-id>
                  <?supplied-pmid 10335555?>
                  <pub-id pub-id-type="pmid">10335555</pub-id>
                </element-citation>
              </ref>
              <ref id="CR169">
                <label>169.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Courneya</surname>
                      <given-names>KS</given-names>
                    </name>
                    <name>
                      <surname>Vallance</surname>
                      <given-names>JK</given-names>
                    </name>
                    <name>
                      <surname>Culos-Reed</surname>
                      <given-names>SN</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>The Alberta moving beyond breast cancer (AMBER) cohort study: a prospective study of physical activity and health-related fitness in breast cancer survivors</article-title>
                  <source>BMC Cancer</source>
                  <year>2012</year>
                  <volume>12</volume>
                  <fpage>525</fpage>
                  <pub-id pub-id-type="doi">10.1186/1471-2407-12-525</pub-id>
                  <?supplied-pmid 23153358?>
                  <pub-id pub-id-type="pmid">23153358</pub-id>
                </element-citation>
              </ref>
              <ref id="CR170">
                <label>170.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Krahn</surname>
                      <given-names>MD</given-names>
                    </name>
                    <name>
                      <surname>Zagorski</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Laporte</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Healthcare costs associated with prostate cancer: estimates from a population-based study</article-title>
                  <source>BJU Int</source>
                  <year>2010</year>
                  <volume>105</volume>
                  <issue>3</issue>
                  <fpage>338</fpage>
                  <lpage>346</lpage>
                  <pub-id pub-id-type="doi">10.1111/j.1464-410X.2009.08758.x</pub-id>
                  <?supplied-pmid 19594734?>
                  <pub-id pub-id-type="pmid">19594734</pub-id>
                </element-citation>
              </ref>
              <ref id="CR171">
                <label>171.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>de Oliveira</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Bremner</surname>
                      <given-names>KE</given-names>
                    </name>
                    <name>
                      <surname>Ni</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Alibhai</surname>
                      <given-names>SM</given-names>
                    </name>
                    <name>
                      <surname>Laporte</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Krahn</surname>
                      <given-names>MD</given-names>
                    </name>
                  </person-group>
                  <article-title>Patient time and out-of-pocket costs for long-term prostate cancer survivors in Ontario, Canada</article-title>
                  <source>J Cancer Surv</source>
                  <year>2014</year>
                  <volume>8</volume>
                  <issue>1</issue>
                  <fpage>9</fpage>
                  <lpage>20</lpage>
                  <pub-id pub-id-type="doi">10.1007/s11764-013-0305-7</pub-id>
                </element-citation>
              </ref>
              <ref id="CR172">
                <label>172.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>de Oliveira</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Bremner</surname>
                      <given-names>KE</given-names>
                    </name>
                    <name>
                      <surname>Pataky</surname>
                      <given-names>R</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Understanding the costs of cancer care before and after diagnosis for the 21 most common cancers in Ontario: a population-based descriptive study</article-title>
                  <source>CMAJ Open</source>
                  <year>2013</year>
                  <volume>1</volume>
                  <issue>1</issue>
                  <fpage>E1</fpage>
                  <lpage>E8</lpage>
                  <pub-id pub-id-type="doi">10.9778/cmajo.20120013</pub-id>
                  <?supplied-pmid 25077097?>
                  <pub-id pub-id-type="pmid">25077097</pub-id>
                </element-citation>
              </ref>
              <ref id="CR173">
                <label>173.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Krol</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Brouwer</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Rutten</surname>
                      <given-names>F</given-names>
                    </name>
                  </person-group>
                  <article-title>Productivity costs in economic evaluations: past, present, future</article-title>
                  <source>Pharmacoeconomics</source>
                  <year>2013</year>
                  <volume>31</volume>
                  <issue>7</issue>
                  <fpage>537</fpage>
                  <lpage>549</lpage>
                  <pub-id pub-id-type="doi">10.1007/s40273-013-0056-3</pub-id>
                  <?supplied-pmid 23620213?>
                  <pub-id pub-id-type="pmid">23620213</pub-id>
                </element-citation>
              </ref>
              <ref id="CR174">
                <label>174.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Herdman</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Gudex</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Lloyd</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)</article-title>
                  <source>Qual Life Res</source>
                  <year>2011</year>
                  <volume>20</volume>
                  <issue>10</issue>
                  <fpage>1727</fpage>
                  <lpage>1736</lpage>
                  <pub-id pub-id-type="doi">10.1007/s11136-011-9903-x</pub-id>
                  <?supplied-pmid 3220807?>
                  <pub-id pub-id-type="pmid">21479777</pub-id>
                </element-citation>
              </ref>
              <ref id="CR175">
                <label>175.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Petrou</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Gray</surname>
                      <given-names>A</given-names>
                    </name>
                  </person-group>
                  <article-title>Economic evaluation alongside randomised controlled trials: design, conduct, analysis, and reporting</article-title>
                  <source>BMJ</source>
                  <year>2011</year>
                  <volume>342</volume>
                  <fpage>d1548</fpage>
                  <pub-id pub-id-type="doi">10.1136/bmj.d1548</pub-id>
                  <?supplied-pmid 21474510?>
                  <pub-id pub-id-type="pmid">21474510</pub-id>
                </element-citation>
              </ref>
              <ref id="CR176">
                <label>176.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hughes</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Charles</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Dawoud</surname>
                      <given-names>D</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Conducting economic evaluations alongside randomised trials: current methodological issues and novel approaches</article-title>
                  <source>Pharmacoeconomics</source>
                  <year>2016</year>
                  <volume>34</volume>
                  <issue>5</issue>
                  <fpage>447</fpage>
                  <lpage>461</lpage>
                  <pub-id pub-id-type="doi">10.1007/s40273-015-0371-y</pub-id>
                  <?supplied-pmid 26753558?>
                  <pub-id pub-id-type="pmid">26753558</pub-id>
                </element-citation>
              </ref>
              <ref id="CR177">
                <label>177.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Barlow</surname>
                      <given-names>WE</given-names>
                    </name>
                  </person-group>
                  <article-title>Overview of methods to estimate the medical costs of cancer</article-title>
                  <source>Med Care</source>
                  <year>2009</year>
                  <volume>47</volume>
                  <issue>7 Suppl 1</issue>
                  <fpage>S33</fpage>
                  <lpage>S36</lpage>
                  <pub-id pub-id-type="doi">10.1097/MLR.0b013e3181a2d847</pub-id>
                  <?supplied-pmid 19536013?>
                  <pub-id pub-id-type="pmid">19536013</pub-id>
                </element-citation>
              </ref>
              <ref id="CR178">
                <label>178.</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Willan</surname>
                      <given-names>AR</given-names>
                    </name>
                    <name>
                      <surname>Briggs</surname>
                      <given-names>AH</given-names>
                    </name>
                  </person-group>
                  <source>Statistical analysis of cost-effectiveness data (statistics in practice)</source>
                  <year>2006</year>
                  <publisher-loc>Oxford</publisher-loc>
                  <publisher-name>Wiley</publisher-name>
                </element-citation>
              </ref>
              <ref id="CR179">
                <label>179.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Willan</surname>
                      <given-names>AR</given-names>
                    </name>
                    <name>
                      <surname>Lin</surname>
                      <given-names>DY</given-names>
                    </name>
                    <name>
                      <surname>Cook</surname>
                      <given-names>RJ</given-names>
                    </name>
                    <name>
                      <surname>Chen</surname>
                      <given-names>EB</given-names>
                    </name>
                  </person-group>
                  <article-title>Using inverse-weighting in cost-effectiveness analysis with censored data</article-title>
                  <source>Stat Methods Med Res</source>
                  <year>2002</year>
                  <volume>11</volume>
                  <issue>6</issue>
                  <fpage>539</fpage>
                  <lpage>551</lpage>
                  <pub-id pub-id-type="doi">10.1191/0962280202sm308ra</pub-id>
                  <?supplied-pmid 12516988?>
                  <pub-id pub-id-type="pmid">12516988</pub-id>
                </element-citation>
              </ref>
              <ref id="CR180">
                <label>180.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Husereau</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Drummond</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Petrou</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Consolidated health economic evaluation reporting standards (CHEERS) statement</article-title>
                  <source>BMJ</source>
                  <year>2013</year>
                  <volume>f1049</volume>
                  <fpage>346</fpage>
                </element-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
